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Review of the literature on clinical trials of adjuvant medical therapy in peripheral bypass 
procedures indicated that there are many deficiencies in published trials, notably in the 
definition of patients and procedures, sample size, the definition of a primary endpoint 
and the availability of clinical outcome data. Consideration of the characteristics of 
patients studied was shown to be important in the interpretation of studies of antiplatelet 
agents.
A multicentre clinical trial was performed in order to determine the efficacy of 
iloprost, a prostacyclin analogue, in the maintenance of femorodistal bypass patency. 
The trial provided a database on 517 patients which included patient characteristics, the 
surgical procedures performed and a 12 month follow-up of bypass patency and clinical 
outcome.
The database was used to develop a score for comparing symptom severity in 
patients with severe leg ischaemia and then to investigate factors associated with 
outcome in terms of bypass patency, limb survival and patient survival. The clinical 
relevance of outcomes measured in terms of bypass patency and vascular surgical 
interventions were evaluated.
Intravenous iloprost was found to be ineffective in the maintenance of bypass 
patency when applied across the range of different procedures included in this trial. 
There was no convincing evidence of long-term efficacy in either vein or prosthetic grafts 
when analysed separately, although early graft occlusions in prosthetic grafts were less 
frequent in the iloprost group. Large differences between centres were found in patient 
selection, including some factors known to influence bypass patency or clinical outcomes. 
Overall clinical outcome was poor in the patients studied and was found to be less 
strongly associated with bypass patency than often thought. The need for reintervention 
was found to represent the clinical success of the initial bypass procedure better than an 
assessment of bypass patency.
Better designed studies are required in this indication. It is proposed that future 
studies should present clinical outcomes in addition to patency or reintervention results. 




1.1. Background, statement of objectives and structure of thesis
11
Background
The use of pharmacological agents in combination with peripheral bypass surgery to 
improve the outcome of the surgical procedures is not highly developed. Consequently, 
the optimal clinical trial methods have yet to be defined.
Objectives
The objectives of these investigations were to accomplish the following:
• Evaluate the standard of clinical trial design in the investigation of adjuvant medical 
therapy in peripheral bypass surgery and the current evidence for the use of such agents 
in the maintenance of peripheral bypass graft patency
• Describe a drug development programme for the maintenance of femorodistal bypass 
grafts
• Determine the efficacy of peri-operative iloprost in reducing distal bypass graft failure
• Investigate the extent and importance of intercentre differences in a multicentre trial in 
distal bypass procedures
• Investigate the relationship between bypass patency and clinical outcome after distal 
bypass surgery and to investigate alternative methods of expressing outcome after distal 
bypass surgery
Structure of the thesis
The introductory sections of the thesis divide the review of relevant literature into several 
sections. The thesis commences with a description of femorodistal bypass surgery and 
factors which may influence its outcome followed by a comprehensive literature review of 
controlled clinical trials in this field including a meta-analysis of trials with antiplatelet 
agents. The development of the prostacyclin analogue, iloprost, in a sequence of studies 
in this indication is then described. These sections are followed by a description of the 
methods used in performing the main trial with iloprost. The methods used in data 
collection and analysis of the treatment effect are described and the outcome of the trial.
The iloprost database was then used to investigate intercentre differences in 
patient selection and to evaluate the clinical relevance of bypass patency as a primary 
trial endpoint in this indication. An overall discussion and conclusions are presented at 
the end of the thesis.
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2. INTRODUCTION
2.1. Femorodistal bypass surgery
13
Clinical Problem
Femorodistal bypass procedures are performed in cases of severe lower limb ischaemia 
resulting from peripheral arterial occlusive disease, usually when patients are suffering 
from pain at rest and ischaemic ulcers or gangrene. In many cases the operation is a last 
attempt to avoid amputation of the leg. Such long bypass procedures are seldom 
necessary in patients who have non-limb threatening intermittent claudication as their only 
symptom.
In the case of severe chronic ischaemia of the lower limb, the fundamental cause 
is atherosclerosis of the major arteries. The development of stenoses and occlusions in 
the proximal arteries, often with the additional involvement of thrombosis, severely 
reduces blood flow to the distal circulation. In the early stages of the disease, formation 
of collateral vessels may compensate for the reduced blood flow through the main 
arteries to supply the nutritive requirements of the tissues. The symptoms of severe 
ischaemia develop when the blood flow is impaired to the extent that this compensatory 
mechanism and other microvascular homeostatic mechanisms are insufficient to maintain 
nutritive microvascular blood flow. Lower limb ischaemia is thought to involve many 
changes in the microvasculature resulting from the reduced perfusion pressure. These 
may include failure of vessel tone autoregulation (Ubbink et al 1990), activation of 
platelets and white cells (d'Angelo et al 1978), fibrin formation and increased blood 
viscosity, and the formation and release of vasoactive mediators (e.g. TxA2, 5-HT) which 
would accompany these other changes (Lowe et al 1990).
The consequences of the severe ischaemia are severe pain, ulcer formation and a 
threat to the survival of the leg. Pharmacotherapy other than pain relief with powerful 
analgesics has had some limited success in resolving symptoms (Dormandy 1994), but 
the treatment of choice remains intervention in the form of balloon catheter dilation of 
short lesions and bypass grafts in the case of more extensive disease.
Patients with severe atherosclerotic lesions in the arteries of the leg commonly 
also have coronary and cerebrovascular disease. Risk factors for atherosclerosis, such 
as hypertension, smoking, diabetes mellitus and hyperlipidaemia, are common and 
patients often have a history of myocardial infarction, stroke and other cardiovascular 
disease (Dormandy et al 1989). There is an increasing incidence of severe leg ischaemia 
with increasing age and the patient’s general state of health and the likelihood of serious 
cardiovascular events have to be considered in the decision on the optimal treatment for 
the patient.
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Pre-operative and intra-operative assessments
The presence of pain at rest, ulcers and gangrene are routinely documented before 
surgery, but not usually quantified. Intermittent claudication, however, is usually 
quantified by means of an exercise tolerance test. Clinical assessment of the patients 
before femorodistal bypass surgery also includes the investigating the presence of arterial 
pulses and the assessment of the systolic pressures in the arteries at the ankle, the 
anterior tibial and the dorsalis pedis, using Doppler ultrasound or strain-gauge 
techniques.
Prior to surgery, the patient’s cardiological and pulmonary status is assessed to 
ensure that the patient is fit enough to undergo a lengthy surgical procedure. Specific 
assessments used in planning and preparing for a femorodistal bypass procedure include 
visualisation of the relevant arteries by conventional angiography or by digital subtraction 
angiography (DSA). The occlusions or stenoses in the arteries which are giving rise to 
the symptoms can be located and the appropriate procedure to bypass these segments 
planned. Angiography is usually performed before surgery, but may also be performed 
‘on table’ at the during the operation. The status of the arteries of the leg may be 
recorded as simply patent or occluded, or may be quantified more precisely by the 
calculation of a run-off score. A number of different angiographic scoring systems have 
been devised. One which has been proposed for general use in order to standardise the 
assessment of patients is commonly known as the Rutherford score (Rutherford et al 
1986).
At the end of the bypass procedure measurements of the flow through the graft 
may be made and calculations of distal resistance to flow can be performed, but this is 
not routine practice at most centres. Bypass quality and function is also checked intra- 
operatively using duplex ultrasound, angiography and occasionally by angioscopy.
Surgical procedures
The procedure involves bypassing stenosed or occluded sections of the femoral, popliteal 
and tibial arteries using a graft from one of the femoral arteries to one of the calf vessels. 
This involves using a relatively long graft of either autogenous vein or a prosthetic 
material and with the distal anastomosis to a relatively small artery.
The location of the proximal anastomosis is selected so as to provide the optimal 
inflow to the bypass graft. The common femoral artery is most often used, but the 
femoral bifurcation, the femoral profunda artery and the superficial femoral artery are also 
frequently used. Rarely used for the proximal anastomosis are the iliac artery and, at the 
distal extreme, the proximal section of the popliteal artery.
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The distal anastomosis is usually to the tibioperoneal trunk, the anterior or 
posterior tibial artery or to the peroneal artery (Figure 1). More distal anastomoses to the 
pedal arteries have been reported, but are rarely performed in most centres. 
Femoropopliteal bypasses below the knee are also sometimes considered to be 
femorodistal grafts, but differ in that they frequently have better outflow through more 
than one calf vessel, and hence greater likelihood of success. The location of the distal 
anastomosis on the calf vessel is conventionally described as being in the upper, middle 
or lower third of the calf. The most proximal site feasible is chosen in order to avoid an 
unnecessarily long graft.
There are conflicting requirements to consider in the choice of location of the 
distal anastomosis. It is easier to anastomose to a larger artery and shorter grafts give 
better results than long ones and increase the likelihood that sufficient good quality 
autogenous vein will be available. This argues for a more proximally located distal 
anastomosis. On the other hand, it is essential that all areas of significant narrowing in 
the chosen artery are bypassed in order to ensure the best possible outflow from the 
graft. This will often lead to a more distal location being chosen despite the practical 
difficulties which this may entail.
The preferred graft material for femorodistal bypass procedures is autogenous 
saphenous vein. This has consistently been found to give superior patency rates to the 
prosthetic alternatives. There are two alternative techniques for using saphenous vein: 
the in situ technique and the reversed vein technique. Each has its advocates, but there is 
no consistent evidence that one is superior to the other (Harris et al 1993).
The in situ vein technique involves leaving the major part of the saphenous vein 
and its vasculature undisturbed while transposing the vein to the chosen arteries at each 
end. This has the advantage that the size of the vein corresponds well to the size of the 
artery at each anastomosis, but the disadvantage that it is necessary to destroy all the 
valves in the vein as they would act to impede flow. The reversed vein technique involves 
removing the chosen length of vein and reversing it so ensuring that the valves are no 
longer effective. The difficulty with this technique is that wider end of the vein has to be 
anastomosed to a small artery and the narrower end of the vein to a large artery. This is 
technically more challenging and is probably not haemodynamically ideal.
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Figure 1. Examples of femorodistal bypass grafts
(a) graft from the superficial femoral artery 
to the tibioperoneal trunk
(b) graft from the superficial femoral t 
to the anterior tibia! artery
The first choice material for the graft is saphenous vein, but it is sometimes the case that 
the vein is of insufficient length or quality due to disease to be used as a conduit for a 
long bypass. In this event there are several other options. The cephalic or basilic vein 
may be taken from the arm, and sections of the saphenous or arm vein may be used 
sequentially to make a composite vein-vein graft or a segment of one of these veins may 
be used in combination with a length of prosthetic material, or a bypass wholly composed 
of a prosthetic material may be used. Other biological materials have also been tried, 
such as modified human umbilical vein, but with only limited success. 
Polytetrafluoroethylene (PTFE) is the prosthetic material of choice for these grafts, but 
grafts with a diameter of less than 4mm have a high likelihood of thrombosis. For this 
reason, when mixed vein and prosthetic material are used in sequence, it is always with 
the prosthetic section forming the upper part of the graft and the vein the more distal 
section with an anastomosis of prosthetic to vein in the middle. The smaller diameter vein
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can then be used for the anastomosis with the smaller artery in the calf. The difference in 
compliance of prosthetic materials and arteries is also considered to be a drawback to the 
use of prosthetic grafts. This problem is currently tackled in one of two ways: 
interposition of a collar (or cuff) between the prosthetic graft and the artery and use of a 
vein patch to modify the shape and haemodynamics of the distal anastomosis (Figure 2).





Additional surgical procedures may be performed concomitantly in order to improve the 
blood supply to the distal vascular bed. Femoral endarterectomy and profundaplasty may 
be indicated to improve inflow into the bypass graft if this is likely to be a limiting factor. 
Arteriovenous fistulae in the distal section of the graft are also performed in some centres 
with the aim of improving the volume flow through the graft, but with no proven benefit.
Both general anaesthesia and epidural anaesthesia are used frequently in patients 
undergoing distal bypass procedures. The choice may be dictated by the general policy 
of the centre or by specific considerations such as the patient's general state of health. 
Epidural anaesthesia theoretically produces vasodilation and therefore an increase in 
peripheral blood flow (Hickey et al 1995), but evidence for a benefit of this in terms of 
reduced early thrombosis following distal bypass is lacking (Schunn et al 1998). Local or 
regional anaesthesia may also be used occasionally.
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Post-operative management
In the immediate post-operative period most patients will receive additional intravenous 
fluids in order to maintain perfusion pressure. These may consist of electrolyte or 
glucose solutions, dextrans, plasma and erythrocytes or whole blood transfusions when 
there has been appreciable blood loss. The use of intravenous fluids to improve 
perfusion pressure has always to be balanced against the risk of fluid overload in patients 
with impaired cardiac function. Additional analgesia over and above that which the 
patient was receiving for control of ischaemic rest pain may also be necessary in this 
period.
Heparin is usually given intra-operatively either systemically via the intravenous 
route or regionally by injection into the distal arterial circulation at the time that the arteries 
are clamped or shortly thereafter. Heparin anticoagulation may be neutralised at the end 
of the operation with protamine, but it is also common for heparinisation to be continued 
for the first day or two post-operatively. The drug may be given subcutaneously for a 
longer period as prophylaxis against venous thrombosis if the patient is not quickly 
mobile.
Oedema in the operated leg is frequently seen in the first two weeks after surgery 
and occasionally requires intervention such as fasciotomy. Wound infection can also 
occur and more seriously infection of the graft itself which is likely to prejudice its survival.
It is generally the policy to mobilise patients within a couple of days of surgery and 
it is not at all uncommon for them to leave hospital within a week. Patients at most 
centres will then be asked to return for regular follow-up which may include graft 
surveillance programmes using duplex ultrasound. These programmes aim to identify as 
early as possible grafts at risk of failing and to intervene before this occurs.
Outcome
The technical difficulty of these procedures together with graft thrombogenicity and a low 
volume flow through the graft due to the poor outflow and later development of stenoses 
produces a high failure rate in these procedures. Patency of femorodistal bypass grafts 
at one year has been reported in some series to be as low as 60% for vein grafts and 
40% for prosthetic grafts. Higher patency rates up to 90% have also been reported and 
results appear to vary considerably depending on factors such as patient selection, 
preferred operation techniques and importantly the skill and experience of the surgeon.
The causes of bypass failure vary with time and graft material. Immediate 
occlusion of the graft occurring in the first 24-48 hours after surgery may be due to 
imperfections in surgical technique or a failure to establish an adequate blood flow
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through the graft after release of the arterial clamps. Failure to establish an adequate 
blood flow might be a result of poor inflow, poor outflow or increased blood viscosity. In 
the first few weeks post-operatively bypass failure is likely to be due to graft 
thrombogenicity or increased blood viscosity, and after the first month the development of 
graft stenosis due to fibrous neointimal hyperplasia becomes a major contributing factor 
to failure. In the longer term, after 12 months, progression of atherosclerosis can also 
lead to bypass failure.
In about half of the cases in which the bypass occludes and is not reopened, the 
patient will require a major amputation. In some patients symptoms of ischaemia may 
return, but not with sufficient severity to warrant amputation and other patients may 
continue to be symptom-free for a while if the bypass had functioned for long enough to 
permit resolution of the original symptoms.
Post-operative assessment
Assessment of the patients after surgery is concerned with the technical success of the 
bypass procedure and the effect of surgery on the patient’s symptoms. Technical 
success is recorded both in terms of the patency of the bypass graft and measurements 
of blood pressure and flow in the lower leg.
Bypass patency is described as (1) primary, if patency has been uninterrupted 
since the bypass graft was performed and no further procedures in the relevant segment 
have been necessary, (2) assisted primary, if the graft has not occluded, but a further 
intervention or surgical procedure was performed in order to ensure continued patency, or 
(3) secondary, if the bypass graft has occluded and been reopened. Patency may be 
assessed by ankle systolic blood pressure or by presence arterial pulses, but is more 
reliably confirmed by angiography or by duplex ultrasound measurement of blood flow 
velocity through the graft.
A successful bypass should improve blood flow to the tissues distal to the graft. 
This can be assessed by blood pressure measurements at the ankle usually using the 
Doppler technique. These are commonly expressed as the systolic ankle pressure or the 
ankle-brachial pressure index (ABPI), which is the ratio of the systolic pressure at the 
ankle to that measured in the brachial artery. Different pressure readings may be 
obtained from different vessels at the ankle, and in this event the highest pressure 
obtained would be quoted or used for calculation of the ABPI.
The status of the graft can also be assessed post-operatively by duplex scanning 
over the length of the graft. By identifying changes in flow velocity, this enables the 
detection of stenoses in the graft, which may develop, particularly in vein grafts over the
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first year or two and threaten the viability of the graft in the long-term. Scanning is usually 
performed at regular intervals between one month and 12 months after the operation.
The clinical outcome of bypass surgery is routinely judged by changes in the 
symptoms of ischaemia at rest (pain and trophic lesions) and exercise capacity and by 
the avoidance of amputations in the relevant leg.
21
2.2. Considerations for clinical trials in peripheral bypass surgery
22
Describing symptom severity
Clinical trials in peripheral bypass surgery frequently include patients with diverse 
symptoms of ischaemia: rest pain, ulcers and gangrene. In the iloprost trial, as in other 
trials, various parameters - pain, analgesic use, presence of ulcers and gangrene - were 
documented separately. The comparison of overall symptom severity in different patient 
groups taking into account the various parameters is therefore difficult. The importance 
of this is that symptom and disease severity may be associated with outcome. A single 
symptom severity score would be an helpful, if it could be shown to be meaningful. 
Association of such a symptom score with patient outcome would be an indication that it 
was a good representation of disease severity.
There is currently no agreed standard for the documenting of patients’ symptoms 
in severe lower limb ischaemia. Proposals have been put forward for classifying patients’ 
symptoms in clinical trials (Rutherford et al 1986, Belch et al 1991), but these have not 
been widely adopted by authors of clinical trial reports and patients are often classified 
very simply into the four stages of peripheral arterial occlusive disease according to 
Fontaine (Table 1).
Table 1. Classification of peripheral arterial occlusive disease according to Fontaine
Stage Description
1 arteriosclerotic lesions without clinical symptoms
2 claudication, no symptoms at rest
3 claudication, pain at rest
4 ulcers and/or gangrene
The scheme for classifying chronic limb ischaemia put forward by Rutherford et al (1986) 
is not a pure symptomatic classification, but also incorporates objective criteria based on 
treadmill and haemodynamic tests (Table 2).
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Table 2. Clinical categories of chronic limb ischaemia according to Rutherford (1986)
Grade Category Clinical description Objective criteria
0 0 • Asymptomatic - no
haemodynamically significant 
disease.







• Completes treadmill exercise; 
AP after exercise <50mmHg, 
but >25mmHg less than BP.
• Between categories 1 and 3.
• Cannot complete treadmill 
exercise and AP after 
exercise <50mmHg.
II 4 • Ischaemic rest pain • Resting AP<40mmHg, flat or 





• Minor tissue loss - non­
healing ulcer, focal gangrene 
with diffuse pedal ischaemia.
• Major tissue loss - extending 
above TM level, functional 
foot no longer salvageable.
• Resting AP<60mmHg, ankle 
or metatarsal PVR flat or 
barely pulsatile; 
TP<40mmHg.
• Same as category 5.
The scheme for scoring symptoms put forward by Belch et al (1991) assesses ulcers and 
gangrene each by three different parameters (Table 3) and the intensity of pain in terms 
of its affect on daily activities (Table 4). The scheme is very sophisticated in its detail, but 
requires subjective judgements on the part of the clinician and the patient.
Table 3. Scoring of ulcers and gangrene by Belch et al (1991)
ULCER Score GANGRENE
Ulcer base Stage of gangrene
bone visible 1 gangrene with osteonecrosis or osteomyelitis
greasy 2 congestion of secretions, pockets of pus
fibrin layer 3 tendency to progress
clean, but not healing 4 tendency to remit
clean and healing 5 new vessel injection at edge
healed 6 healed,/demarcation/casting off
Extension of granulation Extension of gangrene
low 0 forefoot, heel
medium 2 several toes
good 4 one toe
ulcer edge Classification of gangrene




Table 4. Scoring of pain by Belch et al (1991) - rating scale from impression over whole 
day
Score Description of pain
0 Pain present, cannot be ignored, rest or bed-rest required
1 Pain present, cannot be ignored, interferes with all tasks except taking 
care of basic needs (eating, toilet visits)
2 Pain present, cannot be ignored, interferes with concentration
3 Pain present, cannot be ignored, but does not interfere with everyday 
activities
4 Pain present, but can easily be ignored
5 No pain
Alternatives such as the use of visual analogue scales for the assessment of pain have 
been advocated (Heidrich et al 1995), but these also require a subjective judgement by 
the patient. The ideal for comparing symptom severity in different patient groups, either 
within a study or between studies, would be a scoring system which took into account the 
different types of symptom, pain and trophic lesions and their severity, and combined 
these into a single numerical value. Other desirable attributes of such a system would be 
to avoid the need for subjective patient or clinician judgements, to be simple to apply and 
to use unambiguous descriptions of categories which could be easily translated into 
different languages. Finally, there is a need for a symptom score which has some 
relevance for the clinical outcome in a patient.
Factors influencing patency
There is an extensive literature on factors associated with the outcome of peripheral 
bypass surgery. The majority of studies reported have included less than 500 patients 
and been conducted in single centres. There have been few such investigations 
exclusively in femorodistal bypass grafts, the majority of such studies including all infra- 
inguinal bypasses.
Studies including above- and below-knee grafts have typically found that the level 
of the graft is an important determinant of outcome both in studies including a mixture of 
graft materials (Budd et al 1990) and in vein grafts alone (Bergamini et al 1991). 
However, Tordoir et al (1993) also reported that the vessel and site of anastomosis was 
not associated with patency in a smaller series of distal grafts. There are theoretical 
reasons for thinking that the level of the distal anastomosis and length of graft would be 
of greater importance in prosthetic grafts.
Prospective randomised trials comparing autogenous vein and prosthetic grafts 
have found significantly better patency with vein in all femoropopliteal bypasses (Tilanus
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et al 1985) and in below-knee grafts (Veith et al 1986), although the latter study did not 
show any difference between the materials in the first two years of a four year follow-up. 
Another series also showed a significant difference between vein and prosthetic grafts, 
but not in the first 12 months (Ameli et al 1988).
Several randomised studies have investigated, but failed to show any difference 
between the patency rates obtained with the in situ and the reversed techniques (Harris et 
al 1993, Watelet et al 1997). A recent large series of femoropopliteal and femorocrural 
grafts found a superiority after 12 months in primary patency of reversed vein compared 
to in situ vein grafts (Lawson et al 1999). However, this series did not involve a 
randomised assignment of technique and the safest conclusion seems to be that at least 
the reversed technique is no worse than the in situ.
Another aspect of the choice of graft material is the diameter of the vein used. 
This was associated with patency in a report of infrapopliteal bypasses (Wengerter et al 
1990), but not significantly so in a study of above- and below-knee bypasses (Bergamini 
et al 1991), suggesting that this factor may be more important in distal bypass grafts.
The severity of the patients’ arterial disease pre-operatively is generally not found 
to be predictive of bypass patency at 12 months, whether assessed in terms of symptoms 
or arterial pressures. However, there is an exception with two reports on studies which 
included patients with claudication as well as those with severe limb ischaemia. In these 
studies low ankle pressure and presence of gangrene were associated with poorer 
patency (Woodburn et al 1996) and claudicants had a superior patency to those 
undergoing bypass surgery for limb salvage (Belkin et al 1995). Angiographic 
assessments of run-off have been associated with long-term patency in earlier studies 
(Budd et al 1990, Woodburn et al 1996), but were not associated in a study restricted to 
CLI patients undergoing distal bypasses with a mean follow-up of 18 months (Tordoir et al 
1993).
A pre-operative characteristic of the patients often associated with patency is 
patient gender. This has been reported, though not explained, in previous studies of 
peripheral bypasses (Ramsburgh et al 1977, Magnant et al 1993, Enzler et al 1994, 
Woodburn et al 1996, Luther et al 1997), although one study has also reported the 
opposite finding (Shah et al 1988) and one study has reported no difference (Harris et al 
1993). Studies of patients undergoing coronary artery bypass grafting (CABG) have 
reported similar sex-related differences in bypass patency (Tyras et al 1978, Douglas et al 
1981) and in operative mortality (Edwards et al 1998), although one study found the 
incidence of repeat revascularisation greater in women after CABG, but lower in women 
after percutaneous coronary angioplasty (Jacobs et al 1998). It has been postulated that
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sex-related differences in the outcome of CABG might be a result of smaller blood 
vessels in females (Magnant et al 1993). The association of vessel size with gender in 
coronary bypass has been documented (Tyras et al 1978), but no data has been reported 
on the association of vessel size with gender to explain the outcome of peripheral 
reconstructions. Single centre studies have, however, reported an association of vein 
diameter with the patency of reversed vein grafts (Wengerter et al 1990) and of in situ 
vein grafts (Towne et al 1991). These results were reproduced in a prospective study 
with a longer follow-up of five years (Moody et al 1992). However, Wengerter et al (1990) 
failed to find any association of vein diameter with gender. A possible explanation for the 
difference in patencies is a poorer quality of vein conduit available in women. This would 
be consistent with the known higher incidence of venous disease in women (Callam 
1996).
Few other pre-operative characteristics of the patients are consistently shown to 
be associated with bypass patency. Smoking is usually not associated with patency 
(Woodburn et al 1996, Bergamini et al 1991), but this is in contrast to a report of patients 
undergoing difficult distal bypasses (Rutherford et al 1988). Age is generally not 
associated with patency (Luther et al 1997), an exception being the series of Woodburn 
et al (1996). The usual lack of association of outcome with age may be attributable to the 
selection of patients well enough to undergo surgery.
Diabetic patients have more distal atherosclerosis (Rosenblatt et al 1990, 
Menzoian et al 1989) and have been reported to fare worse clinically after peripheral 
bypass grafting compared to non-diabetics (Rosenblatt et al 1990, Fowl et al 1989), but 
the literature does not support a poorer graft patency in diabetic patients. No influence of 
diabetes on patency in vein grafts was reported in three large series of patients mostly 
with CLI and tibial grafts (Bergamini et al 1991, Hurley et al 1987, Jensen et al 1992), 
although a poorer patency in diabetic women mostly with vein grafts has also been 
reported (Luther et al 1997). In contrast, another study found a superior patency with 
diabetic patients in vein grafts (Rutherford et al 1988). This may also be a consequence 
of patient selection, diabetic patients with poorer distal arterial run-off being excluded 
from surgery due to a poorer prognosis.
Factors influencing clinical outcome
In contrast to bypass patency, limb survival has been associated with disease severity. 
Fontaine stage, representing the severity of symptoms, has been found to be associated 
with the major amputation rate (Dietzek et al 1990, Fowl et al 1989) and patient survival 
(Rafferty et al 1987, DeWeese et al 1977). Thus disease severity may be more important
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in determining clinical outcome than the technical outcome of distal bypass surgery. 
Diabetes mellitus has previously been reported to be associated with increased mortality 
(Kalman et al 1997) and not associated with major amputations in infra-inguinal vein 
bypass procedures (Jensen et al 1992, Hurley et al 1987). Other authors, however, have 
reported a higher amputation rate in diabetic patients (Kantonen et al 1998, Rosenblatt et 
al 1990, Rutherford et al 1988).
As in bypass patency, female gender has been found to be associated with a 
poorer limb survival in a study of infra-inguinal grafts (Woodburn et al 1996), which found 
a poorer outcome in women. The same study also reported associations of a good 
ciinical outcome with aspirin use.
Intercentre differences
Published results in peripheral bypass surgery from individual surgical centres show 
considerable variation in the results of femorodistal bypass surgery (Wyatt et al 1995). 
The individual experience of the surgeon may be important, but other more easily 
quantifiable factors, such as characteristics of the patients selected for surgery, may also 
play a part. The same factors may give rise to differences in results between centres in a 
multicentre trial.
The skill of the individual surgeon may be one of the most important 
factors in the outcome of distal bypass surgery, but it is difficult to measure. One 
indicator of this might be the number of such procedures entered into a study during a 
fixed recruitment period. It might be expected that this would be roughly proportional to 
the number of procedures performed by the surgeon and his recent experience. Data 
from the Finnish national vascular registry indicate that the short term amputation rate 
was lower in centres performing more operations for critical leg ischaemia (Kantonen et al 
1998). However, a survey from the United Kingdom found that centres performing more 
procedures did not have a better success rate (Vascular Surgical Society of Great Britain 
and Ireland 1995). An explanation for greater numbers of patients not being associated 
with better technical and clinical outcomes may be that centres performing fewer such 
procedures are often selecting only those patients with the greatest chance of benefiting 
from the operation (Wyatt et al 1995). The number of procedures performed may 
therefore not on its own be a good indication of a centre’s likely success rate.
Centre differences can play a role within studies in this indication as few 
surgical centres perform a sufficient number of many types of peripheral bypass 
procedure to be able to complete a well powered study in a reasonable period of time
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without cooperating with other centres. There is a need then to establish a common 
protocol which may be difficult without compromising a surgeon’s ability to follow his 
instincts and experience in the individual case.
Graft surveillance
A major contributor to the failure of distal bypass grafts is the development of neointimal 
hyperplasia resulting in stenosis of the graft. This reduces the luminal diameter and 
volume of blood flow through the graft, threatening the improvement in clinical symptoms 
and increasing the likelihood of thrombotic occlusion of the graft. Vein graft stenosis was 
first reported by Szilagyi et al (1973) and duplex scanning of grafts as a means of 
detecting stenoses early was reported by Bandyk et al (1985) in a series of in situ 
saphenous vein grafts and by Mills ef a /(1990) in reversed saphenous vein grafts.
The incidence of vein graft stenoses after distal bypass grafting has been reported 
to range from 14% (Tonnesen et al 1998) to 46% (Brennan et al 1991). Duplex 
ultrasound equipment necessary for scanning vein grafts along their entire length for 
stenoses has become standard in most departments performing femorodistal bypass 
procedures, but vein graft surveillance is not routine at all hospitals and its regular 
application is dependent on the willingness of patients to return for regular follow-up to a 
department where this facility is available.
Differences in reported incidence of stenoses may arise from differences in 
scanning techniques, different definitions of a haemodynamically significant lesion as well 
as differences between centres in their choice of surgical techniques and the type of 
procedures performed. Since the definition of what is considered a haemodynamically 
significant stenosis is sometimes not stated in publications, the importance of this as a 
cause of the disparity between results from different centres is difficult to assess.
There are relatively few reports in the literature of stenoses in prosthetic grafts. 
Although stenoses are known to occur at the anastomotic sites of prosthetic grafts 
(Sottiurai 1990), the value of scanning prosthetic grafts is disputed. It has been reported 
to be ineffective (Lalak et al 1994) and not useful in improving prosthetic bypass patency 
(Lundell et al 1995), but a recent study has reported that velocity gradients from duplex 
scanning are useful for the detection of failing prosthetic grafts (Mawatari et al 1998).
The site of the stenosis varies. In a review of fifteen studies it was reported that 
the distal anastomosis was the least common site of stenosis, in 19% of stenosis cases 
when all of the different series were combined (Golledge et al 1996), although two of the 
studies included in the review did report a majority of stenoses in the distal portion of the 
graft (Thompson et al 1989, London et al 1993). The origin of stenosis in grafts is not
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known. Trauma due to surgical clamping and valve disruption have been proposed, but 
the location of the stenoses and the similarity of stenosis rates with the in situ and the 
reversed vein techniques do not support of either of these hypotheses as the sole cause 
of stenosis. The majority of patients have only single stenoses suggesting that local 
factors are more important than the general condition of the patient (Berkowitz et al 1981, 
Bandyk et al 1987, Moody et al 1992).
Vein quality may be an important factor in the origin of graft stenoses. Pre­
existing abnormalities could explain the focal nature of graft neointimal hyperplasia 
(Panetta et al 1992), and the use of composite vein-vein grafts in patients with poor 
quality veins couid explain the higher incidence of stenoses reported after these 
procedures (Tonnesen et al 1998).
The regular surveillance of grafts allows remedial action to be taken, usually in the 
form of a percutaneous intervention, and has been advocated as a means of reducing the 
number of bypasses occluding and obtaining a higher patency rate in the long term 
(Moody et al 1990, London et al 1993). The value of dilatation of vein graft stenoses by 
angioplasty to improve patency rates is supported by a literature review (Golledge et al 
1996) and by a randomised study comparing routine with intensive vein graft surveillance 
(Bergqvist et al 1996), although no improvement in limb salvage has been demonstrated. 
The decision whether or not to intervene on detection of a stenosis will depend on the 
degree of stenosis. A velocity ratio of 2.0 is often used as the definition of a significant 
stenosis, but evidence has been presented recently for intervention not being necessary 
as long as the velocity ratio is below 3.0 (Olojugba et al 1998). Indeed over forty percent 
of the grafts stenoses reported in that study resolved without intervention.
Summary
It is clear that performing and interpreting studies in peripheral bypass surgery presents a 
number of challenges: ensuring comparability of patient groups in terms of disease 
severity, ensuring that the results have not been prejudiced by imbalance in any of the 
clinical factors which may influence outcome or by intercentre differences in a multicentre 
study.
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2.3. Adjuvant medical therapy in peripheral bypass surgery: A critical
review of the methods and results of published clinical trials
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Introduction
Infra-inguinal bypass surgery is performed for the relief of disabling intermittent 
claudication, ischaemic rest pain and trophic lesions. Areas of severe stenosis or 
occlusion are bypassed with grafts from the iliac or femoral arteries to the more distal 
femoral, popliteal or tibial vessels. The more distal the procedure, the more technically 
difficult the operation, due to the smaller arterial diameter, and the higher the risk of 
failure. As techniques have improved, distal procedures have become more common 
with the aim not only of relieving symptoms, but of avoiding amputation. Many bypass 
grafts are now performed to the below-knee popliteal or tibial arteries.
These below-knee grafts often suffer from a high resistance to outflow due to the 
size and state of the distal arteries. Combined with the greater technical problems 
encountered with anastomoses to small arteries and obtaining sufficient length of good 
quality vein this leads to a lower success rate with femorodistal grafts than with 
femoropopliteal grafts. The European Consensus Document on Chronic Critical Leg 
Ischaemia (European Working Group on Critical Leg Ischaemia 1991) quotes one year 
patency rates of 75% for above-knee femoropopliteal, 70% for below-knee 
femoropopliteal and 70% for femorotibial grafts with autogenous vein. With prosthetic 
grafts the respective figures were reported to be 65%, 60% and 40% at one year.
The causes of bypass failure vary with time and graft material. Immediate 
occlusion of the graft occurring in the first 24 - 48 hours after surgery may be due to 
imperfections in surgical technique (Stept et al 1987) or a failure to establish an adequate 
blood flow through the graft after release of the arterial clamps. Failure to establish an 
adequate blood flow might be a result of poor inflow or poor outflow. Thrombogenicity of 
graft materials is an important cause of failure in prosthetic grafts (Hanson et al 1987) 
and after the first month the development of graft stenosis due to fibrous neointimal 
hyperplasia becomes a major contributing factor to occlusion, particularly in vein grafts 
(Bandyk et al 1987). In the longer term, progression of atherosclerosis can also lead to 
bypass failure (Fuchs et al 1978).
Medical therapy used for the prevention of peripheral bypass failure has been 
reviewed by Lindblad et al (1995) and shown to vary from country to country. This 
suggests that the preference for one treatment over another is not based upon objective 
scientific evidence. One reason for this is the relative paucity of published material. 
Perhaps also for this reason, results of the use of oral medications after coronary artery 
bypass grafting have been extrapolated to use after peripheral bypass grafting. This 
applies particularly to the use of antithrombotic medications. A meta-analysis of
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randomised controlled trials of platelet inhibitors to prevent occlusion of coronary artery 
bypass grafts showed a 41% relative reduction in graft occlusion (Antiplatelet Trialists’ 
Collaboration 1994b). Although there are similarities in the two situations, the differences 
in surgical techniques, haemodynamics, duration of blood exposure to graft surfaces and 
the use of prosthetic materials in peripheral grafts suggest that it would be unwise to draw 
too many conclusions about the value of adjuvant therapy in peripheral bypass from 
results in coronary artery bypass studies (Clagett, 1988).
The purpose of this review is to investigate the strength of the evidence for the 
use of various agents which have been tested as adjuvant therapy in infra-inguinal bypass 
procedures. Some of the studies included were reported after the initiation of the trial 
presented in this thesis. A comparison of the standards in these trials versus those in 
published previously was also made. Trials of iloprost initiated and designed by the 
author were excluded from this review as they are summarised in the next chapter.
Methods
Published studies were identified from computer databases (MEDLINE, EMBASE) and by 
manual searches. Initial key terms employed were: antiplatelet, anticoagulant, 
antithrombotic, peripheral bypass graft, vascular reconstruction, peripheral vascular 
disease, occlusion, clinical trial. Subsequently the names of agents tested in trials 
identified initially were used as keywords for searches of further trials with these agents.
All identified comparative clinical studies of adjuvant pharmacological therapy 
during or after infra-inguinal bypass surgery are included provided that technical or clinical 
success was reported. Studies reporting only surrogate endpoints, such as platelet 
uptake, were excluded, as were those without any comparator group. Features of the trial 
designs and methods were reviewed and the findings for each treatment were 
summarised based on the soundness of the experimental design.
Meta-analysis
A formal meta-analysis was performed of the trials with the most frequently tested agents, 
platelet inhibitors acting on the cyclo-oxygenase enzyme, in order to investigate the 
possible sources of heterogeneity in the results. For each trial included in the meta­
analysis, the reported absolute difference in the percentage of bypasses patent at the end 
of follow-up was identified (active treatment patency rate - placebo patency rate) together 
with its standard error. Where a trial involved more than one active treatment arm this
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difference was calculated for each active treatment. Graphical displays were then used to 
identify which of the following appeared to be correlated with the magnitude of treatment 
benefit: treatment regimen being tested, duration of follow-up, trial size, type of bypass 
materials, level of bypass, severity of ischaemia and proportion of smokers.
Bypass materials were classified as vein or prosthetic, with composite vein- 
prosthetic grafts being classified as prosthetic. The level of bypass was classified as 
below-knee or above-knee. The severity of ischaemia was classified as either intermittent 
claudication or more severe ischaemia characterised by pain at rest with or without ulcers. 
Trial size was included to investigate the possibility of reporting bias. As some of the 
trials involved more than one treatment comparison, trial size for each comparison was 
taken to be the number of patients in the smaller treatment group. This approximates the 
amount of information available and is adequate for the graphical analysis.
Relationships which appeared to be of interest were then investigated further 
using a multiple logistic regression analysis. The data were pooled over all trials for a 
fixed effects analysis. The basic ‘unit’ was the treatment group and all models fitted 
included factors identifying both trial and drug, whether singly or in combination. Where 
the value of a particular covariate was only known for a trial as a whole, it was assumed 
that the value applied equally to each treatment group in that trial. Mean results are 
quoted with standard deviations.
Results
The findings of this review are divided into three sections: the first section looks at 
general aspects of study methods and design, the second section reviews the methods 
and results reported by drug or class of drug and the third section deals with a meta­
analysis of the platelet inhibitor trials.
Review of study methods
A total of 38 publications based on 29 studies were identified dealing with the question of 
adjuvant therapy in infra-inguinal bypass surgery (Table 5). The trials can be broadly 
divided into two types: (1) long-term anti-thrombotic treatment started pre- or post-
operatively and continued until the end of the study follow-up and (2) peri-operative or 
early post-operative treatment for a limited period aimed at reducing early postoperative 
graft failure (up to the time of discharge). The first type includes all but two of the trials of 
antiplatelet agents such as aspirin and most of the trials of anticoagulants (coumarins and 
low molecular weight heparins (LMWH)). The second type includes the trials of dextran
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40 and the prostaglandin E-j, which possess a number of properties suitable for the 
reduction of early graft failure.
Table 5. Treatments and number of comparative studies published
Drugs No. of studies No. of publications
Aspirin (± dipyridamole) 14 16
Ticlopidine 2 3
Other platelet inhibitors 4 4
Oral anticoagulants 5 10
Low molecular weight heparin 3 3
Dextran 40 4 4
Prostaglandin E1 2 3
Patients and surgical procedures
The frequencies with which various criteria for selecting the trial patients were reported 
are given in Table 6. The principal criteria for selection of patients for the studies were 
usually the localisation of arterial disease and the procedure which the patients were 
undergoing. However, there were eight studies in which all infra-inguinal bypass 
procedures were included regardless of the vessels of origin and insertion and five of 
them did not report results of the different types of bypass procedures separately. In 
general the majority of bypasses reported were classified as femoropopliteal (Table 7). 
Three studies were exclusively concerned with below-knee femoropopliteal and 
femorotibial grafts and a further four studies analysed results of them separately. These 
grafts have a higher early postoperative failure rate and four of these six studies were 
trials of short-term peri-operative treatment.
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Table 6. Criteria employed either in patient selection or for performing a separate 
analysis
Criteria for defining patients Frequency
(n=29)
Localisation of procedure 22
Bypass material 17
Severity of ischaemia 5
Poor angiographic run-off 2
Table 7. Selection of patients according to localisation of procedure




Trials including any infra-inguinal grafts 8
Trials including only femoropopliteal grafts 18
Trials including only below-knee 
femoropopliteal or tibial grafts
3
Bypass material was sometimes an additional criterion for entry into the study or the basis 
for separate analysis: vein grafts in eleven studies and prosthetic grafts in seven studies. 
Approximately half of the studies, however, contained a mixture of vein and prosthetic 
grafts with the results in most cases not being reported separately. The severity of 
ischaemic symptoms although usually described was seldom stated as a criterion for 
entry into the study.
Four studies attempted to define higher risk patients by the presence of rest pain 
or trophic lesions and only one study was found in which exclusively patients with 
intermittent claudication were included. Other studies additionally defined patients with a 
higher risk of graft failure by poor run-off, assessed angiographically (Rutherford et al 
1984), or with a suboptimal venous conduit or those undergoing redo bypass procedures 
(Sarac et al 1998).
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Study design
The design characteristics of the studies are described in Table 8. All but two of them 
were prospectively planned studies. The exceptions were comparisons with historical 
controls. Less than half of the studies involved a comparison with a placebo treated 
group and were performed in a double-blind fashion and only one of the seven studies 
comparing two active treatments was double-blind. There was no evidence that the use 
of a double-blind design for trials in this indication is increasing, as the median year of 
publication of open and double-blind studies identified was the same. The allocation of 
patients to treatment group was described as randomised in all prospective studies, but 
descriptions of the randomisation procedures used were lacking.
Table 8. Study designs
Design features No. of studies (n=29)
Prospective recruitment 27






The patency of a bypass graft can be described as primary, if no subsequent 
interventions have been performed to improve or recover graft function, assisted primary 
if the graft has not occluded, but an intervention has been performed to improve graft 
function, or secondary if the graft has occluded, but has been re-opened by subsequent 
intervention. All but one of the studies reported graft patency (or conversely graft 
occlusions) as an efficacy variable. This appeared to be primary graft patency in every 
case, but was unambiguously described as such in only seven of the 27 studies. 
Immediate postoperative graft occlusions were sometimes considered to be surgical 
rather than treatment failures and were excluded from the analysis in nine studies or 
excluded from the study by postoperative randomisation of patients with patent grafts.
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Assisted primary patency was reported in two studies, in one of which it was the primary 
endpoint (Katz et al 1998), and secondary patency was explicitly reported only five times.
Although graft patency was the main study endpoint in 97% of the trials, the 
criteria for determining patency were not always clearly defined. Angiography 14%, 
duplex ultrasound 24%, Doppler pressures 62%, arterial pulses 41% and clinical 
symptoms 55% were used routinely either individually or in combination at follow-up to 
determine graft patency. Angiography or duplex ultrasound were additionally used in 48% 
of studies in order to confirm a suspected occlusion of the graft determined by other 
methods. In almost all trials more than one technique was used. One trial reported the 
review of all records concerning graft patency by a blinded validation committee 
(Becquemin 1997). In 21% of trials no methods were described for the determination of 
patency.
Limb survival rates (or conversely amputations) were reported in five studies and 
patient survival in 15 studies. Since these patients usually have widespread vascular 
disease, incidence of all major cardiovascular events is of interest and was also reported 
in five studies. The outcome in terms of intermittent claudication, ischaemic rest pain and 
trophic lesions was also mentioned in only four studies, although these symptoms were 
the reason for undertaking the bypass operation.
Duration of follow-up
It is frequently a feature of the follow-up of patients after arterial reconstructions that the 
period of observation is not uniform in all patients. In 66% of studies follow-up was 
performed for at least 12 months in at least a proportion of the patients.
The duration of follow-up was standardised for all patients in less than half of the 
studies and was 12 months in the majority of these cases (range 6 months to 60 months). 
In other studies results were reported as Kaplan-Meier plots or life-table analysis with 
follow-up of variable duration within each study. The range of follow-up duration within 
studies was sometimes as great as 2 to 5 years and the mean follow-up duration was 
sometimes less than half of the follow-up period reported. Nine studies concerned only 
short-term treatment and had follow-ups ranging from 3 days to 3 months duration. In the 
remaining studies the minimum duration of follow-up reported was 6 months and the 
maximum in any study 14 years.
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Sample size
The number of patients per treatment group in comparative studies with graft patency as 
the primary endpoint ranged from 14 to 286 with a median of 61. After withdrawals from 
the studies and exclusions from analysis, these numbers were usually somewhat smaller. 
The median group size in studies of prosthetic grafts was 34 patients, in studies of vein 
grafts 86 patients and for studies in which all graft materials were analysed together, 70 
patients. Discrepancies between the number of patients studied and the number of grafts 
studied made it clear that it is common practice to include patients receiving more than 
one graft twice in a study, either randomising once and counting the two grafts 
independently or sometimes randomising the same patient a second time once the first 
observation period was over.
Statistical methods
Analysis of an intention-to-treat (ITT) population was reported as having been performed 
in only ten studies. Reasons for exclusions from analysis given in 11 studies were varied. 
Typical of randomised drug trials in general were withdrawal of consent, use of disallowed 
medication and other medical interventions. Particular to trials involving surgical 
procedures were patients receiving the wrong operation or no operation, additional 
secondary procedures and immediate graft occlusion. In the majority of studies (55%) no 
mention was made of exclusions from analysis.
Statistical comparison of graft patency in the different treatment groups was either 
by chi-squared test on categorical data at individual time-points (16 studies), log-rank 
product estimates based on life-table analysis of patency over time (12 studies), Fisher’s 
exact test (two studies) or analysis of time to graft occlusion (ie. duration of patency) by 
Mann-Whitney U-test in one study. Some studies used more than one method, five 
studies did not report any statistical methods and two papers made no statistical 
comparisons. The varied follow-up durations within studies resulted in sample sizes at 
the end of the follow-up period often being smaller than at the beginning.
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Changes in trial design over time
The trial presented and discussed in this thesis was commenced in 1990. However, ten 
of the studies included in this review were reported after commencement of this trial. As 
mentioned previously, there was no increase in the use of a double blind design over 
time, only three of the ten studies reported after 1990 used such a design and only two 
used a placebo control. However, the use of a multicentre design did appear to increase 
with five of the eight truly multicentre studies (>2 centres) being reported after 1990. The 
sample size was correspondingly larger in the later studies: a median of 104 patients per 
treatment group in the later studies compared to 50 patients prior to 1990.
Review of treatments
Aspirin
The most studied agent for the maintenance of vascular patency in peripheral bypass 
grafts is aspirin. Sixteen publications were identified in which the results of fourteen 
studies of aspirin alone or aspirin in combination with dipyridamole were reported (Table 
9). Seven of these studies included a placebo control group, three included a comparison 
with an anticoagulant-treated group and four with an untreated control group. Treatment 
allocation was randomised in all studies. The placebo-controlled studies will be 
considered in greatest depth.
Four placebo-controlled studies with a mean treatment group size of 95 patients 
showed a statistically significant benefit of aspirin on graft failure and three with a mean 
treatment group size of 152 patients showed no significant difference. Only one of these 
latter studies found more graft failures in the aspirin group and this difference was not 
statistically significant. One feature which distinguishes all of the positive studies from the 
negative studies with aspirin is the duration of follow-up. Those studies with positive 
results all contained the follow-up data only up to 12 months after surgery. Two of the 
three negative studies analysed data from two to three years follow-up. The daily dose of 
aspirin, which varied from 300mg to 1.5g did not seem to influence the results, and time 
of starting treatment, pre-operatively in five studies and post-operatively in two studies 
also did not seem to be important. The use of dipyridamole together with aspirin had no 
consistent effect.
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Table 9. Comparative studies of aspirin (ASA) and aspirin + dipyridamole (ASA + DP)
Study No. of patients 
(AS A/total)
Design Follow-up Endpoints p-value
Zekert (1975) ASA 119/247 DB, R, PC, S 14 days graft patency n.s.
Ehresmann (1977) 
Boehme (1977)
ASA 215/428 DB, R, PC, M(2) <12 months graft patency p<0.003
Harjola (1981) ASA+DP 93/364 
ASA 92/364
O, R, C, S mean 10 
days
graft patency pO.001 ASA+DP 
n.s. ASA
Green (1982) ASA+DP 16/49 
ASA 16/49
DB, R, PC, S 12 months graft patency p=0.05
Goldman (1983) 
and (1984)
ASA/DP 22/53 DB, R, PC, S 12 months graft patency p<0.05
Kohler (1984) ASA+DP 50/100 DB, R, PC, M(2) 2 years graft patency n.s.
Donaldson (1985) ASA+DP 33/65 DB, R, PC, S 12 months graft patency p<0.05
Satiani (1985) ASA 45/100 O, R, C, S 12 months graft patency n.s.














Waibel (1976) 16/28 0 , R, AC, S 
vs coumarin
6 months graft patency n.s.
Schneider (1979) 30/90 0 , R, AC, S 
vs coumarin
2 years graft patency p<0.05 against ASA
Edmondson (1994) 106/200 SB, R, AC, M(8) 
vs LMWH
12 months graft patency p=0.02 against ASA
Design: DB = double-blind, SB = single-blind, 0  = open,
C = controlled (not placebo), PC = placebo controlled, U = uncontrolled, AC = active control 
S = single centre, M (2) = multicentre (2 centres)
R = Randomised parallel group, H = historical controls
Three placebo-controlled studies included only patients with prosthetic grafts. All showed 
a benefit of aspirin despite treatment group sizes of only 16 to 33 patients (Donaldson et 
al 1985, Goldman et al 1983, Green et al 1982). In contrast, the only study to include 
exclusively patients receiving vein grafts, although relatively large, failed to find a 
significant effect of treatment (McCollum et al 1991). Both absolute and relative 
reductions in occlusion rates were considerably greater in studies with prosthetic 
bypasses (Table 10). This suggests that the benefit of the drug may be greater in
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preventing occlusion of prosthetic grafts, a conclusion supported by an open controlled 
study which found that overall significant differences were largely due to an effect in the 
prosthetic grafts included (Clyne et al 1987).
Table 10. Change in incidence of occlusions according to bypass material in controlled 
















Prosthetic only 4 64 -39 -71
Any material 7 22 -9 -39
Vein only 1 33 -3 -9
All studies 12 37 -10 -32
The lack of significant benefit in studies with longer follow-up could reflect a real loss of 
benefit over time, perhaps due to disease progression, or poorer compliance with the 
treatment regimen in a longer study, or it may be a consequence of the life-table analysis 
of patients with different follow-up durations. Another factor was highlighted by Franks et 
al (1992) who showed that compliance with aspirin therapy was poor enough in one large 
study (McCollum et al 1991) to influence the statistical conclusions. In this case it could 
be concluded that the trial results accurately reflect the value of prescribing aspirin to a 
population, but do not reflect the value of the drug to an individual patient who diligently 
takes the treatment.
The results of the controlled studies with aspirin stand up to scrutiny of the trial 
methods in most respects. All were randomised and most were double-blind. Follow-up 
was in most cases for at least 12 months. There was a tendency for smaller studies and 
those with the shorter follow-up to be more positive for aspirin, but this may have been 
related to the predominance of prosthetic grafts in the smaller and shorter studies. The 
failure of the largest placebo-controlled study to show a significant difference may have 
been related to the factors already mentioned, but it is also notable that this was the only 
truly multicentre study amongst the placebo-controlled studies. The studies included 
mostly or sometimes exclusively femoropopliteal grafts and only one study (Green et al
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1982) reported results for below-knee grafts separately. These data were favourable, but 
not statistically significant.
Cardiovascular mortality was significantly lower with aspirin treatment in one 
placebo-controlled study (McCollum et al 1991), but overall mortality was not. Amongst 
the other double-blind studies, the number of deaths was too small due to shorter follow- 
up or a smaller sample size to reach any firm conclusions on an effect on survival.
In spite of the generally larger size of the negative studies, a meta-analysis 
including mostly the same placebo-controlled studies has shown that in general there is a 
significant benefit of aspirin on graft patency in peripheral arterial reconstructions 
(Antiplatelet Trialists' Collaboration 1994a), although this meta-analysis also included a 
small number of patients undergoing thrombo-endarterectomy. Comparisons of aspirin 
with anticoagulant therapy after peripheral bypass surgery have been made in three 
studies, two of which found greater benefit with anticoagulants. All of these studies were 
randomised, but none of them was double blind.
Ticlopidine
Two controlled trials of the platelet inhibitor, ticlopidine, in peripheral bypass grafts have 
been reported (Table 11). The open, controlled trial (Shionoya et al 1990) showed 
treatment benefit only in a subgroup of patients with hyperlipidaemia and not overall or in 
a number of other subgroups analysed. The second trial published had a multicentre, 
double-blind, placebo-controlled design and showed a significant treatment benefit up to 
two years in terms of graft patency whether analysed by life-table techniques or by 
intention-to-treat analysis of patients alive with primary or secondary graft patency 
(Becquemin 1997). In the ITT analysis the primary patency was 66% with ticlopidine 
compared to 51% in the placebo group. This study concerned only patients with 
saphenous vein grafts (39% of which were femorotibial grafts) and included objective 
confirmation of graft patency, providing strong evidence of the efficacy of ticlopidine in the 
maintenance of vein graft patency. No data in prosthetic grafts or on comparisons with 
other agents are currently available.
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Table 11. Comparative studies of ticlopidine
Study No. of 
patients
(active/total)
Design Follow-up Endpoints p-value
Shionoya (1989) + 
Shionoya (1990)
112/220 0 , R, C, M(8) 2 years graft patency n.s.






Design: DB = double-blind, SB = single-blind, O = open,
C = controlled (not placebo), PC = placebo controlled, U = uncontrolled, AC = active control 
S = single centre, M (2) = multicentre (2 centres)
R = Randomised parallel group, H = historical controls
Other platelet inhibitors
Studies of platelet inhibitors other than aspirin and ticlopidine in this indication included 
two controlled studies of sulphinpyrazone, and one of indobufen (Table 12). Dipyridamole 
was included as an addition to aspirin in ten studies (included in a previous section) and 
also tested alone against aspirin and control groups in one study with a short follow-up 
(Harjola 1981). This open study of a variety of arterial reconstructive procedures showed 
a small, but not statistically significant reduction in graft occlusions with dipyridamole 
compared to an untreated control group (6% dipyridamole v 14% control).
The two studies of sulphinpyrazone were both placebo-controlled, double-blind 
and randomised. They included 232 patients in total and both reported follow-up of over 
85% of the patients entered. There was no reduction in graft occlusion in either study. 
The larger of the two studies included aortoiliac as well as femoropopliteal procedures, 
but 137 out of 164 cases followed up were femoropopliteal procedures. Both vein and 
prosthetic bypasses were included and stratification was employed at the time of 
randomisation. The other study included only 6% prosthetic grafts and reported a very 
low failure rate (15%) even in the placebo group. Despite the performance of controlled 
trials with sulphinpyrazone and dipyridamole, there is currently no firm evidence to 
support their use in this indication. The size of the trials, the small number of prosthetic 
grafts included and the number of graft occlusions reported could, however, have resulted 
in a worthwhile clinical benefit being missed.
Another platelet inhibitor working by cyclo-oygenase inhibition, indobufen, was 
compared in one study with aspirin in a double-blind multicentre study of 12 months
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therapy in 113 patients with PTFE grafts. Indobufen was not shown to offer any 
advantage over aspirin (patency 60% indobufen v 52% aspirin) and there are no reports 
of placebo-controlled studies with this agent.
Table 12. Comparative studies of platelet inhibitors other than aspirin
Study No. of 
patients
(active/total)
Design Follow-up Endpoints p-value
Dipyridamole 
Harjola (1981)
93/364 0 , R, C, S mean 10 days graft patency n.s.
Sulphinpyrazone 
Blakely (1977)






27/54 DB, R, PC, S 6 months graft patency n.s.
Indobufen 
d'Addato (1992)
56/113 DB, R, AC, M(9) 12 months graft patency n.s.
Design: DB = double-blind, SB = single-blind, O = open,
C = controlled (not placebo), PC = placebo controlled, U = uncontrolled, AC = active control 
S = single centre, M (2) = multicentre (2 centres)
R = Randomised parallel group, H = historical controls
Oral anticoagulants
Studies have been reported with various coumarin derivatives as long-term prophylactic 
anti-thrombotic treatment. These are summarised in Table 13. A total of five different 
studies of patients receiving coumarins after peripheral bypass surgery appear to have 
been performed. In two studies successive reports have been published with either 
extended follow-up or increased numbers of patients. This was possible because none of 
the studies was double-blind and placebo-controlled.
Of the five studies, one included a total of only 28 patients in a comparison with 
aspirin, too few patients to demonstrate whether the effect observed was likely to be 
genuine. Another study with 30 patients / treatment group did show a superior effect to 
aspirin on graft patency after 2 years (p<0.05) in patients receiving femoropopliteal vein 
grafts. The two largest studies had similar sample sizes and both had untreated control 
groups, but reported contradictory results after 5 year follow-ups. A Swedish study failed 
to find any significant differences in graft patency (46% coumarin v 42% control), limb 
salvage or patient survival (Arfvidsson et al 1990). A variety of reconstructions were
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studied including both vein and prosthetic bypasses. In contrast, Kretschmer et al (1988) 
reported a significant improvement in patient survival with coumarin, but did not appear to 
have shown a significant effect on graft patency after 5 years (82% coumarin v 71% 
control). However, earlier and later analyses of what was probably largely the same 
group of patients with a shorter and longer follow-up did show a significant reduction in 
graft failure (Kretschmer et al 1986 and 1996). Only femoropopliteal vein grafts were 
included. Anticoagulant treatment in the different studies was instituted at varying times 
between 1 and 14 days post-operatively.
The last and most recent study demonstrated a significant benefit of long-term 
warfarin when added to aspirin in the treatment of high risk vein grafts, those with poor 
run-off poor quality vein or re-do procedures (74% warfarin v 51% control). The benefit 
was evident in both graft patency and limb salvage despite a small sample size of 64 
grafts in 56 patients (Sarac et al 1998).
Blinding investigators in studies with oral anticoagulants is clearly difficult due to 
the need to monitor the anticoagulant effect. However, one double-blind study has been 
reported in patients with arterial disease, in which the anticoagulant treatment was 
monitored at a different centre from that monitoring the clinical outcome (de Smit et al 
1987). Unfortunately, this study did not include patients with infra-inguinal bypasses. 
Without such studies of graft patency and in view of the rather mixed results published so 
far, the case for using oral anticoagulants routinely for the maintenance of peripheral 
bypass patency does not seem to have been proven. The evidence in their favour to date 
has been obtained only in vein grafts.
Low molecular weight heparin
Two comparative trials of subcutaneously administered low molecular weight heparins 
(LMWH) have been reported in this indication. These were open randomised 
comparisons of dalteparin sodium with aspirin plus dipyridamole in 200 patients 
undergoing femoropopliteal bypass (Edmondson et al 1994) and of enoxaparin with 
unfractionated heparin (UFH) in 201 patients with below-knee grafts (Samama et al 
1995). In the former study most patients received prosthetic grafts (73.5%) and had an 
above-knee distal anastomosis (69%). There was an absolute difference in primary 
patency of 15.4% in favour of LMWH at 12 months (aspirin rate 72%). This was 
significant on a log-rank test, but further investigation of the different indications for 
surgery showed that the difference was large in patients with severe ischaemic symptoms
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(36%) and very small in those with only claudication (5%). The difference in indications 
was independent of other factors which might have influenced outcome.
Table 13. Comparative studies with oral anticoagulants and low molecular weight 
heparins (LMWH)




Design Follow-up Endpoints p-value
Waibel (1976) 
and (1981)






Schneider (1979) 30/90 O, R, AC, S 2 years graft patency p<0.05
Kretschmer (1986) 34/71 O, R, C, S 18 months graft patency p<0.04
and (1987) 42/88 30 months graft patency p<0.03




























94/200 SB, R, AC, M(8) 12 months Primary patency p=0.02
Samama (1995) 101/201 0 , R, AC, M(14) 30 days graft patency p=0.025
McMillan (1997) 28/69 0 , H, AC, S 30 days graft patency n.s.
Design: DB = double-blind, SB = single-blind, O = open,
C = controlled (not placebo), PC = placebo controlled, U = uncontrolled, AC = active control 
S = single centre, M (2) = multicentre (2 centres)
R = Randomised parallel group, H = historical controls
The latter study looking at enoxaparin, consisting mostly of vein grafts (68%) with a 
majority below-knee (90%), followed the patients for only 30 days, but showed a 
significant absolute reduction of 13% in the number of occlusions (patency in LMWH 89% 
v UFH 76%). Another smaller study with enoxaparin which used historical controls and
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also followed the patients for only 30 days did not show any difference in graft occlusions, 
but reported a very low 4% overall failure rate despite including mostly prosthetic below- 
knee grafts (McMillan et al 1997). No double-blind trial with a LMWH has been reported.
Dextrans
Dextrans have been investigated as an intravenous infusion given intra-operatively and 
for three days after surgery (Table 14). Graft patency at 3 days (Waibel 1976) and one 
week (Rutherford et al 1984) after surgery has been shown to be improved by dextran 40 
in comparison with an untreated control group or in addition to standard intra-operative 
treatment with heparin. The second of these two studies was a randomised, multicentre 
trial, but neither study was conducted in a double-blind fashion. The benefits found by 
Rutherford et al (1984) were evident only in grafts to the tibial or peroneal vessels and 
were not seen in autogenous vein grafts. Over two hundred patients were randomised 
into this study, but 26% were excluded from the efficacy analysis. Only a one month 
follow-up was reported initially (patency 85% dextran v 79% control) and a later 
publication on the patient population of the trial confirmed that no long-term effect on 
patency was observed (Rutherford et al 1988). A more recent single centre study in 
reversed vein grafts confirmed in an ITT analysis that there was no benefit at 30 days in 
graft patency or in the number of patients alive with a patent bypass (90% dextran v 91% 
control) (Katz et al 1998). Two further studies have been published on this use of dextran 
40: an uncontrolled series of 26 patients with femoropopliteal bypasses (Foster et al 
1966) and a study of dextran 40 alone compared to the combination with warfarin (Kluge 
et al 1972) which suggested that the combination gave better results. This last paper 
reported carefully defined clinical endpoints instead of graft patency, but no mention was 
made of randomisation or blinding.
Two controlled studies suggest an effect of dextran 40 on short-term patency of 
high risk grafts (up to 1 week post-operation), but the largest study was negative in a 
more general population. Studies with a placebo control and a controlled longer follow-up 
are lacking, preventing any firm conclusion from being drawn.
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Table 14. Comparative studies of dextran 40
Study No. of patients 
(dextran/total)
Design Follow-up Endpoints p-value
Waibel (1976) 64/131 O, R, C 3 days graft patency p<0.05






Kluge (1972) ?/43 0 , AC, S 58 months clinical
improvement
p<0.01
Katz (1998) 126/273 0 , R, C, S 30 days graft patency n.s.
Design: DB = double-blind, SB = single-blind, O = open,
C = controlled (not placebo), PC = placebo controlled, U = uncontrolled, AC = active control 
S = single centre, M (2) = multicentre (2 centres)
R = Randomised parallel group, H = historical controls
Prostaglandin E1
In three publications on two studies, prostaglandin E1 (PGE^ was administered for 2-10 
days either intra-arterially or intravenously (Table 15). Both studies included only patients 
with below-knee grafts, but with distal anastomoses on both the popliteal and crural 
arteries. Significant benefit of PGE1 on graft patency or limb salvage was reported in both 
papers in either the distal bypasses or the whole study group. However, neither trial was 
double-blind and only one trial was randomised with a parallel control group (Fietze- 
Fischer et al 1987). The other study employed historical controls (Tanabe et al 1984). 
Short-term benefits were shown in the open parallel-group controlled study with 10% 
reduction in failure at 3 days and a reduction in forefoot and borderline amputations at 
discharge. Primary patency at discharge was 90% with PGE1 and 80% in the control 
group. However, no follow-up after discharge from hospital was reported in these 
patients. A long-term follow-up in a double-blind, placebo-controlled study is still required 
in order to demonstrate any prolonged clinical benefit of early post-operative parenteral 
therapy with PGE<|.
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Table 15. Comparative studies of prostaglandin E1
Study No. of patients 
(PG E/total)
Design Follow-up Endpoints p-value
Fietze-Fischer (1987) 
Gruss (1988)








Tanabe (1984) 28/113 fern-pop 
14/52 fem-tib






Design: DB = double-blind, SB = single-blind, 0  = open,
C = controlled (not placebo), PC = placebo controlled, U = uncontrolled, AC = active control 
S = single centre, M (2) = multicentre (2 centres)
R = Randomised parallel group, H = historical controls
Meta-analysis of platelet inhibitor trials
A meta-anlysis was performed, as described, of all randomised trials of platelet inhibitor 
drugs acting on the cyclo-oxygenase enzyme, aspirin and sulphinpyrazone. This was 
essentially a repeat of a published meta-analysis (Antiplatelet Trialists’ Collaboration 
1994a) with the addition of two additional trials and, importantly, an investigation of the 
sources of the heterogeneity noted amongst the results of these trials.
Eleven trials were identified which satisfied the criteria for inclusion, being 
randomised, prospectively planned and with a concurrent control group not receiving any 
antithrombotic treatment. These trials are listed with the principal data which were 
included in the analysis (Table 16). The trials were published in the period between 1975 
and 1991. There was no evidence of an association of outcome with the date of 
publication, i.e. more recent trials were not consistently more, or less, positive than 
earlier trials.
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A 1 9 /1 4 8 2 8 /1 5 0 6 4 1 <1 - 53 - -
Ehresmann
1977






















1 12 100 84 47 55
Comberg
1983
s 4 /2 7 4 /2 7 0 10 1 6 6 31 - -
Goldman
1983
A + DP 7 /2 1 1 9 /2 8 35 14 1 12 100 79 45 81
Kohler
1984
A + DP 1 5 /4 4 1 2 /4 4 -7 10 2 24 30 67 62 -
Donaldson
1985
A + DP 4 /3 3 1 5 /3 2 35 10 1 12 100 0 34 -
Satiani
1985
A 8 /4 5 8 /5 5 -3 7 1 12 37 88 68 63
Clyne
1987
A + DP 1 2 /7 2 2 5 /7 0 19 7 1 12 37 59 80 61
McCollum
1991
A + DP 86 / 286 86 / 263 3 4 48 30 0 60 59 41
* A=aspirin, DP=dipyridamole, S=sulphinpyrazone
Five trials compared aspirin alone with a control group and seven trials compared aspirin 
plus dipyridamole with a control group. Two of the trials included both aspirin alone and 
aspirin plus dipyridamole and presented comparisons of each with a common control 
group. One trial was a comparison of sulphinpyrazone with placebo. Nine of the trials 
identified were double-blind, placebo controlled trials previously included in the meta­
analysis and two were open comparisons with an untreated control group which had not 
been included in the published meta-analysis.
Overall the mean results from the comparisons with aspirin alone indicated 17% 
(±24) higher patency with active treatment while the results from comparisons with aspirin 
plus dipyridamole showed 19% (±17) higher patency with active treatment. The dose of 
aspirin used ranged from 300 mg/day to 1500 mg/day. There was no clear relationship 
between the dose of aspirin used in the trial and the result of the trial (Figure 3). The 
difference in outcome between the two treatment groups was 8% (±16) in the open trials 
and a mean of 18% (±20) from the double-blind trials, both in favour of the active 
treatment.
Figure 3. Relationship between daily aspirin dose and 
the difference in patency rates.
Bubble diameter is proportional to the sample size
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The duration of treatment and follow-up ranged from 10 days in one trial to thirty 
months in another. Trials with very short follow-up of less than one month had rather 
small differences between the treatment groups, as did the two with the longest duration 
of treatment period. Those trials with a follow-up duration of 12 months, however, had 
generally good results for anti-platelet therapy resulting in no consistent trend over time 
(Figure 4).
Figure 4. Association of duration of follow-up with 
the difference in patency between the groups.
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The difference in patency rates was greatest amongst those trials with the small 
sample size (Figure 5). There was a weak inverse association of difference in patency 
with sample size, r=-0.55. This did not appear to be related to the number of centres 
recruiting patients. Single centre trials, which comprised the majority of the trials, 
provided both the best and worst results for the active treatment.
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Figure 5. Association of sample size with difference in 




Information on the proportion of patients receiving prosthetic bypass grafts was available 
from nine trials which included ten different active groups. There was a strong 
association between outcome and the proportion of prosthetic bypasses included, with a 
larger proportion of prosthetic grafts being associated with a more favourable outcome for 
anti-platelet treatment. This is shown as a bubble plot to illustrate the sample size 
(Figure 6) and as a scatter plot with standard errors of the differences between the 
patency rates to show the precision of the estimate (Figure 7). The proportion of 













































Figure 6. Association of the percentage of patients with
prosthetic grafts with the difference in patency between the
groups. Bubble size is proportional to sample size.
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Figure 7. Association of the percentage of patients with 
prosthetic grafts with the difference in patency between the 
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Figure 8. Association of the percentage of patients having
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The level of bypass was described in nine trials. The majority of trials included only infra- 
inguinal bypass procedures. There was weak evidence of an association of the 
proportion of above-knee grafts with the result of the trial, more above-knee grafts 
corresponding to a greater benefit of platelet inhibition (Figure 9). Flowever, the 
proportion of above-knee grafts also appeared to be associated with the proportion of 










































Figure 9. Association between the percentage of patients
with above-knee grafts and the difference in patency rates.
Bubble diameter is proportional to sample size.
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Figure 10. Association of the percentage of patients with prosthetic 
bypasses with the percentage of patients with above-knee grafts. 
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The severity of ischaemic symptoms was described in ten trials. In all but one trial a 
mixture of patients with intermittent claudication and those with ischaemic rest pain or 
trophic lesions were included, but the proportion of patients in the trial with severe 
ischaemic symptoms did not appear to be associated with the efficacy of platelet 
inhibitors. Only seven of the trials reported the number of current smokers included and 
no clear relationship was discernible between the proportion of such patients in the trial 
and the efficacy of aspirin.
Multiple logistic regression analysis confirmed the overall benefit of platelet 
inhibitor treatment, but also confirmed that the trial results were heterogeneous. Inclusion 
in the analysis of information on the proportion of patients in each trial receiving prosthetic 
bypass grafts indicated that this was a significant source of the heterogeneity in the 
outcomes. The analysis indicated that the sample size of the trials was a less significant 
contributor to the heterogeneity observed and neither the treatment regimen used nor the 
level of bypass contributed significantly to the differences between the trials in this 
analysis.
The logistic regression analysis was repeated with subsets of the trials in order to 
test the robustness of the conclusions. Exclusion of the open and single-blind trials not 
previously included in the published meta-analysis and exclusion of the single trial using 
sulphinpyrazone each failed to alter the conclusion that the proportion of prosthetic grafts 
in a trial was a significant source of the heterogeneity of the trial results. The 
effectiveness of platelet inhibitors in reducing peripheral bypass occlusion was strongly 
associated with the proportion of patients having prosthetic bypass grafts.
Discussion of meta-analysis results
A conclusion of the previously published meta-analysis of platelet inhibitor trials in the 
maintenance of vascular patency was that such therapy was effective in reducing the 
number of occlusions in vascular reconstructions (Antiplatelet Trialists’ Collaboration 
1994). However, previous work has shown that graft occlusion is influenced by a number 
of factors (Bergamini et al 1991, Sayers et al 1994) and the principal mechanisms of graft 
failure are considered to differ according to the graft material (Bergqvist 1985).
Subgroup analysis of patients with vein and prosthetic bypass grafts in one of the 
trials included in this review indicated the possibility that aspirin might be principally of 
benefit in patients receiving prosthetic grafts (Clyne et al 1987). Those findings are 
supported by this review, which suggests that the evidence for a benefit of platelet 
inhibition in the maintenance of vein graft patency is weak.
58
The evidence in this analysis for the prosthetic grafts being the source of positive 
results with aspirin in these trials is complicated by two possible confounding factors. The 
sample size of the treatment groups and the type of bypass procedure performed, above­
knee or below-knee, were also associated with both the outcome and the use of 
prosthetic graft material. It is possible that sample size was the important factor and that 
there is a more pronounced publication bias in small, single centre trials leading to non­
publication of small negative trials. However, the evidence of subgroup analyses from 
various trials suggests that the positive results were likely to have been due to the use of 
prosthetic grafts. The smaller size of the trials including only patients with prosthetic 
grafts is probably due to the smaller number of such procedures performed in most 
centres when compared to the number of vein graft procedures. The association of the 
proportion of prosthetic grafts used with the level of the bypass procedure is to be 
expected, since prosthetic materials are rarely used in below-knee procedures due to the 
generally better results obtained in long bypasses to the smaller arteries with autogenous 
saphenous vein (European Working Group on Critical Limb Ischaemia 1991). A poorer 
outcome from anti-platelet therapy in more distal grafts could result from a greater role of 
poor run-off in the failure of these procedures, which would not be expected to be 
affected by antiplatelet therapy. Previous investigations of a relationship between the 
level of bypass and the efficacy of anti-platelet therapy have, however, failed to show any 
difference in results between above and below-knee procedures (Kohler et al 1994, 
Ehresmann et al 1977).
It has been postulated that the outcome of the largest trial exclusively in vein 
grafts (McCollum et al 1991) was confounded by poor compliance in the aspirin group 
and uncontrolled use of aspirin in the control group (Franks et al 1992). This could also 
have been true of other trials. However, in this context it should be noted that over the 
period in which these trials took place there was no consistent trend for a reduction in 
difference between aspirin and placebo, although the prescription of aspirin as an anti­
thrombotic agent has probably increased in this period.
The aspirin trials in this review are the same as those previously included in a 
meta-analysis with the addition of one single-blind trial (Satiani 1985) and one open, 
controlled trial (Clyne et al 1987). The likelihood of bias in open or single-blind trials would 
usually dictate that only double-blind, placebo-controlled trials should be included in such 
an analysis. However, both the trials included were otherwise well designed and the 
principal outcome variable of bypass patency was objectively verifiable making bias less 
likely. Exclusion of these trials did not change the conclusions of the present analysis. 
The previous meta-analysis also included three trials of other platelet inhibitory drugs.
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Two were excluded from this review, because one of them concerned principally patients 
undergoing thrombo-endarterectomy and the other was published only as an congress 
abstract with too little information for a satisfactory analysis of the trial methodology. One 
trial of sulphinpyrazone in peripheral bypass procedures was included in this review. 
Exclusion of the sulphinpyrazone trial did not alter the statistical conclusions.
The analysis of differences between the results of trials in this area is 
constrained by the rather small number of randomised controlled trials. However, there 
are sufficient data to demonstrate that the results of meta-analysis of anti-platelet therapy 
with cyclo-oxygenase inhibitors such as aspirin for prevention of graft failures should not 
be applied indiscriminately to all peripheral bypass procedures, since the reduction in 
bypass graft occlusion obtained was strongly associated with the proportion of prosthetic 
grafts included in the trial. It is important that clinical trials are designed to investigate 
separately the efficacy of platelet inhibition in vein and prosthetic bypass grafts. The 
value of aspirin in the general reduction of cardiovascular morbidity and mortality 
(Antiplatelet Trialists Collaboration 1994a) is not challenged by this result, however, only 
its value in preventing vein graft occlusion.
The greater efficacy of aspirin in preventing occlusion of prosthetic grafts may be 
due to the greater thrombogenicity of prosthetic grafts. In contrast to the trial results with 
aspirin, a recent trial in femorodistal vein bypass grafts with a different type of inhibitor of 
platelet aggregation, ticlopidine, has shown a significant effect of the drug in reducing 
bypass occlusion (Becquemin 1997). Ticlopidine is thought to act by reducing ADP- 
induced platelet aggregation, whereas the action of aspirin is to inhibit platelet 
aggregation by the inhibition of thromboxane A2 production. In vitro tests indicate a more 
greater effect of aspirin on collagen and arachidonic acid induced platelet aggregation 
than on that induced by ADP. This suggests that different types of antiplatelet agents 
may be appropriate in different types of grafts.
/
This analysis also serves to reinforce the argument that plausible sources of 
heterogeneity should always be investigated when undertaking a meta-analysis. 
Sometimes this aspect is not fully investigated arguing that there is usually insufficient 
power to detect heterogeneity through formal statistical testing. However, it has been 
argued that sensible investigation of sources of heterogeneity involving statistical testing, 
graphical display and clinical insight should increase the scientific and clinical relevance 
of the analysis (Thompson et al 1994). Ideally, this meta-analysis would have been 
carried out using patient level data. These were not available and so some further 
assumptions and approximations were necessary. Nevertheless, the level of 
heterogeneity present in this situation could still be identified using standard multiple
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logistic regression models. Absence of patient level data therefore should not preclude 
such investigations.
In summary, further analysis of the studies in peripheral bypass grafts does not 
support the conclusion that antiplatelet agents are effective in all types of bypass grafts. 
This analysis also exemplifies the importance of examining potential sources of 
heterogeneity as part of a meta-analysis and shows that this can be a useful source of 
information on the value of pharmacotherapy in the maintenance of peripheral bypass 
grafts.
General discussion of the literature review
Certain design characteristics are clearly desirable in clinical trials of adjuvant therapy in 
bypass surgery. The presence of a placebo control group and the use of a double-blind 
randomised design are general requirements for proof of efficacy of a new treatment 
which are applicable in this indication. Well-defined patient groups, adequate sample 
size, relevant endpoints and intention-to-treat analysis are also important. As an 
alternative to a placebo control, a recognised active treatment could be used as a 
comparator. Aspirin would seem to be the most acceptable here, particularly in prosthetic 
grafts.
It might seem that the use of blinding in assessment of outcomes is unnecessary 
when the main study endpoint is graft patency, since this can be objectively determined 
and verified. However, an important benefit of blinding the clinicians performing a study is 
to ensure the impartial allocation of patients to treatment group. With the presence of 
other factors, such as bypass material and indication for surgery, which can influence 
outcome, this is essential to be sure that an unbiased result has been obtained. The use 
of randomisation without blinding is not a guarantee of this since there are always 
patients who are considered for entry into a clinical trial, but who are ultimately not 
entered for one reason or another. Knowledge of the treatment to be given could 
influence this decision.
Half of the trials reviewed here did not have a double-blind design. These were 
most commonly trials of anticoagulants, dextran 40 and prostaglandin E.,. The lack of 
blinded studies of these agents seriously undermines the value of the evidence in their 
favour. In the case of coumarins, the requirement to monitor the prothrombin time 
regularly throughout the period of treatment makes complete blinding genuinely difficult, 
but not impossible, as demonstrated by the study of de Smit et al (1987). The solution in
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that study was to have the patients assessed by observers who were not involved in the 
administration and monitoring of the study drug. Dextran 40 and prostaglandin E  ^ are 
both administered by intravenous infusion which makes administration of a placebo 
treatment more difficult practically and ethically, although similar problems have not 
prevented the conduct of placebo-controlled trials of intravenous prostaglandins in other 
indications. Double-blind trials have also been performed with LMWH in coronary artery 
disease despite the need for subcutaneous injections with these agents, demonstrating 
that this should be possible in peripheral vascular trials (Cohen et al 1997). The high 
proportion of double-blind studies amongst those investigating aspirin use gives a greater 
degree of confidence in the results with this agent, although the greater use of placebo 
probably reflects also the greater ease of giving placebos for an oral therapy.
The use of matching placebos help to keep the observer blind as to treatment 
allocation, but a degree of unblinding can occur with some treatments. Examples of how 
this can occur inadvertently are the reporting of typical side-effects such as bleeding 
events in patients on antithrombotic drugs or flushing in patients on some vasoactive 
medications. Unblinding may also occur if additional investigations on the patient reveal 
recognisable effects as in the inhibition of platelet aggregation tests by aspirin. 
Nonetheless, masking the treatment identity is effective in eliminating certain biases from 
patient allocation to treatment group and will reduce, if not completely remove, the 
possibility of bias in assessment of outcome.
Despite the greater failure rate of distal bypass grafts compared to more proximal 
procedures, there have been relatively few studies investigating the use of adjuvant 
therapy specifically in these difficult procedures. There are probably two reasons for this. 
Firstly, distal bypasses are a relatively recent development in vascular surgery, and 
secondly, multicentre trials would usually be required in order to enrol a sufficient number 
of patients. The results of studies in more proximal procedures may also be relevant to 
choosing the appropriate pharmacotherapy for distal bypass, but the results of trials with 
dextran 40, for example, suggest that certain agents may be indicated only in the more 
difficult distal bypasses. Different procedures should therefore be the subject of separate 
trials or a separate analysis specified a priori. The same is true of the different graft 
materials. The graft materials included were mixed in about half of the studies despite 
the commonly held view that the mechanisms of failure may differ in vein and prosthetic 
grafts (Bergqvist 1985). It could therefore be expected that different treatments might 
prove to be appropriate for different materials. Evidence for just such a finding was noted 
in the section on trials of aspirin and confirmed in the meta-analysis. Analysing different
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graft materials together may therefore result in exaggeration of the effect in one material 
or underestimating the effect in another material.
The technical success of the bypass procedure is most clearly demonstrated by 
determining the patency of the graft. However, the clinical outcome is also important and 
it was notable that few studies reported the outcome in terms symptoms of ischaemia or 
the patient's quality of life. This could most easily be assessed by amputation rates, 
which are particularly appropriate when more distal 'limb salvage1 procedures are being 
studied, and by documenting the patient's symptoms in terms of exercise capacity, rest 
pain, analgesia consumption and presence of trophic lesions. In the case of an 
appropriate choice of operation, it might be expected that the clinical outcome would 
correlate with graft patency, but cases of grafts occluding without regression of symptoms 
to their previous severity and patients with patent grafts being amputated are well known. 
The impact of adjuvant therapy on the patient's quality of life should be investigated at 
least in this simple manner. Patient survival, although more often reported than limb 
survival, was also missing from half of the reports reviewed and is of great importance in 
a group of patients who usually have widespread atherosclerotic disease and have a 20% 
mortality rate within one year (Wolfe 1986, Zdanowski et al 1998).
Some of the studies had insufficient power to show any but the most remarkable 
effects on bypass patency. The average primary patency rate at 12 months in the control 
groups in the studies reviewed was of the order of 70%. The mean treatment effect 
shown in the reviewed trials in a controlled study was a 20% absolute improvement in 
patency. A sample size of at least 72 patients per treatment group would be required to 
demonstrate such a difference with only 80% power. With 90% power 92 patients per 
group would be required. A more modest target of an absolute improvement in the 
patency rate of 15% would probably be the most achievable in vein grafts and would 
require respectively 91 or 119 patients per treatment group for 80% or 90% power. An 
improvement of 10% might also be considered clinically worthwhile, but would require 
more patients still. In fact only seven of the 27 trials included more than 90 patients per 
group giving reasonable confidence in the result.
A specific requirement of trials in bypass surgery is a follow-up duration of at least 
12 months which is required to show a clinically worthwhile result. This is should be of 
interest even when the treatment is specifically aimed at reducing immediate graft failure. 
In this case it is important to know if the effect is only temporary or if the whole patency 
curve is shifted upwards. The trials of dextran 40 and prostaglandin E1 failed to address 
the long-term value of the treatment. Results of longer follow-up would also be of
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interest, but the 12 month period encompasses the early post-operative period during 
which the failure rate is greatest and also the time from three to 12 months when grafts 
are at greatest risk from restenosis.
The fate of all patients in a trial should ideally be determined for the whole follow- 
up period reported. However, it is common practice in bypass studies to show Kaplan- 
Meier plots including many patients who have been followed for varying lengths of time 
with the later fate of many patients quite unknown. It is more time-consuming to follow all 
patients for a long period, but this reflects the common tendency to analyse and publish 
results soon after the last patient has been recruited. One consequence of this is that the 
sample size analysed at the end of the follow-up is often substantially less than the 
number of patients entered. It has recently been shown that it cannot be assumed that 
patients whose fate is known are representative of all those entered into a study of distal 
bypass procedures (Jensen et al 1996). Such analysis may seriously underestimate the 
bypass failure rate. Although life-tables and Kaplan-Meier plots are the most widely used 
methods of illustrating the graft patency rate in a patient population, the method is not 
without drawbacks (Underwood et al 1984). Life-tables are of assistance in estimating 
the likelihood of graft patency only in the case that the patient survives up to a given time 
point without undergoing a major amputation. Patients who are lost to follow-up of graft 
patency due to death, amputation with a patent graft or other causes are censored, i.e. 
excluded from the analysis after the interval in which the last patency assessment was 
available. In other words the number of patients represented in the analysis is ever 
decreasing, so that the patency rate quoted at the end of follow-up is not the actual 
percentage of the original population who had a patent graft at the end of the planned 
observation period. There is probably no perfect solution to this problem, but it might be 
of additional value to report the percentage of patients entered who are known to be alive 
with a viable limb and a patent graft at the end of follow-up. This would permit the 
performance of an analysis on an intention-to-treat population without the appreciable 
numbers of missing patients common to the life-table method.
The majority of trials were single centre, and only three truly multicentre, double­
blind, randomised trials have been published. Only one of these showed a difference 
between the treatment groups. This may reflect a real difficulty in performing multicentre 
trials in surgical procedures. Technical factors can vary and are strong determinants of 
outcome. Policy on patient selection for surgery may also vary between centres. The 
combination of these factors increases the difficulty in agreeing protocols for multicentre 
trials and may act as a disincentive to participation. However, the influence of these
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centre differences on outcome also makes it difficult to assess the relevance of the 
results of single centre trials to the general use of adjuvant therapy.
The importance of trial design in the assessment of adjuvant therapy for peripheral 
bypass procedures should not be underestimated. It may not be coincidental that 73% 
(11/15) of the open or single-blind trials reviewed showed a significant effect of treatment 
on graft patency compared to only 43% (6/14) of the double-blind trials. Some of the 
deficiencies in the published studies outlined above have been addressed in the 
recommendations of a committee on reporting standards in vascular surgery (Rutherford 
et al 1997) and it was noted in this review that sample sizes have tended to be higher in 
more recent studies, but there is still considerable room for improvement.
Currently there are few trials which have demonstrated an effect of adjuvant 
pharmacotherapy on peripheral graft patency in an adequately powered, multicentre, 
randomised, double-blind, placebo-controlled design. The current widespread use of 
aspirin and coumarins to maintain the patency of infra-inguinal bypass grafts regardless 
of graft material is not therefore strongly supported by the published trials. The aspirin 
data is strongest in prosthetic grafts and data on coumarins strongest in vein grafts, but 
only the general reduction of cardiovascular events by aspirin justifies its current 
widespread use (Antiplatelet Trialists Collaboration 1994b).
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2.4. An overview of the development of iloprost as an adjuvant medical 
treatment for the reduction of distal bypass graft failure
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Iloprost
Chemical, pharmaceutical and pharmacological properties
Iloprost is a chemically stable analogue of the endogenous locally acting mediator, 
prostacyclin (PGI2). The structure of the compounds is shown below (Figure 11).
Figure 11. Chemical structure of iloprost






Iloprost is stable at room temperatures in a 1 ml aqueous solution of 0.1 mg iloprost, 
0.242mg Tris-(hydroxymethyl)-aminomethane (TRIS), 0.1N hydrochloric acid (to pH 8.3), 
9.0mg sodium chloride and 0.01ml ethanol (96 vol.%). The drug is further dissolved in 
500 ml of physiological saline for intravenous or intra-arterial infusion. Although 
chemically stable, the drug has a short biphasic plasma half-life with an a-phase of 3-4 
minutes and a (3-phase of 20-30 minutes after intravenous infusion. The metabolism of 
the drug is by p-oxidation of the a-side chain to form inactive metabolites. The principal 
pharmaceutical advantage of iloprost over prostacyclin is its chemical stability in solution. 
Prostacyclin needs to be stored in solid form, dissolved in a buffered solution at pH 5.5
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and used within a few hours. Iloprost has the pharmacokinetic advantage that its plasma 
half-life is longer.
Iloprost has been shown to act as an agonist on the PGI2 receptor with some 
additional less potent PGEr like activity. The pharmacological properties of iloprost 
relevant for its use in vascular disease include inhibition of platelet aggregation, dilation of 
peripheral arteries, reduction of activation of neutrophils and reduction of ischaemia- 
reperfusion injury in skeletal muscle (Belkin et al 1990, Schillinger et al 1986).
The minimum plasma concentration for pharmacological activity of iloprost in man 
has been demonstrated to be 100 pg/ml. This plasma level is achieved at steady state 
with an infusion of 0.5 ng iloprost/kg body weight/min. In a 70 kg man this dose 
corresponds to an infusion rate of 10 ml/h. For clinical studies infusion rates of 10 to 40 
ml/h have been used with the upper limit, corresponding to 2.0 ng/kg/min, determined by 
the tolerance of acute side-effects. Typical dose-limiting side-effects are facial flushing, 
headache, diarrhoea, nausea, vomiting and hypotension. They are dose dependent and 
resolve rapidly on reduction of the infusion rate or termination of the infusion.
Studies indicating a desensitisation of platelet prostacyclin receptors to iloprost 
and prostacyclin after continuous infusion of more than 8 hours duration led to the 
adoption of a treatment regimen consisting of 6 to 8 hour daily infusions with a drug-free 
interval of 16-18 hours between infusions (Yardumian et al 1985, Sinzinger et al 1987). 
This practice also proved convenient for the daily working routine in the hospitals and 
allowed treatment on a day patient basis in some cases.
Previous clinical experience with iloprost
A number of large, multicentre, placebo-controlled clinical trials with intravenous iloprost 
in patients with severe peripheral arterial occlusive disease have shown benefit from daily 
6 hour infusions for 14 to 28 days. Improved healing of ischaemic ulcers has been shown 
in both diabetic (Brock et al 1990) and non-diabetic patients (Diehm et al 1989) and relief 
of rest pain in both patients with and without trophic lesions (Bliss et al 1991, Balzer et al
1991). A reduction in major amputations and death in these patients has also been 
demonstrated (Bliss et al 1991, Loosemore et al 1994), but a large study investigating the 
healing of below-knee amputations failed to show any benefit of a 14-21 day treatment 
with iloprost (Dormandy et al 1994).
A number of smaller studies have been performed in patients with intermittent 
claudication using shorter treatment regimens, usually 3-5 days (Hay et al 1987, Muller- 
Buhl et al 1987, Wilkinson et al 1988). The studies have mostly failed to show any 
convincing benefit in this patient population.
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Clinical trials have also been performed in a number of other indications including 
thromboangiitis obliterans (Fiessinger et al 1990), secondary Raynaud's phenomenon 
(McHugh et al 1988, Wigley et al 1994) and primary pulmonary hypertension (Dinh Xuan 
et al 1990) which have all shown clinical benefit with iloprost.
Rationale for the use of iloprost in distal bypass surgery
The benefit of iloprost treatment in patients with ischaemia of various origins is thought to 
be the result of a number of actions of iloprost including the reduction in platelet 
aggregation and vasospasm, improvement in microvascular perfusion and protection of 
the vascular endothelium.
It has been shown that there is a correlation between a high resistance to flow 
through the bypass graft and bypass failure. One component of the resistance in the 
early post-operative period may be a reduction in microcirulatory flow distal to the graft. 
This was thought to be potentially reversible or preventable by administration of iloprost 
during the operation. In addition, the administration of iloprost for a short period post- 
operatively might reduce graft failure through anti-thrombotic platelet inhibitory effects.
Objective of development plan
The objectives of the development plan were to investigate and obtain a marketing 
authorisation for peri-operative iloprost in femorodistal bypass grafts:
(1) by assessment of haemodynamic effects
(2) by establishing long-term influence on patency.
Patients studied
Patients studied were those undergoing femorodistal bypass surgery with the distal 
anastomosis on either the tibioperoneal trunk, the anterior or posterior tibial artery or the 
peroneal artery with the addition of patients having a below-knee popliteal anastomosis in 
one study.
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The haemodynamic investigations were carried out only in patients with 
saphenous vein grafts, but patients receiving both vein and prosthetic grafts were 
included in the studies of bypass patency and the results analysed separately.
Steps in the development of iloprost
Dose finding for intraoperative administration
A dose escalation study was performed in twenty patients undergoing distal bypass 
surgery to investigate the tolerability and safety of iloprost and the dose response for 
improvement of graft blood flow (Shearman et al 1990). The doses used ranged from 
50ng to 5pg iloprost given as a single short infusion (2-3 minutes) into the proximal end of 
the bypass graft after completion of the anastomoses and release of the arterial clamps. 
The drug was given via a cannula through an unligated side branch of the vein graft. 
Blood flow through the graft was recorded for 20 minutes by electromagnetic flow probe 
and systemic blood pressure was recorded via a radial artery cannula.
No measurable change in graft blood flow was recorded with doses from 50 to 
750ng. Doses of 1pg and over produced an increase in flow. A dose response 
relationship was seen for graft blood flow for doses in the range 1pg to 5jug, but doses of 
4pg and 5pg also led to a transient fall in systolic blood pressure of at least 30mmHg.
The 3jLxg dose was considered the optimum dose, producing a mean increase in 
blood flow of 128% 20 minutes after infusion without clinically significant effects on 
systolic blood pressure. The effect was quite dramatic in most cases with a visible 
increase in skin blood flow in the part of the limb distal to the bypass graft in contrast to 
the other leg (Figure 12).
Haemodynamic effects of intragraft administration
Two studies were performed to confirm the haemodynamic effects of intragraft iloprost 
studied by the comparison of iloprost 3pg and placebo (Hickey et al 1991, Smith et al 
1992). Fifteen patients per treatment group were planned in each of the two randomised, 
double-blind parallel group design studies. Graft blood flow was measured by Doppler 
probe and distal resistance calculated.
Iloprost significantly increased graft blood flow for at least 20 minutes after 
injection by 94% and 52% compared to mean changes in the placebo groups of less than 
10%. Mean distal resistance was decreased by 40% by iloprost for at least 20 minutes 
compared to a mean increase in the placebo group (p<0.01). Clinical follow-up of
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patients showed a significant reduction in bypass occlusion after one month (p<0.05) in 
the patients from the two studies combined (Smith et al 1993).
Figure 12. Acute effect on skin blood flow of injection of iloprost into a distal bypass 
graft
Haemodynamic effects of additional post-operative infusion
A comparison was made of the haemodynamic effects of adding a post-operative iv or ia 
infusion or no post-operative infusion to intra-graft iloprost. Twenty-seven patients in an 
open, parallel-group design study were randomised into 3 groups:
• Intra-graft iloprost 3pg + post-operative 8 hour iv infusion up to 2.0 ng/kg/min
• Intra-graft iloprost 3pg + post-operative 8 hour ia infusion into the affected 
artery up to 0.5 ng/kg/min
• Intra-graft iloprost 3pg + no post-operative infusion
Graft blood flow was measured by Doppler probe and values during and after post­
operative infusion compared with those at the end of the operation. Both post-operative 
intra-arterial (p=0.006) and intravenous (p=0.05) infusions increased blood flow during 
the infusion compared to the group receiving no post-operative iloprost infusion. 
Patients receiving post-operative intra-arterial infusions also had higher blood flow at the 
end of infusion compared to the patients not receiving any post-operative iloprost at the 
same time point, eight hours after surgery (p=0.04), but results in the group receiving 
intravenous infusions lay between the other two and were not significantly different from
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either. Although the intra-arterial infusion gave the best haemodynamic effect, it was also 
associated with more practical problems such as graft infection and there was sometimes 
difficulty in finding a suitable side-branch for the cannula. The intravenous post-operative 
infusion was considered to be the preferred option as it appeared to offer a practical 
regimen to sustain the improvement in graft blood flow after the end of surgery.
In order to achieve a long-term improvement in graft patency, it was concluded 
that the best treatment regimen would be an intragraft infusion intra-operatively 
supplemented by daily intravenous infusions for as many days as was practicable post- 
operatively.
Long-term effects of a 3 day treatment regimen on bypass patency 
The effects of iloprost on bypass patency were investigated in two multicentre, 
multinational, double-blind, placebo-controlled studies using a 3 day treatment regimen. 
The treatment comprised 3pg iloprost intragraft infusion intra-operatively and three 6 hour 
iv infusions given post-operatively with the addition of a one hour iv infusion at the start of 
surgery commencing after induction of anaesthesia. Bypass patency was assessed at 
the end of treatment, discharge from hospital (or 14 days, if sooner), 6 weeks, 3 months, 
6 months and 12 months.
The number of patients included in the two studies were 517 and 175. The larger 
study showed no significant differences in vein graft primary patency over 12 months 
(iloprost 53%, placebo 52%), but showed a significant improvement in prosthetic graft 
primary patency at the end of treatment (iloprost 95%, placebo 74%, p=0.01), although 
not at 12 months (iloprost 46%, placebo 42%). Secondary patency results were similar. 
The results of this study are described in more detail (Chapter 4) and form the major part 
of this thesis as well as providing the basis for investigations of trial methodology.
The smaller of these two studies (Data on file, Schering AG, Berlin, 1997) also 
showed no significant difference in the vein graft primary patency at 12 months (iloprost 
55%, placebo 42%), but there was a significant improvement in vein graft secondary 
patency at 12 months (iloprost 73%, placebo 54%, p=0.03). Differences in prosthetic 
graft patency were not significant.
These two studies suggest that although there may be some influence of iloprost 
on bypass patency, the long-term effects of a 3 day regimen may be too small or variable 
to be consistently apparent in studies of this size.
The methodology and results of the larger of these two studies form the basis of 
this thesis and are described and explored in more detail later.
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Long-term effects of a 14 day treatment regimen on bypass patency 
The effects on bypass patency of a 14 day regimen of iloprost were also investigated, but 
this study used an open design with patients allocated according to a randomisation 
schedule to receive either iloprost or heparin/saline infusions. Treatment consisted of 2-3 
jug iloprost as an intra-graft infusion and a 6 hour iv infusion daily for 14 days post- 
operatively. Bypass patency was determined at the end of treatment, 3 months, 6 months 
and 12 months. The number of patients randomised was 424.
Primary and secondary patency rates were marginally higher in the iloprost group, 
but the differences were not statistically significant: primary patency in vein grafts at 12 
months, iloprost 65%, placebo 63%. Although the study is open to criticism due to the 
lack of a double-blind design, these results were consistent with the conclusions drawn 
from the double-blind studies with the 3 day regimen.
Additional studies investigating mechanisms of action and use of iloprost in distal bypass 
procedures
Further clinical studies and investigation were performed with iloprost in peripheral bypass 
surgery in order to investigate pharmacological actions of the drug. These showed that 
platelet deposition in the vein graft and the distal vascular bed was not influenced by 
intra-operative administration (Smith et al 1992), but that capillary swelling in the distal 
microvasculature was reduced by the 3 day iloprost regimen (Thomson et al 1993).
The pharmacokinetics of the 3 i^g intra-graft administration were investigated and 
gave results comparable to those previously obtained with intravenous infusions. This 
confirmed that the prolonged action on distal resistance and graft blood flow was not the 
result of a longer than expected plasma half-life (Watson et al 1997). This study also 
showed an association of the systemic plasma concentration with the transient fall in 
systolic blood pressure seen in some patients.
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Flow chart summarising main steps in the development plan
Dose-escalation, dose finding for intra-graft infusion 
20 patients
Confirmation of haemodynamic effects of single intra-graft infusion 
Two randomised, double-blind, placebo-controlled studies 
30 completed patients in each study
u
Haemodynamic effects of adding post-operative infusions to the intra-graft infusion 
Open, randomised, parallel group study comparing 3 regimens
27 patients
u u u
Long-term effects on graft Long-term effects on graft Long-term effects on graft
patency* patency patency
Multicentre placebo- Multicentre placebo- Multicentre standard
controlled study controlled study therapy comparison
3 day regimen 3 day regimen 14 day regimen
517 patients 175 patients 424 patients
‘ Study described in this thesis
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Discussion of development plan
There are a number of possible pitfalls in the investigation of potential adjuvant therapies 
in this indication: the choice of surrogate endpoint for early trials, dose-finding and the 
choice of treatment regimen, heterogeneity of patients and procedures, and the 
extrapolation of results of early trials to large multicentre trials.
Graft blood flow as a surrogate endpoint for bypass patency
Patency of the bypass graft as a clinical trial endpoint suffers from a number of 
disadvantages. Even in the relatively high risk group of patients receiving distal 
bypasses, occlusions do not occur with a high frequency in a short follow-up period. Any 
effect of therapy is also only of clinical relevance if it is sustained over at least 12 months. 
These two factors mean that treatment group sizes of over a hundred and follow-up 
periods of at least one year for all patients are necessary in order to demonstrate the 
effects likely to be seen with an adjuvant treatment. An intermediate or "surrogate" 
endpoint is therefore desirable and can be justified on practical, ethical and financial 
grounds.
There is currently no widely used or accepted surrogate endpoint for graft 
patency. This is partly due to the multifactorial nature of graft failure. Prevention of 
myointimal hyperplasia and graft stenosis will not help to predict the outcome of a graft in 
which the cause of failure is unsatisfactory runoff, for example.
In the development of iloprost as an adjuvant therapy, the intragraft dose, the 
route of administration post-operatively and the decision to investigate a long-term effect 
on graft patency were made on the basis of an effect on distal resistance and graft blood 
flow. In effect, these variables were used as surrogate endpoints. It has been suggested 
that the choice of a surogate endpoint should be based on three provisos (Boissel et al
1992). These are that the surrogate endpoint should be easier to assess (e.g. occurring 
more frequently than the clinical endpoint), that there should be a well established 
qualitative and quantitative relationship with the clinical endpoint and that it should be 
possible to derive an estimate of the expected clinical benefit from the change in the 
surrogate endpoint. These criteria undoubtedly represent the ideal situation, but will be 
difficult to satisfy in many disease areas, not least in bypass graft patency.
The first proviso is clearly satisfied in the case of iloprost and bypass patency, 
although the measurability of resistance is limited to the intra-operative period and post­
operative measurement of graft blood flow is not very precise or reproducible.
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Secondly, it is also clear that in the short term there is a qualitative relationship 
between graft blood flow and patency. If the graft is not patent, blood flow will be zero. 
To what extent blood flow is predictive of future patency and clinical improvement, 
however, is less clear. The hypothesis that pharmacological manipulation of outflow 
resistance and graft blood flow could lead to a increased likelihood of graft patency rested 
on the premise that an important component of the initial outflow resistance is amenable 
to long-term improvement. It was hypothesised that a certain proportion of patients suffer 
from a "low reflow" phenomenon after surgery as a consequence of the partial ischaemia 
during arterial clamping during the operation on top of the chronic ischaemic state of the 
lower iimb. The mechanism of the low reflow phenomenon was suggested to be capillary 
swelling, vasopasm and luminal obstruction by activated neutrophils, a breakdown in the 
normal microvascular homeostatic mechanisms (Gidlof et al 1987). In contrast to the fixed 
component of the outflow resistance, due to the number of patent vessels distal to the 
bypass and the degree of stenosis in these vessels, the increased resistance due to the 
state of the microvasculature might be amenable to improvement.
Outflow resistance and graft blood flow have both been investigated for 
their association with graft patency. Ascer et al (1984) found that intra-operative 
measurement of outflow resistance was a good predictor of patency for up to 3 months 
and that transient reduction by papaverine was not associated with an improved likelihood 
of success. This association has been both confirmed (Davies et al 1993) and challenged 
(Peterkin et al 1988) by other studies. Investigations of intra-operative graft blood flow 
have shown that a very low volume flow (Dean et al 1975) and flow velocity (Bandyk et al 
1985, Wilson et al 1988) are predictive of graft failure. The predictive value of 
angiographic runoff, in contrast seems to be more limited (Scott et al 1989).
The third criterion for accepting a surrogate endpoint is not met in this case 
beyond the finding that increasing blood flow above a certain critical level might open up a 
chance of a successful outcome. This, however, would just be supposition.
Iloprost is not the only agent which has been shown to give an immediate increase 
in blood flow through peripheral bypass grafts. Intra-arterial naftidrofuryl (Davies et al
1993), intra-arterial papaverine and oral nifedipine (Karacagil et al 1995) have all been 
shown to have a favourable short-term effect on graft haemodynamics. Epidural 
anaesthesia has also been shown to reduce peripheral resistance and increase graft 
blood flow after distal reconstructions (Hickey et al 1995). None of these agents , 
however, has been investigated for an effect on bypass patency and the effect of 
papaverine, at least, is known to be very transient (Parvin et al 1985). There is, therefore,
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no confirmation from research with other agents that graft blood flow is a meaningful 
surrogate endpoint.
Studies showing graft blood flow and outflow resistance to be correlated with graft 
patency have generally concentrated on early graft failure up to one or three months. 
After this period development of graft stenosis is responsible for the failure of many vein 
grafts and graft thrombogenicity for the failure of prosthetic grafts. The magnitude of any 
effect of 3 days iloprost on graft stenosis development would be likely to be small and the 
antiplatelet effects of the drug are reversible and limited to the duration of infusion. A 
prolonged benefit of the peri-operative iloprost treatment up to one year would only be 
expected, therefore, if the whole patency-time curve is shifted upwards.
It could be concluded that early post-operative graft blood flow as a surrogate 
endpoint is probably useful only in predicting patency up to 3 months. Beyond this time 
other mechanisms of graft failure predominate and these may be influenced by other 
medication taken by the patients. Demonstrating a long-term shift in the patency curve 
on the basis of a treatment designed to improve early post-operative graft blood flow is 
likely to prove difficult. A combination of this approach with administration of long-term 
treatment to reduce the likelihood of thrombosis may be more successful.
Treatment regimen
The pattern of change in graft blood flow after peripheral bypass operations described by 
Cronenstrand et al (1970) showed that almost all patients have a maximum flow 
established through the graft two days after the operation and that most have achieved 
this after 24 hours. The first placebo-controlled study suggested that a single intra­
operative administration of iloprost might be enough to give a prolonged improvement in 
graft blood flow. Although a second study showed a trend in the same direction, the data 
were less convincing and suggested a tailing off of the effect over the first few post­
operative days. Consequently, it was decided to extend the duration of iloprost treatment 
by giving additional post-operative infusions. This had the additional theoretical 
advantage of affording the patients the benefit of an anti-thrombotic effect from the 
inhibition of platelet aggregation by iloprost. However, there was no real dose-finding 
study performed with the post-operative infusions in this indication.
A comparison of the risks and benefits of different routes of administration post- 
operatively indicated that the intra-arterial route, although giving the greatest 
enhancement of graft blood flow, exposed the patient to additional hazards which were 
probably not justified by the potential benefit. There was a concern that the systemic 
plasma levels of iloprost resulting from intravenous infusion might lead to a reduction in
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graft blood flow due to a steal effect. There was no evidence of this, however, and the 
intravenous infusion group showed a maintenance of the high graft blood flow produced 
by the intra-graft injection when compared to the group receiving no post-operative 
iloprost. The 3 day treatment duration was decided upon for purely practical reasons. It 
was thought to be advantageous to give iloprost for as long as possible, but there were 
practical limitations on the duration. Patients are generally mobilised as early as possible 
after distal bypass surgery making intravenous infusions an inconvenience and it is policy 
in some centres to transfer patients to a convalescent hospital within 5 days of the bypass 
operation. Three days was the longest period for which it could be guaranteed that all 
patients would receive uninterrupted treatment.
It is conceivable that a longer period of treatment might have yielded a greater 
benefit. The results of the study with 14 days treatment suggest, however, that 
continuous treatment might be necessary to exert a meaningful effect. This would be 
dependent on the availability of an oral or other more convenient dosage form. Even the 
14 day infusion regimen was accepted by medical staff and ethics committees only in an 
open study, so that patients in the control group did not have to be kept in hospital 
unnecessarily. This aspect of the design of this study unfortunately also reduces the 
value of the results, as it opened the possibility of bias in the allocation of patients to 
treatment groups, choice of additional therapy and assessment of clinical outcome.
The use of an intermittent infusion regimen consisting of daily 6 hour infusions 
was based on small clinical pharmacology studies showing a desensitisation of platelets 
to the inhibitory effect of iloprost and a possible hyperaggregability with sustained 
infusions (Yardumian et al 1985). Despite the theoretical risk this entails, no adverse 
clinical sequelae of prolonged iloprost infusions have been attributed to a prothrombotic 
effect of this kind of administration even with continuous infusion of patients with primary 
pulmonary hypertension for many months. It is perhaps indicative of the importance 
given to risk avoidance in pharmaceutical development that continuous infusions were not 
investigated in this indication, although the principal desired effects, reduction in distal 
resistance and improvement in graft performance, had not been shown to be best 
achieved by an intermittent infusion regimen. There were theoretically possible beneficial 
effects of to be derived from a sustained inhibition of platelet function. These include 
reduced likelihood of thrombosis and reduced release of platelet derived growth factor, 
which has been implicated in myointimal hyperplasia in vein grafts. However, an objective 
assessment of the demonstrated haemodynamic benefits and the likely risks might 
conclude that a continuous post-operative intravenous infusion held the greatest potential 
for improving the outcome of distal bypass surgery.
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Patient selection
The choice of patients undergoing femorodistal bypass surgery as a target group was 
based on the unsatisfactory success rate of the procedures and the perception that there 
was an early post-operative problem in many cases. Femoropopliteal bypasses, in 
contrast, particularly those to the above-knee popliteal artery usually have a better run-off 
and have a much higher success rate with mid-term development of graft stenosis the 
major cause of graft failure. Long bypasses to the dorsalis pedis carry a particularly high 
risk of failure, but are relatively seldom performed and do not, therefore, make an easy 
study population.
The primary interest was to investigate the effect of iloprost in vein grafts. These 
make up the majority of distal bypasses performed. Prosthetic and vein prosthetic 
composite grafts, which are less often used due to their higher failure rate below the 
knee, were thought to be a less attractive target group for short-term iloprost treatment 
since the problem of thrombogenicity of these grafts is not limited to the immediate post­
operative period. The early dose-ranging and haemodynamic studies were performed 
only in patients with vein grafts for these reasons.
The inclusion of both vein and prosthetic grafts in the multicentre studies of graft 
patency was unavoidable due to the adoption of a treatment regimen beginning shortly 
after induction of anaesthesia. At this stage in the operation it is not always clear whether 
it will be possible to use the patient’s own vein for a bypass or whether it will be necessary 
to use exogenous material. Having already started treatment with the study drug when 
this becomes known, the choice for the study designer is to stop treatment of all the 
patients with prosthetic grafts and exclude them from the analysis, or to continue the 
treatment and follow-up and analyse the data from all patients. This latter course was 
chosen, but with the decision being made a priori to analyse the outcome of vein and 
prosthetic grafts separately. This was based on the knowledge that the predominant 
causes of graft failure may differ in vein and prosthetic grafts and the efficacy of a drug 
could not, therefore, be assumed to be the same in both types of surgical procedure.
Statistical power
The two larger studies designed to investigate effects on graft patency were both 
intended to have 80% power (with an a=0.05) to show an improvement in patency at 12 
months from an estimated 75% in the control group to 88% in the iloprost group. The 
smaller patency study had sufficient power only to show a greater difference in patency 
rates and was planned with the intention of using the data in a meta-analysis if no
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difference was found in this study alone. The differences in all studies were in favour of 
iloprost, but were smaller than the studies were designed to detect. The question of 
whether the numerical differences seen are likely to represent a real difference in the 
treatments could be answered only by further larger studies or by a meta-analysis of the 
data from all studies.
Influences on drug development within the pharmaceutical industry 
Any analysis of a drug development programme must take into account the various 
influences which contribute to shaping the development. Medical science, the prior 
knowledge of the drug's properties and the pathophysiology of the condition being 
treated, are only some of these influences. In the case of iloprost as adjuvant therapy in 
distal bypass it could be argued that medical science points to a likely effect of the drug in 
high risk cases.
Distinct from medical science is clinical need. The need in this case is for a 
therapy which has an impact on long-term outcome. Here the desires of the clinicians 
and the marketing departments in the pharmaceutical industry coincide. They both want 
to see a long-term effect. Where these two parties may diverge in this indication is in the 
choice of target population. The clinicians will usually attach the highest priority to 
improving outcome of those cases at greatest risk of failure, the prosthetic grafts or the 
more problematic vein grafts. The marketing departments in contrast would tend to 
prefer a drug to be used more widely, for example in all distal bypasses, and would 
therefore like trials to be conducted in a broader group of patients. A wider use helps to 
meet the pharmaceutical industry’s need to recoup development costs.
A further influence on drug development is time. This is not only because drugs in 
development cost the company money and drugs on the market may earn money. The 
inexorable progress towards the expiry of the patent on a drug means that the rewards 
are potentially greater with an earlier conclusion to a development programme. This time 
pressure often translates into proceeding on the strength of incomplete information to the 
next stage in the development. An example in the iloprost development would be the 
adoption of a treatment regimen for large scale studies which had only partly been tested 
in dose-finding studies in this indication.
In an ideal development programme, the intra-operative dose-finding and the 
choice of dose-regimen would have been more extensively investigated. A more limited 
aim of improving short-term outcome in a more carefully selected high-risk group of 
patients might also have led to a more successful outcome.
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Summary
Following careful review of the literature and of the clinical programme described, it was 
felt desirable to consider how trial design in this area might be improved. The next two 
chapters, chapters 3 and 4, describes the methods and results of the main trial with 
iloprost in detail. These include further analyses performed on this database in order to 
investigate potential improvements in trial design and the determination of outcome.
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METHODS
Contribution of the author to planning and execution of the study
The author was responsible for discussing the results of earlier studies with iloprost 
(described in section 2.4) with a small number of leading vascular surgeons in order to 
determine what evidence would be needed to establish the efficacy of a drug in the 
maintenance of distal bypass patency. Having decided on the need for a large study with 
bypass patency as the primary endpoint, the author proposed a study design and protocol 
which was finalised after discussion with the same small group of clinicians.
The next stages were to design the record forms for data collection and to select 
appropriately experienced surgical centres for the trial. The author was also responsible 
for writing an explanation of the trial for patients and for ensuring that the necessary 
regulatory and ethics committee approvals were obtained for each participating centre. 
The surgeons were then responsible for enrolling patients into the trial.
During the enrolment and follow-up of the patients, the author’s role was to 
supervise a team of data monitors who visited each site at regular intervals in order to 
validate the data being recorded and to take any decisions on questions about the 
conduct of the study which were not answered by the protocol. These mostly concerned 
the suitability of certain patients for inclusion in the trial and the acceptability of 
unanticipated surgical procedures or concomitant medications.
The author worked together with a statistician to agree a statistical analysis plan 
for the data generated and subsequently to agree on the interpretation of the results. 
This analysis, performed by the statistician, covered the principal comparison of iloprost 
and placebo treatment groups described. The analyses subsequently performed on the 
database and described in the later sections of the results chapter were planned and 
performed by the author.
Study design
The design of the study was a double blind, randomised, prospective, multicentre trial for 
the comparison of two parallel treatment groups, iloprost and placebo. There was an 
assessment of the patients one day before treatment, a treatment period of three days 
duration including the day of surgery and a post treatment follow-up period of 12 months. 
The study design is illustrated in Figure 13. Patients were recruited in 21 vascular 
surgical centres from six countries in Northern Europe (Denmark, Ireland, the 
Netherlands, Norway, Sweden and the United Kingdom). Data collection was monitored 
from a co-ordinating centre and validated by reference to original data sources such as 
hospital records. The protocol was submitted to and approved by the appropriate Ethics
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Committee for each of the participating centres and by the regulatory authorities with the 
responsibility for research into new medicines in the respective countries.
Patient were recruited into the study over an 18 month period between September 
1990 and March 1992. Clinical follow-up of the patients was completed a further 12 
months later in March 1993.
Selection of patients
It was planned to study patients undergoing bypass surgery for critical ischaemia with the 
proximal anastomosis above the knee and the distal anastomosis to the tibioperoneal 
trunk, the anterior tibial, posterior tibial or peroneal artery. Critical ischaemia was defined 
as: 1) the presence of trophic lesions or 2) persistent rest pain requiring analgesia for at 
least two weeks plus an ankle pressure of less than 50mmHg, except in the case of 
patients with diabetes mellitus and calcified arteries where absent palpable foot pulses 
were accepted as sufficient evidence of severe vascular disease. This was in accordance 
with the recommendations of the Second Consensus Document of the European Working 
Group on Critical Limb Ischaemia (1991). Patients with only intermittent claudication 
(PAOD Fontaine stage II) or a planned distal anastomosis proximal to the origin of the 
anterior tibial artery were not to be included.
Specific criteria for exclusion of patients for safety reasons were known deficient 
haemostatic function (except where this was the result of treatment with oral 
anticoagulant drugs), active gastrointestinal bleeding and a history of intracranial 
bleeding).
Both male and female patients were included. Informed consent was obtained 
from all patients according to the requirements of the Declaration of Helsinki (Hong Kong, 
1989). Consent was obtained pre-operatively and no study-specific procedures were 
performed on the patients before consent had been obtained. Patients not giving consent 
to participation were not randomised and no data on these patients was recorded in the 
study files.
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Figure 13. Flow chart of study design
Selection of patients pre-operatively
JJ
Randomisation into two treatment groups
U
Iloprost treatment started pre-op. Placebo treatment started pre-op.
I] li
Femorodistal bypass graft operation 
II II
Study medication completed on the second post-operative day
II II
Assessment at 14 days or discharge (if sooner)
U II
Assessment at 3 months 
II II
Assessment at 12 months 
II
Unblinding of study after all data entered into database
U
Statistical analysis of the data
Randomisation procedure
Randomisation of the patient to one of the two treatment groups was stratified by centre 
and performed in the following manner. Each trial centre was given a sequence of 
randomisation numbers in blocks of ten, e.g. 01-10, 11-20. Each block of ten numbers 
contained an equal number of iloprost and placebo treatments.
Appropriate patients were identified pre-operatively. When a patient satisfied the 
entry criteria, the clinician gave the patient the next available number in the sequence. 
This number corresponded with a treatment box containing the iloprost or placebo 
treatment. Each treatment box contained ampoules labelled with the study number and 
randomisation number and nothing to distinguish the iloprost from the placebo ampoules 
without the randomisation code. For each randomisation number the clinician also had a 
sealed envelope containing the treatment allocation. The envelope was only to be
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opened in the case of emergency where knowledge of the treatment received would help 
the management of the patient.
The generation of the randomisation schedule was performed by an independent 
statistician using a computer random number generation programme. The randomisation 
schedule was known only to this statistician and to the pharmacist responsible for 
labelling the study medication appropriately. The study manager, hospital staff, data 
monitors, data entry staff, the statistician who performed the analysis and the patients 
were not aware of the treatment allocation.
Adjuvant drug treatment
Iloprost was supplied as one millilitre ampoules clearly identified with the name of the 
manufacturer, protocol number and patient trial number. The ampoules contained 0.1 mg 
iloprost per millilitre in a sterile 0.9% NaCI solution with the addition of TRIS buffer. A box 
containing five ampoules was provided for each patient in the study. Those ampoules 
containing placebo were labelled in the same way and contained all of the 
aforementioned excipients.
One millilitre ampoules of iloprost or placebo were diluted into 500 ml of 
physiological saline. The treatment consisted of an intravenous infusion up to 20 ml/h for 
1 hour starting after induction of anaesthesia, an injection of 15 ml into the proximal end 
of the bypass graft on completion of the procedure but before skin closure, a 6 hour 
infusion up to 20 ml/h starting 1 hour after the end of the operation and a further 6 hour 
intravenous infusion on each of the two following days up to a maximum of 40 ml/h. The 
treatment schedule is illustrated in Table 17.
The intravenous infusions at the beginning of the operation and post-operatively 
were given via a peripheral line to an arm vein. The infusions were titrated up starting at 
10 ml/h in increments of 10 ml/h at 30 minute intervals to a maximum of 20 ml/h or 40 
ml/h as described. Systemic haemodynamics and side-effects were monitored during the 
infusions. The increase in dose was stopped if side-effects such as headache, nausea or 
muscular cramps supervened and, if necessary, the infusion rate was reduced in steps of 
10 ml/h to a more tolerable level. The tolerated dose was then maintained to the end of 
the stipulated infusion period. A reduction in doses usually allows a rapid resolution of 
any side-effects, but if any of the following symptoms occurred, it was recommended to 
interrupt the infusion until the situation normalised and then to continue at no more than 
half of the flow rate. These were a clinically significant decrease in blood pressure, an 
increase in heart rate above 130 / min. or a vagal reaction with bradycardia, nausea or 
vomiting.
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The injection of 3000 ng of iloprost or placebo into the bypass graft was performed 
after completion of the anastomoses, after removal of the arterial clamps and after a 
completion angiogram, if one was performed. The injection, consisting of 15 ml of the 
solution, was given slowly over a period of 1-2 minutes in order to minimise the acute 
effect on systemic haemodynamics. In the case of vein grafts, the injection was given 
through an unligated vein branch near the proximal end of the graft left for this purpose. 
In the case of prosthetic grafts, the injection was given either through the wall of the graft 
with a fine needle or intra-arterially proximal to the graft provided that the femoral 
profunda artery was clamped to ensure delivery of the drug through the graft.
The infusion rates of 20 ml/h and 40 ml/h were planned to be equivalent in the 
average patient to iloprost doses of 1.0 and 2.0 ng/kg/min, assuming a 67 kg body 
weight, and the intra-graft injection of 15 ml was equivalent to a dose of 3000 ng iloprost.
Table 17. Summary of treatment schedule
Day Procedures
1: Day of operation • An iv infusion of study medication given for 
30 minutes immediately after induction of 
anaesthesia and stabilisation of the patient.
• An injection of 15ml of study medication 
given slowly into the bypass graft after 
establishing blood flow through the graft.
• One 6 hour iv infusion of study medication 
started 1 hour after end of operation.
2: 1 st post-operative day • One 6 hour iv infusion of study medication.
3: 2nd post-operative day • One 6 hour iv infusion of study medication.
Concomitant medications
Peripheral vasodilators for the treatment of critical limb ischaemia were stopped two 
weeks before surgery and were not permitted during the treatment period of the study. 
Papaverine, however, was allowed for diagnostic purposes during the operation. 
Analgesics for the treatment of ischaemic pain were continued as required.
Heparin, oral anticoagulants and dextrans were used both during and after 
treatment with the study substance according to each centre's policy provided that their 
use was recorded. The use of aspirin and other platelet aggregation inhibitors was not 
permitted during the three days of study treatment, but was allowed thereafter according 
to the policy of each individual centre. Peripheral vasodilators and other drugs for the
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treatment of critical ischaemia were not allowed during the study. All concomitant 
medications were recorded.
Pre-operative assessment
Demographic data, past medical history, concurrent illnesses, risk factors and medication 
being taken by the patient were recorded pre-operatively. In addition to recording 
patient’s height and weight, the body mass index and body surface area were calculated 
according to the following formulas:
Body mass index was calculated according to the formula:
Body mass index in kg/m2 = weight in kg / height in metres2.
Body surface area was calculated according to the Dubois formula:
Body surface area in cm2 = V(body weight in kg x height in cm x 167.2).
Clinical status was assessed as shown in Table 18 and according to these symptoms, the 
patient was classified according to Fontaine in stages I to IV of peripheral arterial 
occlusive disease. Each of the ischaemic symptoms were assigned a numerical score 
depending on severity as shown in the last column of Table 18 and these were summated 
to produce a single numerical value between 0 and 6 representing the presence and 
overall severity of ischaemic symptoms.
Table 18. Assessment of clinical status
Parameter Categories Score
Rest pain in the previous 24 hours None 0
Intermittent 1
Continuous 2
Analgesic use in the previous 24 None 0
hours Non-opiate alone 1
Opiate with or without non-opiate 2





Dry and wet 1
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Ankle and brachial Doppler pressures were recorded pre-operatively. Ankle-brachial 
pressure index (ABPI) was calculated. Angiographic run-off was calculated using a 
method which takes into account both the number and state of the vessels distal to the 
graft (Rutherford et al 1986). The run-off was scored between 1 and 10 where 1 
represents excellent outflow and 10 represents no outflow.
Surgical procedures and post-operative management
Technical details of the operation were recorded. These included the leg operated, the 
type of anaesthesia (general, epidural, intradural, local nerve block), location of the 
proximal and distai anastomoses in terms of vessel and level, graft length and minimum 
graft diameter, graft material. Concomitant vascular procedures such as endarterectomy 
in the region of the anastomosis, profundaplasty, the use of a vein cuff or patch to 
improve the distal anastomosis and arterio-venous fistulae were also recorded, as were 
the intra-operative use of angiography, Doppler, Duplex or endoscopy techniques and the 
need for revision of either the proximal or distal anastomoses during the operation.
Information on the post-operative management of the patients recorded included 
the use of glucose and electrolyte infusions, blood transfusion requirements, antiplatelet 
and anticoagulant treatment, graft complications and oedema formation.
Postoperative follow-up
Post-operative follow-up on all patients was 12 months. Graft patency, clinical symptoms 
and Doppler pressures were recorded at 2 days, 3 days, 14 days (or discharge if sooner), 
3 months and 12 months. Assessments of graft patency at 6 weeks and 6 months and 
graft surveillance by duplex ultrasound at all time-points were optional. Graft stenoses 
were considered to be clinically significant if the ratio of blood flow velocity at the point of 
greatest stenosis was at least twice that at another point within 2 cm. The method of 
measurement is described below.
Clinical status and Doppler pressures were assessed in the same manner as pre- 
operatively. Further vascular interventions in the relevant leg including amputations were 
recorded whenever they occurred. The classification of these is described below.
Definition of patency and amputation levels
Primary patency was defined as patency of the graft without any further intervention after 
skin closure in the initial bypass operation. Further intervention to improve bypass 
function without the graft having first occluded led to a definition of assisted primary 
patency, for example if a dilatation of a vein graft stenosis was performed. Successful
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intervention after graft occlusion led to secondary patency. Secondary patency was 
classified as being achieved primarily by surgical or pharmacological intervention. 
Patency of the bypass graft had to be confirmed either by angiography or Duplex 
ultrasound.
Revision of the anastomoses during the original bypass operation before 
administration of the study drug into the graft and before skin closure was not classified 
as a loss of primary patency if it occurred before the patient left the operating theatre. 
Loss of primary patency occurred only when the bypass occluded or had to be revised to 
avoid occlusion after skin closure at the end of the initial bypass operation. Analysis of 
secondary patency rates followed the convention of including all patients with primary, 
assisted primary and secondary patency. Similarly, calculation of assisted primary 
patency rates included all patients with primary and assisted primary patency.
Amputations were classified as major or minor. Major amputations were defined 
as above-knee, through-knee or below-knee amputations in which the ankle joint was not 
retained. Minor amputations were those in which the ankle joint was retained.
Definition of graft stenoses
Graft stenoses were detected by the method of Grigg et al (1988) in which areas of high 
velocity flow within the graft are identified by Duplex scanning along the entire length of 
the graft. The presence of a graft stenosis was defined by an increase in peak systolic 
velocity of >50% over a distance of <2cm along the graft. That is, where V2=velocity at 
the site of stenosis and V.,=velocity in an unstenosed portion of the graft within 2cm of the 
stenosis, the ratio V2 : V1 should be >1.5.
The V2 : V., ratio and % stenosis were recorded together with confirmation of the 
stenosis by intravenous digital subtraction angiography. The relationship of stenosis to 
velocity change is illustrated below (Figure 14) and rests upon the fact that flow in terms 
of volume per unit time must be the same at each point along the vessel and that it is the 
product of the cross-sectional area and velocity at that point.
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Figure 14. Derivation of % stenosis from velocity changes where V 1 is the velocity at an 
unstenosed section of the graft and V2 is the velocity at the stenosis
F lO W
volume flow = cross-sectional area (A) x velocity (V)
r2 = V(r,2xV1/V2)
% stenosis = (r, - r2) / r, x 100 
% stenosis = 100 x [1 - V( V 1 / V2)]
Haemodynamic measurements
In addition to ankle pressures measured by Doppler and the calculation of ABPI, duplex 
ultrasound was used to measure the peak systolic flow velocity in a non-stenosed section 
approximately halfway along the graft. The cross-sectional area of the graft was 
measured and an estimate of mean volume flow through the graft was calculated. These 
duplex assessment of graft function were optional and not performed by all centres.
Adverse events
All adverse medical events were recorded on the basis that it is not always clear which 
events can be attributed to the treatment under test and accurately described as side- 
effects. Events were recorded on each day of treatment. At the time of discharge and at 
subsequent follow-up visits, adverse medical events which had occurred in the 
intervening period were recorded.
On the basis of previous studies the possibility of an acute transient effect on 
blood pressure was known (Hickey et al 1991). Blood pressure and heart rate were
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monitored throughout the administration of the study medication and for a short period 
after each infusion.
Unexpected medical events occurring in the per-operative and post-operative 
periods could also be recorded as surgical complications or as graft complications if they 
were felt to be primarily a result of the surgical procedure.
Summary of assessment schedule 





















X X X X X
Operative & post­
op management
X X X X
PAOD symptoms X X X X X X
Angiography X X
Haemodynamics X X X X X X X
Graft patency X X X (X) X (X) X
Graft stenoses (X) (X) (X) (X)
Adverse events X X X X X X
Footnote: X = assessment required, (X) = assessment optional 
Data collection and management
Data were recorded in triplicate on self-copying case report forms specially designed for 
the study. The three copies of the report forms provided an original for the study co­
ordinating centre, a copy for the study site and a copy for data entry. The completion of 
the forms was monitored according to Good Clinical Practice guidelines and a proportion 
of the data on the forms was checked against the entries in the patient’s hospital notes for 
accuracy. The items checked for all cases included patient’s identification, surgical
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procedures and the principal outcome parameters of patency, amputation and death. 
Entries in the case report forms were made and altered only by the clinical staff at the 
centres.
Visits were made to monitor the data on site prior to collection at six to eight 
weekly intervals. Monitoring was performed by the study manager (the author) or by 
experienced clinical trial monitors from the study co-ordinating centre, which was 
independent of any of the participating surgical centres. The total duration of the data 
collection phase of the study was 27 months.
The data entry and analysis was performed in a blinded fashion. All data were 
entered twice by different data entry clerks and checked automatically for consistency of 
the two entries as well as for internal consistency of data on the same patient from 
different examination dates. Prior to data entry, a plausibility check was programmed, so 
that any implausible data would automatically be rejected unless checked and 
reconfirmed. A final manual check of a sample of the data was performed before locking 
the database and breaking the randomisation code to analyse the data.
Manipulation and analysis of the data was performed using SigmaStat® statistical 
software version 2.03 for Windows® 95 (Jandel Scientific Software GmbH, Erkrath, 
Germany). Graphical displays were generated using SigmaPlot® version 4.0 (Jandel 
Scientific Software GmbH, Erkrath, Germany). The operating system used was 
Windows® 95 (Microsoft, Inc., United States).
Statistical considerations
The primary efficacy variable selected for the trial was primary patency of the bypass 
graft (definition given earlier in this section). It was planned to analyse the patients 
according to graft material, with the primary analysis of interest being the analysis of 
patients with vein grafts. The study sample size was chosen based on the ability to 
detect an absolute difference of 12.5% in primary patency rates between iloprost and 
placebo. Literature review prior to the start of the study suggested cumulative primary 
patency in vein grafts in the control group to be 75%, which resulted in a hypothesised 
87.5% cumulative patency rate for the iloprost group. Calculations were based on a test 
of independent proportions performed with a = 0.05 and (3 = 0.10. A total of 221 
evaluable patients were required per treatment group to demonstrate a difference in 
patency rate between the iloprost and placebo groups.
Statistical analyses were performed on all available data for all patients (intention 
to treat) for whom graft patency could be assessed. Patients were divided into two 
groups for the analysis of patency data: those receiving vein grafts and those receiving
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grafts partly or wholly consisting of prosthetic material. Bypass patency, vascular 
intervention, amputation and survival curves were based on Kaplan-Meier product-limit 
estimates, and overall differences between pairs of curves were compared using log-rank 
tests. Data were grouped according to assessment intervals for patency and in monthly 
intervals for interventions, amputations and deaths. Actuarial (life-table) estimates are 
more commonly used for grouped data, but Kaplan-Meier and life-table estimates are 
nearly identical for these data.
Thirty day months were assumed and conversions to months were used in the 
calculation and analysis of cumulative patency rates (Table 20).
Table 20. Time points used in the calculation of cumulative patency rates
Time point Months
1st day post-operation 0.033
2nd day post-operation 0.067
3rd day post-operation 0.10





Missing values due to death or amputation before loss of patency or loss to follow up are 
all counted as censored data and not treated as failures in the calculation of Kaplan-Meier 
product limit estimates. The analysis makes use of this censoring procedure to estimate 
the true rates which would be evident if all patients were evaluable throughout the entire 
follow-up period.
Distribution of the data were assessed for normality using the Kolmogorov- 
Smirnov test (with Lilliefors’ correction). Results are expressed as mean ± standard 
deviation for normally distributed variables and as medians and ranges for non-normal 
data. Comparisons of categorical variables and continuous variables were aided by the 
calculation of 95% confidence intervals. Confidence intervals for event rates were 
calculated according to the following formula:
95% Cl = 1.96 x V(rate(1-rate)/n)
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where the rate is the number of events or number of patients divided by the 
number of patients in the group.
Handling of withdrawals
Non-evaluable withdrawals were those patients randomised with the intention of 
performing a bypass operation, but who were found to be unsuitable for a bypass graft for 
technical reasons. Patients randomised, but for whom no data was recorded were not 
included in the evaluation.
Patients who withdrew from the study of their own volition or who discontinued 
study medication on the advice of the clinician were followed up as far as possible 
according to the study protocol. All available data on patients who died or underwent 
amputation of the leg before bypass occlusion were evaluated.
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4. RESULTS
Efficacy and safety of peri-operative iloprost in a placebo controlled 
trial in femorodistal bypass surgery
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4.1 Description of patients
Disposition of patients
Over a two year period 528 patients were randomised into the study. Eleven were 
excluded after randomisation. Of these eleven, eight were found to be unsuitable for 
bypass on commencement of the operation and did not undergo the planned bypass 
procedure. The other three of those excluded after randomisation received the study 
medication, but had no data recorded in the case report forms making classification and 
analysis of these cases impossible. This resulted in 517 patients being available for 
analysis of bypass patency, 267 randomised to iloprost and 250 to the placebo group. 
Twenty-one centres contributed patients to the study. The number of cases entered by 
individual centres varied between 1 and 100 with a median of 17 patients per centre.
Demographic characteristics of patients
The 517 patients consisted of 317 males and 199 women (and 1 unclassified) with a 
mean age of 71.2 years (Figure 15). Female patients comprised 110 (41.2%) of the 
iloprost group and 90 (36.0%) of the placebo group. The demographic characteristics of 
the two treatment groups did not differ significantly (Table 21).
Table 21. Demographic characteristics (mean ± standard deviation)
Characteristic Iloprost (n=267) Placebo (n=250) Total (n=517)
Age (years) 71.2 ±9.4 
n=267




Height (cm) 169 ± 10 
n=220
170 ± 10 
n=213
169 ± 10 
n=433
Weight (kg) 68.6 ± 14 
n=249
70.9 ± 14 
n=241
69.7 ± 14 
n=490
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Figure 15. Distribution of age in the study population
26-30 31-36 36-40 41-45 46-50 51-55 56-60 61-65 66-70 71-75 76-80 81-85 86-90
Age (years)
The distribution of the patients' pre-operative general clinical characteristics (Table 22) 
shows that the two treatment groups were generally well matched with respect to a 
number of concurrent clinical conditions and risk factors which might have had a bearing 
on the clinical outcome.
Table 22. Pre-operative clinical characteristics
Characteristic Number of patients (%)
Iloprost (n=267) Placebo (n=250) Total (n=517)
Hypertension 60 (22.5) 63 (25.2) 123 (23.8)
Diabetes mellitus 99 (37.1) 85 (34.0) 184 (35.6)
Hyperlipidaemia 16 (6 .0 ) 18 (7.2) 34 (6.6)
Cardiac failure 25 (9.4) 18 (7.2) 43 (8.3)
Previous Ml 58 ( 2 1 .7 ) 59 (23.6) 117 (22.6)
Previous CVA 31 (11.6) 26 (10.4) 57 (11.0)
Mobility restricting 
illness
9 (3.4) 15 (6.0) 24 (4.6)
Other severe ac­
companying illness
41 (15.4) 38 (15.2) 79 (15.3)
Current smoker 89 (33.3) 94 (37.6) 183 (35.4)
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Pre-operative arterial disease
Patients' arterial disease was classified as Fontaine stage III (34%) or Fontaine stage IV 
(65.2%) in all but four cases. The distribution of patients into the two treatment groups 
was quite well balanced with respect to stage and duration of symptoms with just a small 
excess of patients in stage IV in the iloprost group (Table 23).
Table 23. Pre-operative Fontaine stage and duration of symptoms
Fontaine stage Number of patients (%)
Iloprost (n=267) Placebo (n=250) Total (n=517)
Stage II 3 (1.1) 1 (0.4) 4 (0.8)
Stage III 84 (31.5) 92 (36.8) 176 (34.0)
Stage IV 180 (67.4) 157 (62.8) 337 (65.2)
Duration of stage III 4.4 ± 6.4 years 4.5 ± 5.0 years 4.4 ± 5.7 years
Duration of stage IV 5.0 ± 6.4 years 4.8 ± 5.0 years 4.9 ± 5.8 years
Rest pain was reported in 499 patients (96.5%), but only 406 patients (78.5%) were 
receiving any analgesia (Table 24). There was a greater proportion of patients with both 
ulcers and necroses in the iloprost group than in the placebo group: 85 patients (31.8%, 
95%CI 26.2-37.4) compared to 55 patients (22.0%, 95%CI 16.9-27.1) (Table 25).
Table 24. Pre-operative rest pain and analgesic use
Rest pain Analgesic







None None 8 (3.0) 2 (0.8) 10 (1.9)
Non-opiates 3 (1.1) 4 (1.6) 7 (1.4)
Opiates 0 (0.0) 1 (0.4) 1 (0.2)
Intermittent None 46 (17.2) 29 (11.6) 75 (14.5)
Non-opiates 40 (15.0) 54 (21.6) 94 (18.2)
Opiates 25 (9.4) 26 (10.4) 51 (9.9)
Continuous None 14 (5.2) 12 (4.8) 26 (5.0)
Non-opiates 70 (26.2) 63 (25.2) 133 (25.7)
Opiates 61 (22.8) 59 (23.6) 120 (23.2)
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Table 25. Pre-operative ulcers and gangrene
Ulcers Gangrene







Absent None 87 (32.6) 92 (36.8) 179 (34.6)
Dry 33 (12.4) 38 (15.2) 71 (13.7)
Wet 3 (1.1) 1 (0.4) 4 (0.8)
Dry and wet 3 (1.1) 3 (1.2) 6 (1.2)
Present None 56 (21.0) 60 (24.0) 116 (22.4)
Dry 56 (21.0) 32 (12.8) 88 (17.0)
Wet 17 (6.4) 11 (4.4) 28 (5.4)
Dry and Wet 12 (4-5) 12 (4.8) 24 (4.6)
The overall symptom severity scores did not differ greatly between the two groups with 
median values of 4.0 for the iloprost group (IQ range 2.0-5.0) and 3.0 for the placebo 
group (IQ range 2.0-5.0).
Arterial pressures were similar in the two groups: the mean overall ankle pressure 
recorded in the relevant leg was 56.2 mmHg with 188 patients (36.4%) having a pressure 
of < 50 mmHg and the mean ABPI was 0.37 with 462 cases (89.3%) being < 0.6 (Table 
26).
Table 26. Pre-operative Doppler pressures
Variable Iloprost Placebo Total
Brachial artery 152 ±26 (n=261) 153 ±27 (n=246) 153 ±27 (n=507)
Ankle: mean ± SD 58 ±44 (n=243) 55 ±38 (n=223) 56 ±41 (n=466)
< 50mmHg 96 (36%) 92 (37%) 188 (36%)
> 50mmHg 147 (55%) 131 (52%) 278 (54%)
ABPI: mean ± SD 0.65 ± 0.33 (n=251) 0.65 ± 0.32
COCOCMIIc 0.65 ± 0.32
COnc
0 - 0.30 34 (14%) 29 (12%) 63 (13%)
0.31-0.60 83 (33%) 87 (37%) 170 (35%)
0.61 -0.90 81 (32%) 64 (27%) 145 (30%)
>0.90 53 (21%) 56 (24%) 109 (22%)
Angiographic run-off scores in the two groups were similar (Table 27). Insufficient 
information from the angiograms on the distal vessels did not permit the calculation of a 
run-off scores in approximately 15% of cases.
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Table 27. Pre-operative angiographic run-off score (Rutherford system)
Number of patients (%)
Run-off score Iloprost (n=267) Placebo (n=250) Total (n=517)
0-2 .0 52 (19.5) 58 (23.2) 110 (21.3)
2.5-4.0 60 (22.5) 47 (18.8) 107 (20.7)
4.5-6.0 34 (12.7) 38 (15.2) 72 (13.9)
6.5-8.0 39 (14.6) 27 (10.8) 66 (12.8)
8.5-10.0 41 (15.4) 41 (16.4) 82 (15.9)
Invalid score 41 (15.4) 39 (15.6) 80 (15.5)
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4.2 Surgical procedures
The duration of surgery was a mean of 4.0 hours (range 2.0-8.5) in all patients and did 
not differ either between the treatment groups or between those patients undergoing 
bypass with vein and prosthetic grafts (Table 28).
Table 28. Duration of surgery (hours) by treatment group and by graft material
Graft material Statistic Iloprost Placebo
All patients mean ± SD 3.9 ± 1.4 4.0+ 1.3
range 1.5 ± 11.0 2.0-8.5
n 267 250
Vein grafts mean ± SD 3.8 ± 1.3 4.1 ± 1.3
range 1.5-10.0 2.0-8.0
n 209 215
Prosthetic grafts mean ± SD 4.1 ± 1.9 4.0 ± 1.3
range 1.5-11.0 2.0-8.5
n 57 35
General anaesthesia with or without epidural was used in 287 cases (55.5%), epidural 
alone in 198 (38.3%) and intradural (3.7%) or local nerve blocks (2.5%) in the remainder. 
The frequency of use of the different types of anaesthesia was similar in the two 
treatment groups and with the different types of graft material used (Table 29).
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Table 29. Numbers of patients operated under each type of anaesthesia








All patients General 150 (56.2) 137 (54.8) 287 (55.5)
Epidural 100 (37.5) 98 (39.2) 198 (38.3)
Intradural 10 (3.7) 9 (3.6) 19 (3.7)
Local 7 (2.6) 6 (2.4) 13 (2.5)
Vein grafts General 115 (55.0) 112 (52.1) 227 (53.5)
Epidural 80 (38.3) 90 (41.9) 170 (40.1)
Intradurai 9 (4.3) 8 (3.7) 17 (4.0)
Local 5 (2.4) 5 (2.3) 10 (2.4)
Prosthetic grafts General 35 (60.3) 25 (71.4) 60 (64.5)
Epidural 20 (34.5) 8 (22.9) 28 (30.1)
Intradural 1 (1.7) 1 (2.9) 2 (2.2)
Local 2 (3.4) 1 (2.9) 3 (3.2)
The proximal anastomosis was most commonly made to the common femoral artery, 
femoral bifurcation or proximal superficial femoral artery (SFA) (438 cases (84.8%)) and 
only rarely to the mid superficial femoral artery or above-knee popliteal artery (Table 30). 
Prosthetic grafts were anastomosed to the common femoral artery more frequently than 
vein grafts and rarely to the mid SFA, femoral profunda or above-knee popliteal artery, 
reflecting a tendency to place prosthetic grafts more proximally. Iloprost and placebo 
groups were well-matched in the frequency of the various sites of proximal anastomosis.
103
Table 30. Site of proximal anastomosis
Number of patients (%)
Artery Iloprost Placebo Total
All grafts 
Iliac 3 (1.1) 3 (1.2) 6 (1.2)
Common femoral 147 (55.1) 144 (57.6) 291 (56.3)
Femoral bifurcation 36 (13.5) 30 (12.0) 66 (12.8)
Proximal superficial femoral 43 (16.1) 38 (15.2) 81 (15.7)
Femoral profunda 5 (1.9) 7 (2.8) 12 (2.3)
Mid superficial femoral 18 (6.7) 16 (6.4) 34 (6.6)
Above-knee popliteal 14 (5.2) 12 (4.8) 26 (5.0)
Not recorded / not done 1 (0.4) 0 (0.0) 1 (0.2)
Vein grafts 
Iliac 1 (0.5) 1 (0.5) 2 (0.5)
Common femoral 103 (49.3) 117 (54.4) 220 (51.9)
Femoral bifurcation 30 (14.4) 27 (12.6) 57 (13.4)
Proximal superficial femoral 39 (18.7) 37 (17.2) 76 (17.9)
Femoral profunda 5 (2.4) 5 (2.3) 10 (2.4)
Mid superficial femoral 17 (8.1) 16 (7.4) 33 (7.8)
Above-knee popliteal 14 (6.7) 12 (5.6) 26 (6.1)
Not recorded / not done 1 (0.5) 0 (0.0) 1 (0.2)
Prosthetic grafts 
Iliac 2 (3.5) 2 (5.7) 4 (4.3)
Common femoral 44 (77.2) 27 (77.1) 71 (77.2)
Femoral bifurcation 6 (10.5) 3 (8.6) 9 (9.8)
Proximal superficial femoral 4 (7.0) 1 (2.9) 5 (5.4)
Femoral profunda 0 (0.0) 2 (5.7) 2 (2.2)
Mid superficial femoral 1 (1.8) 0 (0.0) 1 (1.1)
Above-knee popliteal 0 (0.0) 0 (0.0) 0 (0.0)
The distal anastomoses were distributed evenly between the anterior tibial, posterior tibial 
and peroneal arteries in both treatment groups with a smaller proportion on the 
tibioperoneal trunk (Table 31). Although not falling within the inclusion criteria of the 
study, a small number of patients with a distal anastomosis on the below-knee popliteal 
artery or on the dorsalis pedis artery were entered.
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Table 31. Sites of distal anastomoses
Artery Level of distal anastomosis (no. of patients (%))
Upper Mid Lower Totals
Below-knee
popliteal
9 (1.8) 0 (0.0) 0 (0.0) 9 (1.8)
Tibioperoneal
trunk
40 (7.7) 2 (0.4) 2 (0.4) 44 (8.5)
Anterior tibial 56 (10.8) 53 (10.3) 70 (13.5) 179 (34.6)
Posterior tibial 22 (4.3) 57 (11.0) 65 (12.6) 144 (27.9)
Peroneal 46 (8.9) 55 (10.6) 38 (7.4) 139 (26.9)
Dorsalis pedis 0 (0.0) 0 (0.0) 2 (0.4) 2 (0.4)
All vessels 173 (33.5) 167 (32.3) 177 (34.2) 517 (100.0)
The distribution of different vessels for the distal anastomosis in the two treatment groups 
was well balanced (Table 32).
The distal anastomoses were also evenly distributed between the upper, mid and 
lower thirds of the calf vessels in the study population as a whole and in the patients 
receiving vein grafts without any differences between the two treatment groups (Table 
33). Amongst patients who received prosthetic grafts, more in the iloprost group, 33.3% 
(95%CI 21.1-45.5), than in the placebo group, 17.1% (95%CI 4.6-29.6), were 
anastomosed to the distal third of the calf vessels, but this difference between the 
treatment groups was not significant.
Vein grafts, including composite grafts from two sections of vein, were used in 424 
cases (82%) and prosthetic or prosthetic-vein composite grafts in 92 (18%) (Table 34). 
The in situ technique was used in 68.9% of the vein grafts performed, 21.2% of vein 
grafts were reversed vein grafts and 9.9% were composite grafts consisting of two pieces 
of vein. Of the prosthetic grafts, 67.4% were simple PTFE grafts and 31.5% were 
composite grafts part vein and part PTFE. A greater proportion of the prosthetic grafts 
were performed in the iloprost group, 21.3% (95%CI 16.2-26.2), compared to the placebo 
group, 14.0% (95%CI 9.7-18.3).
105
Table 32. Site of distal anastomosis
Artery Number of patients (%)
Iloprost Placebo Total
All grafts
Below-knee popliteal 7 (2.6) 2 (0.8) 9 (1.7)
Tibio-peroneal trunk 20 (7.5) 24 (9.6) 44 (8.5)
Anterior tibial 94 (35.2) 85 (34.0) 179 (34.6)
Posterior tibial 75 (28.1) 69 (27.6) 144 (27.9)
Peroneal 70 (26.2) 69 (27.6) 139 (26.9)
Dorsalis pedis 1 (0.4) 1 (0.4) 2 (0.4)
Vein grafts 
Below-knee popliteal 5 (2.4) 1 (0-5) 6 (1.4)
Tibio-peroneal trunk 14 (6.7) 18 (8.4) 32 (7.5)
Anterior tibial 76 (36.4) 75 (34.9) 151 (35.6)
Posterior tibial 61 (29.2) 60 (27.9) 121 (28.5)
Peroneal 52 (24.9) 60 (27.9) 112 (26.4)
Dorsalis pedis 1 (0.5) 1 (0-5) 2 (0.5)
Prosthetic grafts 
Below-knee popliteal 2 (3.5) 1 (2.9) 3 (3.3)
Tibio-peroneal trunk 6 (10.5) 6 (17.1) 12 (13.0)
Anterior tibial 18 (31.6) 10 (28.6) 28 (30.4)
Posterior tibial 14 (24.6) 9 (25.7) 23 (25.0)
Peroneal 17 (29.8) 9 (25.7) 26 (28.3)
Dorsalis pedis 0 (0.0) 0 (0.0) 0 (0.0)
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Table 33. Level of distal anastomosis in the calf
Number of patients (%)
Level on calf artery Iloprost Placebo Total
All grafts
Upper third 91 (34.1) 86 (34.4) 177 (34.2)
Mid third 80 (30.0) 84 (33.6) 164 (31.7)
Lower third 95 (35.6) 80 (32.0) 175 (33.8)
Unknown 1 (0.4) 0 (0.0) 1 (0.2)
Vein grafts
Upper third 73 (34.9) 71 (33.0) 144 (34.0)
Mid third 60 (28.7) 70 (32.6) 130 (30.7)
Lower third 76 (36.4) 74 (34.4) 150 (35.4)
Prosthetic grafts
Upper third 18 (31.6) 15 (42.9) 33 (35.9)
Mid third 20 (35.1) 14 (40.0) 34 (37.0)
Lower third 19 (33.3) 6 (17.1) 25 (27.1)
Table 34. Graft material
Graft material Number of patients (%)
Iloprost (n=267) Placebo (n=250) Totals (n=517)
In situ saphenous vein 141 (52.8) 151 (60.4) 292 (56.5)
Reversed saphenous vein 47 (17.6) 43 (17.2) 90 (17.4)
PTFE 39 (14.6) 23 (9.2) 62 (12.0)
Other prosthetic 0 (0) 1 (0.4) 1 (0.2)
Vein-prosthetic composite 18 (6.7) 11 (4.4) 29 (5.6)
Vein-vein composite 21 (7.9) 21 (8.4) 42 (8.1)
Unclassified 1 (0.4) 0 (0) 0 (0.2)
Information on the graft length was recorded for 62.1% of grafts (321 patients), 63.9% of 
vein grafts and 54.3% of prosthetic grafts. The mean graft length was similar in both 
treatment groups (Table 35). Minimum graft diameters were recorded for 71.2% of grafts 
(368 patients), 71.7% of vein grafts and 69.5% of prosthetic grafts (Table 36). The 
minimum graft diameters in patients receiving vein bypasses were not evenly distributed
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and were somewhat smaller in the iloprost group than the placebo group: 3.7mm (95%CI 
3.5-3.9) and 4.0mm (95%CI 3.8-4.2) respectively.
Table 35. Graft length (cm)
Graft material Statistic Iloprost Placebo
All patients mean ± SD
range
n
57.1 ± 14.2 
14.0-92.0 
164
58.0 ± 13.9 
15.0-90.0 
157






57.6 ± 14.1 
15.0-90.0 
137




32.0 - 74.0 
30
60.6 ± 11.7 
42.0 - 80.0 
20
Table 36. Minimum graft diameter (mm)
Graft material Statistic Iloprost Placebo
All patients mean ± SD 4.1 ± 1.3 4.2 ± 1.5
range 2.0-8.0 2.0-11.0
n 192 176
Vein grafts mean ± SD 3.7 ± 1.0 4.0 ± 1.4
range 2.0-7.0 2.0-11.0
n 152 152




Concomitant procedures were performed in similar numbers of cases in each treatment 
group (Table 37). Endarterectomy and profundaplasty were most commonly performed in 
patients receiving vein bypasses. Amongst prosthetic bypass grafts, procedures to 
improve the haemodynamics at the distal anastomosis were performed in the majority of 
operations and with equal frequency in the two treatment groups. Vein collars or cuffs 
were used in about 40% of cases and vein patches such as the Taylor patch were used in
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almost 20% of cases. Arteriovenous fistulae were performed rarely and only at one 
centre participating in the trial.
Table 37. Concomitant surgical procedures at time of bypass procedure
Number of patients (%)
Concomitant procedure Iloprost Placebo Total
All grafts 
Endarterectomy 46 (17.2) 43 (17.2) 89 (17.2)
Profundaplasty 11 (4.1) 9 (3.6) 20 (3.9)
Miller collar 24 (9.0) 16 (6.4) 40 (7.7)
Taylor or other vein patch 14 (5.2) 13 (5.2) 27 (5.2)
Arteriovenous fistula 7 (2.6) 4 (1.6) 11 (2.1)
Vein grafts 
Endarterectomy 40 (19.1) 40 (18.6) 80 (18.9)
Profundaplasty 10 (4.8) 9 (4.2) 19 (4.5)
Miller collar 2 (1.0) 1 (0.5) 3 (0.7)
Taylor or other vein patch 3 (1.4) 6 (2.8) 9 (2.1)
Arteriovenous fistula 2 (1.0) 1 (0.5) 3 (0.7)
Prosthetic grafts 
Endarterectomy 6 (10.5) 3 (8.6) 9 (9.8)
Profundaplasty 1 (1.8) 0 (0.0) 1 (1.1)
Miller collar 22 (38.6) 15 (42.9) 37 (40.2)
Taylor or other vein patch 11 (19.3) 7 (20.0) 18 (19.6)
Arteriovenous fistula 5 (8.8) 3 (8.6) 8 (8.7)
Techniques used for intra-operative assessment of the patients included angiography, 
measurement of Doppler pressures, duplex ultrasound and endoscopy. The frequency of 
use of these different techniques was similar in the two treatment groups and showed that 
intra-operative assessment was performed principally with angiography and Doppler 
measurements (Table 38). Endoscopy was rarely performed in this study and only at one 
centre.
109
Table 38. Intra-operative assessments
Number of patients (%)
Type of assessment Iloprost Placebo Total
All grafts 
Angiography 152 (56.9) 131 (52.4) 283 (54.7)
Doppler 168 (62.9) 160 (64.0) 328 (63.4)
Duplex 15 (5.6) 15 (6.0) 30 (5.8)
Endoscopy 6 (2.2) 1 (0.4) 7 (1.4)
Vein grafts 
Angiography 114 (54.5) 114 (53.0) 228 (53.8)
Doppler 141 (67.5) 148 (68.8) 289 (68.2)
Duplex 14 (6.7) 14 (6.5) 28 (6.6)
Endoscopy 6 (2.9) 1 (0.5) 7 (1.7)
Prosthetic grafts 
Angiography 38 (66.7) 17 (48.6) 55 (59.8)
Doppler 27 (47.4) 12 (34.3) 39 (42.4)
Duplex 1 (1.8) 1 (2.9) 2 (2.2)
Endoscopy 0 (0.0) 0 (0.0) 0 (00)_
Intra-operative graft revision was performed in 44 operations (8.5%), usually at the distal 
anastomosis (Table 39). The frequency of revisions was similar in the two treatment 
groups, but was twice as common in prosthetic bypass procedures as in veins. Other 
intra-operative technical complications were reported in a total of 67 cases (13.0%): 
iloprost 32 cases (12.0%) and placebo 35 cases (14.0%).
Surgeons’ assessment of prognosis at the end of the operation were good for over 
two thirds of patients and tended to be rather more positive for patients with vein grafts 
than prosthetic grafts (Table 40). Very few patients were considered to be in imminent 
danger of amputation at the end of the operation.
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Table 39. Frequency of intra-operative graft revision
Number of patients (%)
Site of revision Iloprost Placebo Total
All grafts
Any revision 24 (9.0) 20 (8.0) 44 (8.5)
Proximal 3 (1.1) 4 (1.6) 7 (1.4)
Distal 18 (6.7) 15 (6.0) 33 (6.4)
Proximal and distal 3 (1.1) 0 (0.0) 3 (0.6)
Mid-graft 0 (0.0) 1 (0.4) 1 (0.2)
Vein grafts
Any revision 15 (7.2) 16 (7.4) 31 (7.3)
Proximal 2 (1.0) 3 (1.4) 5 (1.2)
Distal 11 (5.3) 12 (5.6) 23 (5.4)
Proximal and distal 2 (1.0) 0 (0.0) 2 (0.5)
Mid-graft 0 (0.0) 1 (0.5) 1 (0.2)
Prosthetic grafts
Any revision 9 (15.8) 4 (11.4) 13 (14.1)
Proximal 1 (1.8) 1 (2.9) 2 (2.2)
Distal 7 (12.3) 3 (8.6) 10 (10.9)
Proximal and distal 1 (1.8) 0 (0.0) 1 (1.1)
Mid-graft 0 (0.0) 0 (0.0) 0 (0.0)
The operations were performed by the principal surgeon in the group in over seventy 
percent of cases and by a junior or training surgeon in the remainder (Table 41). In the 
event that more than one surgeon was involved this reflects the surgeon who performed 
the distal anastomosis. Markedly more of the prosthetic grafts overall were performed by 
the principal surgeon of group than was the case for the vein grafts. This trend was 
similar in both treatment groups. The frequency of the prosthetic grafts being performed 
by the principal surgeon was higher in the placebo group, 91.4% (95%CI 82.1-100), than 
it was in the iloprost group, 80.7% (95%CI 70.5-90.9).
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Table 40. Subjective assessment of prognosis
Number of patients (%)
Assessment of prognosis Iloprost Placebo Total
All grafts 
Good 186 (69.7) 176 (70.4) 362 (70.0)
Doubtful 65 (24.3) 65 (26.0) 130 (25.1)
Danger of amputation 13 (4.9) 9 (3.6) 22 (4.3)
Unknown 3 (1.1) 0 (0.0) 3 (0.6)
Vein grafts 
Good 156 (74.6) 155 (72.1) 311 (73.3)
Doubtful 44 (21.1) 53 (24.7) 97 (22.9)
Danger of amputation 6 (2.9) 7 (3.3) 13 (3.1)
Unknown 3 (1.4) 0 (0.0) 3 (0.7)
Prosthetic grafts 
Good 30 (52.6) 21 (60.0) 51 (55.4)
Doubtful 21 (36.8) 12 (34.3) 33 (35.9)
Danger of amputation 7 (12.3) 2 (5.7) 9 (9.8)
Unknown 0 (0.0) 0 (0.0) 0 (0.0)
Table 41. Surgeon performing operation
Number of patients (%)
Surgeon Iloprost Placebo Total
All grafts 
Principal surgeon 197 (73.8) 178 (71.2) 375 (72.5)
Assistant surgeon 70 (26.2) 72 (28.8) 142 (27.5)
Vein grafts 
Principal surgeon 151 (72.2) 146 (67.9) 297 (70.0)
Assistant surgeon 58 (27.8) 69 (32.1) 127 (30.0)
Prosthetic grafts 
Principal surgeon 46 (80.7) 32 (91.4) 78 (84.8)
Assistant surgeon 11 (19-3).. 3 (8.6) 15 (15.2)
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4.3 Administration of study medication and adverse medical events
The majority of patients received the planned treatment of iloprost or placebo. The 
infusion of study medication at the start of the operation was given to 506 patients 
(97.9%) and the intra-graft injection of iloprost or placebo to 498 (96.4%). Post- 
operatively 222 iloprost patients (83.1%) and 212 placebo patients (84.8%) received all 
three intravenous infusions. Six iloprost patients (2.2%) and 6 placebo patients (2.4%) 
did not receive any post-operative treatment with the study medication.
The planned infusion rate of 20 ml/h for the intravenous infusion given at the start 
of the operation was administered to 85% of patients overall, most of the remainder 
receiving an infusion at a rate of 10 ml/h (Table 42).










Intravenous Oml/h 4 (1.5) 7 (2.8) 11 (2.1)
infusion 10 ml/h 35 (13.1) 31 (12.4) 66 (21.8)
20 ml/h 228 (85.4) 212 (84.8) 440 (85.1)
Intragraft 0 ml 7 (2.6) 11 (4.4) 18 (3.5)
injection 15 ml 257 (96.3) 235 (94.0) 492 (95.2)
>15 ml 2 (0.7) 4 (1.6) 6 (1.2)
Over the three days of post-operative infusions, progressively more patients required a 
reduction in the infusion rate or stopped treatment completely (Table 43). A small 
number of patients (13 patients, 2.5%) on the first day also received an infusion at a 
higher dose than the 20 ml/h required by the protocol. However, the majority of patients 
received the planned infusion on each of the first three days of postoperative treatment. 
There were no major differences between the two treatment groups in the proportions of 
patients requiring dose reduction or cessation of treatment.
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Day 1 Oml/h 7 (2.6) 9 (3.6) 16 (3.1)
10 ml/h 11 (4.1) 4 (1.6) 15 (2.9)
20 ml/h 242 (90.6) 231 (92.4) 473 (91.5)
30 ml/h 2 (0.7) 3 (1.2) 5 (1.0)
40 ml/h 5 (1.9) 3 (1.2) 8 (1.5)
Day 2 0 ml/h 22 (8.2) 20 (8.0) 42 (8.1)
10 ml/h 3 (1.1) 6 (2.4) 9 (1.7)
20 ml/h 10 (3.7) 6 (2.4) 16 (3.1)
30 ml/h 14 (5.2) 4 (1.6) 18 (3.5)
40 ml/h 218 (81.6) 214 (85.6) 432 (83.6)
Day 3 0 ml/h 41 (15.4) 37 (14.8) 78 (15.2)
10 ml/h 6 (2.2) 5 (2.0) 11 (2.1)
20 ml/h 12 (4.5) 6 (2.4) 18 (3.5)
30 ml/h 18 (6.7) 10 (4.0) 28 (5.4)
40 ml/h 190 (71.2) 192 (76.8) 382 (73.9)
Intra-operative adverse events
Considerably more iloprost patients had side-effects during the operation: 18.0% (95%CI 
13.4-22.6) compared to 5.2% (95%CI 2.4-8.0) had any adverse event. The most 
common of these was hypotension: iloprost 39 patients (14.6%, 95%CI 10.2-18.8) and 
placebo 10 patients (4.0%, 95%CI 1.6-6.4). There were no significant differences in any 
other intra-operative events although (Table 44) vomiting occurred exclusively in the 
iloprost group, in 5 cases (1.9%, 95%CI 1.3-3.5) suggesting the possibility that this may 
be an uncommon iloprost-related event.
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Table 44. Intra-operative adverse events






One or more 48 (18.0) 13 (5.2)
Hypotension 39 (14.6) 10 (4.0)
Nausea 6 (2.2) 2 (0.8)
Vomiting 5 (1.9) 0 (0.0)
Haemorrhage 2 (0.7) 0 (0.0)
Chest pain 2 (0.7) 0 (0.0)
Oedema 1 (0.4) 0 (0.0)
Lung oedema 1 (0.4) 0 (0.0)
Bigeminy 1 (0.4) 0 (0.0)
Headache 1 (0.4) 0 (0.0)
Myocardial infarction 1 (0.4) 0 (0.0)
Injection site inflammation 1 (0.4) 0 (0.0)
Flushing 1 (0.4) 0 (0.0)
Cardiovascular disorder 0 (0.0) 1 (0.4)
Hypoxia 0 (0.0) 1 (0.4)
Increased sweating 0 (0.0) 1 (0.4)
The incidence of hypotension during surgery (as judged by the clinician) did not differ 
greatly between patients operated under general anaesthesia and those receiving 
epidural anaesthetics (Table 45). In each case episodes of hypotension were significantly 
more common in patients receiving iloprost, 15.7% (95%CI 8.6-22.8), than placebo, 3.0% 
(95%CI 0-6.3%), and there was no indication of an interaction between the type of 
anaesthesia and the study treatment. The numbers of cases operated under intradural or 
local anaesthesia were too small to allow a valid comparison to be made. Similarly, the 
number of reports of other adverse events intra-operatively were too few to enable any 
judgement of relative frequency with general or epidural anaesthesia (Table 44). The 
single case of myocardial infarction during surgery occurred in a patient under epidural 
anaesthesia receiving iloprost and two additional cases of chest pain during surgery were 
reported in patients under epidural anaesthesia, one in each treatment group.
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Table 45. Incidence of intra-operative hypotension (as judged by clinician) by treatment 
group and by type of anaesthesia




















Recorded changes in systemic haemodynamics during surgery also indicated a higher 
incidence of hypotension in the iloprost group, showing a higher frequency of decreases 
in systolic and diastolic pressure both after the intravenous infusion at the beginning of 
the operation and after intra-graft injection at the end of the bypass procedure (Table 46 
and 47). Heart rate was also increased, but only after the intravenous infusion, not after 
intra-graft injection (Table 48).
Table 46. Changes in blood pressure after intravenous infusion at the start of the 
operation






Systolic + >30 10 4 (2-6) 6 3 (1-5)
pressure + 11-30 27 10 (6-14) 37 15 (11-20)
±0-10 132 50 (44-56) 144 59 (53-65)
-  11-30 67 25 (20-30) 36 15 (10-19)
-> 30 29 11 (7-15) 22 9 (5-13)
Diastolic + >30 0 0 3 1 (0-2)
pressure + 11-30 25 10 (6-13) 20 8 (5-11)
±0-10 168 66 (60-72) 189 78 (73-83)
-  11-30 53 21 (16-26) 28 12 (8-16)
->30 9 4 (2-6) 3 1 (0-3)
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Table 47. Changes in blood pressure after intragraft injection






Systolic + >30 1 0 (0-1) 1 1 (0-1)
pressure + 11-30 8 3 (1-5) 22 9 (5-13)
±0-10 108 43 (37-49) 179 75 (69-81)
-  11-30 80 32 (26-38) 33 14 (10-18)
->30 55 22 (17-27) 3 1 (0-3)
Diastolic + >30 0 0 0 0
pressure + 11-30 4 2 (0-3) 8 3 (1-5)
±0-10 172 70 (64-76) 212 90 (86-94)
-  11-30 68 28 (22-33) 16 7 (4-10)
->30 2 1 (0-2) 0 0
Table 48. Changes in heart rate after intra-operative treatment
Change in heart rate Iloprost n=252 Placebo n=238
(mmHg) Number % (95%CI) Number % (95%CI)
Intravenous + >15 15 6 (3-9) 8 3 (1-5)
infusion ±0-15 221 83 (79-88) 228 93 (90-96)
->15 29 11 (7-15) 9 4 (1-6)
Intragraft + >15 8 3 (1-5) 1 0 (0-1)
injection ±0-15 240 95 (93-98) 234 99 (97-100)
->15 4 2 (0-3) 2 1 (0-2)
The hypotensive effect of iloprost after the intra-operative intravenous infusion was 
evident from systolic and diastolic blood pressure measurements only in patients under 
general anaesthesia (Table 49 and 50). Under epidural anaesthesia changes in systolic 
and diastolic pressure after intravenous infusion were similar in the iloprost and placebo 
groups.
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Table 49. Effect of iloprost on changes in systolic blood pressure after intra-operative










General + >30 8 5 (2-8) 5 4 (2-6)
n=265 + 11-30 15 10 (6-14) 23 17 (12-22)
±0-10 65 44 (38-50) 74 56 (50-62)
-  11-30 40 27 (21-33) 17 13 (9-17)
->30 21 14 (10-18) 14 11 (7-15)
Epidural + >30 1 1 (0-2) 1 1 (0-2)
n=193 + 11-30 12 12 (8-16) 12 12 (8-16)
±0-10 56 56 (50-62) 60 61 (55-67)
-  11-30 24 24 (19-29) 17 17 (12-22)
->30 7 7 (4-10) 8 8 (4-12)
Table 50. Effect of iloprost on changes in diastolic blood pressure after intra-operative 










General + >30 0 0 2 2 (0-3)
n=265 + 11-30 15 11 (7-15) 15 12 (8-16)
±0-10 84 60 (54-66) 100 76 (71-81)
-  11-30 33 24 (19-29) 12 9 (5-13)
->30 7 5 (2-8) 2 2 (0-3)
Epidural + >30 0 0 1 1 (0-2)
n=193 + 11-30 9 9 (5-13) 3 3 (1-5)
±0-10 73 73 (68-78) 78 80 (75-85)
-  11-30 17 17 (12-22) 15 15 (10-20)
->30 1 1 (0-2) 1 1 (0-2)
The proportion of patients with decreases in systolic and diastolic blood pressure after 
intra-operative intragraft injection were greater in the iloprost group both amongst patients 
operated under general anaesthesia and amongst those under epidural anaesthesia 
(Table 51 and 52).
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Table 51. Effect of iloprost on changes in systolic blood pressure after intra-operative










General + >30 0 0 1 1 (0-2)
n=265 + 11-30 5 4 (2-6) 12 10 (6-14)
±0-10 61 44 (38-50) 93 74 (68-80)
-  11-30 46 33 (27-39) 17 14 (10-18)
->30 27 19 (14-24) 3 2 (0-4)
Epidural + >30 1 1 (0-2) 0 0
n=193 + 11-30 3 3 (1-5) 8 8 (4-12)
±0-10 41 43 (37-49) 77 79 (74-84)
-  11-30 26 27 (21-33) 12 12 (8-16)
->30 25 26 (21-31) 0 0
Table 52. Effect of iloprost on changes in diastolic blood pressure after intra-operative 










General + >30 0 0 0 0
n=265 + 11-30 3 2 (0-4) 3 2 (0-4)
±0-10 88 66 (60-72) 114 92 (88-96)
-  11-30 41 31 (25-37) 7 6 (3-9)
->30 1 1 (0-2) 0 0
Epidural + >30 0 0 0 0
n=193 + 11-30 1 1 (0-2) 4 4 (1-7)
±0-10 71 74 (69-79) 87 90 (86-94)
-  11-30 24 25 (20-30) 6 6 (3-9)
->30 0 0 0 0
The changes in heart rate after intra-operative intravenous infusions and intragraft 
injections of iloprost and placebo were not markedly different in patients under general 
and epidural anaesthesia, although the numbers of patients with clinically significant 
changes were too few to yield any firm conclusions (Tables 53 and 54).
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General + >15 9 6 (2-10) 5 4 (1-7)
±0-15 119 80 (73-87) 121 91 (86-96)
->15 21 14 (8-20) 7 5 (1-9)
Epidural + >15 t; 5 (1-9) 3 3 (0-6)
±0-15 87 87 (80-95) 93 95 (91-99)
->15 8 8 (3-11) 2 2 (0-4)











General + >15 2 1 (0-3) 1 1 (0-2)
±0-15 135 97 (94-100) 123 98 (96-100)
->15 2 1 (0-3) 1 1 (0-2)
Epidural + >15 4 4 (0-8) 0 0
±0-15 91 95 (91-99) 97 100
->15 1 1 (0-3) 0 0
Postoperative adverse events
Hypotension, nausea, headache, flushing and injection site reactions were all significantly 
more common during post-operative treatment with iloprost than with placebo (Table 55). 
One hundred and fifty-four iloprost cases (57.7%, 95%CI 51.8-63.6)) compared to 93 
placebo cases (37.2%, 95%CI 31.2-43.2)) reported some kind of adverse experience 
during the three day post-operative treatment period. However, these were not serious 
enough to result in more iloprost than placebo patients discontinuing infusions (Table 43). 
The types of events clearly more common in the iloprost group were nausea, headache, 
flushing and inflammation at the injection site. There was a slightly greater incidence of
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tachycardia in the placebo group, 3.2% (95%CI 1.0-5.4) compared to iloprost, 0.7% 
(95%CI 0-1.7).
Table 55. Adverse events during post-operative treatment






One or more 154 (57.7) 93 (37.2)
Nausea 68 (25.5) 27 (10.8)
Hypotension 64 (24.0) 41 (16.4)
Headache 44 (16.5) 13 (5.2)
Flushing 36 (13.5) 8 (3.5)
Dizziness 13 (4.9) 7 (2.8)
Injection site inflammation 13 (4.9) 4 (1.6)
Gastrointestinal disorder 10 (3.7) 7 (2.8)
Hypertension 7 (2.6) 9 (3.6)
Haemorrhage 6 (2.2) 2 (0.8)
Atrial fibrillation 5 (1.9) 2 (0.8)
Bradycardia 4 (1.5) 4 (1.6)
Myocardial infarction 4 (1.5) 4 (1.6)
Chest pain / angina pectoris 4 (1.5) 5 (2.0)
Psychosis 4 (1.5) 3 (1.2)
Lung oedema 3 (1.1) 1 (0.4)
Anaemia 2 (0.7) 0 (0-0)
Anuria 2 (0.7) 0 (0-0)
Dyspnoea 2 (0.7) 1 (0-4)
Malaise 2 (0.7) 0 (0.0)
Tachycardia 2 (0.7) 8 (3.2)
Arterial anomaly 1 (0.4) 0 (0.0)
Arrhythmia 1 (0.4) 0 (0.0)
Cerebrovascular accident 1 (0.4) 2 (0.8)
Confusion 1 (0.4) 0 (0.0)
Death 1 (0.4) 1 (0-4)
Fever 1 (0.4) 1 (0-4)
Atrial flutter 1 (0.4) 0 (0.0)
Heart failure 1 (0.4) 1 (0.4)
Hypoventilation 1 (0.4) 0 (0.0)
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Hypovolaemia 1 (0.4) 0 (0.0)
Oliguria 1 (0.4) 0 (0.0)
Pain 1 (0.4) 1 (0.4)
Somnolence 1 (0.4) 0 (0.0)
Increased sweating 1 (0.4) 2 (0.8)
Apnoea 0 (0.0) 1 (0.4)
Cardiovascular disorder 0 (0.0) 1 (0.4)
Dry mouth 0 (0.0) 1 (0.4)
Pulmonary embolus 0 (0.0) 1 (0.4)
Ventricular extrasystoles 0 (0.0) 1 (0.4)
Eye disorder 0 (0.0) 1 (0.4)
Haematuria 0 (0.0) 1 (0.4)
Cerebral ischaemia 0 (0.0) 1 (0-4)
Abnormal liver function test 0 (0.0) 1 (0.4)
Pruritis 0 (0.0) 1 (0.4)
Peripheral vascular disorder 0 (0.0) 1 (0-4)
Vertigo 0 (0.0) 1 (0.4)
Division of the incidence of haemorrhage between those patients who were receiving oral 
anticoagulants and those who were not revealed that all eight cases of haemorrhage 
recorded as adverse events were in patients not receiving oral anticoagulants. The 
division between iloprost and placebo is shown above (Table 55). The incidences of 
cardiovascular events with a possible thrombotic aetiology during the three-day post­
operative study treatment period did not differ significantly with iloprost irrespective of the 
use of oral anticoagulants (Table 56).
Table 56. Major cardiovascular events by use of oral anticoagulant
Number of patients (%)






































In both treatment groups there was an expected large proportion of patients exhibiting an 
increase in blood pressure during the first postoperative infusion of study medication 
(Table 57). There was no evidence of a larger number of patients with hypotension in the 
iloprost group, in agreement with the judgement of the clinician (Table 55), but diastolic 
pressure measurements showed evidence of less patients exhibiting an increase in blood 
pressure during the course of the infusions on the first and second day (Table 58). 
Measurements of heart rate indicate that changes with postoperative treatment did not 
differ between the two treatment groups except on day 3 when a greater number of 
patients receiving iloprost exhibited a rise in heart rate of >15 beats/min during the 
infusion (Tables 59).
Table 57. Maximum changes in systolic blood pressure during postoperative intravenous 
infusions of study medication







Day 1 + >30 59 23 (18-28) 65 27 (21-33)
+ 11-30 83 33 (27-36) 75 32 (26-38)
±0-10 90 35 (29-41) 75 32 (26-38)
-  11-30 17 7 (4-10) 17 7 (4-10)
->30 5 2 (0-4) 5 2 (0-4)
Day 2 + >30 21 9 (5-13) 28 12 (8-16)
+ 11-30 79 33 (27-36) 89 39 (33-45)
±0-10 122 51 (45-57) 94 42 (36-48)
-  11-30 16 7 (4-10) 11 5 (2-8)
->30 3 1 (0-2) 5 2 (0-4)
Day 3 + >30 24 11 (7-15) 24 11 (7-15)
+ 11-30 73 32 (26-38) 70 33 (27-39)
±0-10 121 53 (47-59) 107 51 (45-57)
-  11-30 10 4 (2-7) 10 5 (2-8)
->30 0 0 1 1 (0-1)
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Table 58. Maximum changes in diastolic blood pressure during postoperative intravenous 
infusions of study medication







Day 1 + >30 18 8 (5-11) 14 6 (3-9)
+ 11-30 75 31 (25-37) 94 42 (36-48)
±0-10 135 57 (51-63) 105 47 (41-53)
-11-30 11 5 (2-7) 13 6 (3-9)
->30 0 0 0 0
Day 2 + >30 1 0 (0-1) 9 4 (2-7)
+ 11-30 59 26 (21-31) 60 28 (22-34)
±0-10 162 71 (65-77) 141 65 (59-71)
-  11-30 6 3 (1-5) 5 2 (0-4)
->30 0 0 2 1 (0-2)
Day 3 + >30 5 2 (0-4) 4 2 (0-4)
+ 11-30 51 24 (19-29) 49 24 (19-29)
±0-10 160 74 (69-79) 150 74 (68-80)
-  11-30 0 0 0 0
->30 0 0 0 0
Table 59. Maximum changes in heart rate during postoperative infusions of study 
medication







Day 1 + >15 92 36 (30-42) 80 34 (28-40)
±0-15 157 62 (56-68) 144 61 (65-67)
->15 5 2 (0-4) 12 5 (2-8)
Day 2 + >15 65 27 (21-33) 48 21 (16-26)
±0-15 172 71 (65-77) 173 77 (71-82)
->15 4 2 (0-3) 5 2 (0-4)
Day 3 + >15 55 24 (19-29) 31 3 (0-6)
±0-15 171 75 (70-80) 178 95 (91-99)
->15 2 1 (0-2) 1 2 (0-4)
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Postoperative adverse events after the treatment period
During the first 14 days post-operatively (up to discharge from hospital) the incidences of 
all adverse events and most importantly major cardiovascular events such as myocardial 
infarction, cerebrovascular accident and death from any cause did not differ greatly in the 
two treatment groups (Table 60). The incidences for iloprost and placebo respectively for 
the most important events were: myocardial infarction 7 (3%, 95%CI 1-5) and 10 (4%, 
95%CI 2-7), cerebrovascular accident 3 (1%, 95%CI 0-2) and 2 (1%, 95%CI 0-2), death 
from any cause 8 (3%, 95%CI 1-5) and 5 (2%, 95%CI 0-4).
Table 60. Post-operative adverse medicai events from the end of the treatment period up 
to 14 days (or discharge). All events occurring in more than one patient.






One or more 51 (19.5) 52 (21.2)
Death 8 (3.1) 5 (2.0)
Myocardial infarction 7 (2.7) 10 (4.1)
Cerebrovascular accident 3 (1.1) 2 (0.8)
Lung oedema 3 (1.1) 0 (0.0)
Cardiac arrest 3 (1.1) 0 (0.0)
Pulmonary embolus 2 (0.8) 0 (0.0)
Heart failure 2 (0.8) 1 (0.4)
Hypotension 2 (0.8) 1 (0.4)
Infection 2 (0.8) 3 (1.2)
Oliguria 2 (0.8) 0 (0.0)
Chest pain / angina pectoris 3 (1.2) 3 (1.2)
Sepsis 2 (0.8) 0 (0.0)
Shock 2 (0.8) 1 (0.4)
Abscess 1 (0.4) 1 (0.4)
Arterial anomaly 1 (0.4) 1 (0.4)
Apnoea 1 (0.4) 1 (0.4)
Dyspnoea 1 (0.4) 2 (0.8)
Atrial fibrillation 1 (0.4) 3 (1.2)
Necrosis 1 (0.4) 1 (0.4)
The incidence of major cardiovascular events and death from all causes did not differ 
between the two treatment groups (Table 61) over the whole 12 month study period.
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Death occurred in 19.0% of patients and the most common cardiovascular event, other 
than graft occlusion or surgical intervention for PAOD, was myocardial infarction in 8.3% 
of cases.
Table 61. Selected major cardiovascular adverse events from beginning of surgery to the 
end of 12 months follow-up (number of patients experiencing an event)









Death 53 (19.9) 45 (18.0) 98 (19.0)
Myocardial infarction 23 (8.6) 20 (8.0) 43 (8.3)
Cerebrovascular accident 9 (3.4) 3 (1.2) 12 (2.3)
Heart failure/left ventricular failure 11 (4.1) 7 (2.8) 18 (3.5)
Thrombosis 3 (1.1) 2 (0.8) 5 (1.0)
Haemorrhage 10 (3.7) 5 (2.0) 15 (2.9)
Pulmonary embolus 3 (1.1) 3 (1.2) 6 (1.2)
Cardiac arrest 3 (1.1) 1 (0.4) 4 (0.8)
126
4.4. Postoperative management
Heparin was administered to the majority of patients in both treatment groups intra- 
operatively at doses of <5000 international units (Table 62). Post-operatively only a 
minority of patients in each group received intravenous heparin, usually at a daily dose of 
5,000 or 10,000 international units. There were no great differences between the 
treatment groups in terms of number of patients receiving heparin or the doses most 
commonly administered.
Table 62. Administration of heparin intra-operatively and postoperatively






Operation OU 92 (34.5) 84 (33.6) 176 (34.0)
1 - 5000 U 169 (63.3) 150 (60.0) 319 (61.7)
5001 - 7500 U 3 (1.1) 9 (3.6) 12 (2.3)
7501 - 15000 U 2 (0.7) 4 (1.6) 6 (1.2)
15001-40000 U 1 (0.4) 3 (1.2) 4 (0.8)
Day 1 post-op 0 U 157 (58.8) 139 (55.6) 296 (57.3)
1 - 5000 U 41 (15.4) 32 (12.8) 73 (14.1)
5001 - 7500 U 1 (0.4) 2 (0.8) 3 (0.6)
7501 - 15000 U 51 (19.1) 54 (21.6) 105 (20.3)
15001-40000 U 17 (6.4) 23 (9.2) 40 (7.7)
Day 2 post-op 0 U 155 (58.1) 139 (55.6) 294 (56.9)
1 - 5000 U 26 (9.4) 26 (10.4) 52 (10.1)
5001 - 7500 U 2 (0.7) 0 (0-0) 2 (0.4)
7501 - 15000 U 67 (25.1) 63 (25.2) 130 (25.1)
15001-40000 U 17 (6.4) 22 (8.8) 39 (7.5)
Day 3 post-op OU 152 (56.9) 139 (55.6) 291 (56.3)
1 - 5000 U 22 (8.2) 23 (9.2) 45 (8.7)
5001 - 7500 U 2 (0.7) 0 (0.0) 2 (0.4)
7501 - 15000 U 70 (26.2) 67 (26.8) 137 (26.5)
15001-40000 U 21 (7-9) 21 (8-4) 42 (8.1)
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The number of patients using other antithrombotic agents during the follow-up period was 
not very different in the iloprost and placebo groups, although the proportion of patients 
taking aspirin was marginally higher in the placebo group, 31% (95%CI 25-36), compared 
to the iloprost group, 25% (95%CI 20-30) (Table 63).
Table 63. Postoperative antithrombotic medication other than heparin. Numbers 
represent the patients taking the medication at any of the postoperative assessments.






Any anticoagulant 98 (36.7) 92 (36.8) 190 (36.8)
Warfarin 50 (18.7) 51 (20.4) 101 (19.5)
Marcoumar 10 (3.7) 8 (3.2) 18 (3-5)
Acenocoumarol 37 (13.9) 33 (13.2) 70 (13.5)
Dicoumarol 1 (0.4) 0 (0.0) 1 (0.2)
Any platelet inhibitor 68 (25.5) 78 (31-2) 146 (28.2)
Aspirin 67 (25.1) 77 (30.8) 144 (27.9)
Dipyridamole 1 (0.4) 0 (0.0) 1 (0.2)
Other 1 (0.4) 1 (0.4) 2 (0.4)
Wound infections in the early postoperative period were reported in less than 15% of 
patients overall and in similar numbers in the two treatment groups (Table 64).
Table 64. Wound infections in the early postoperative period






























Post-operative graft surveillance with duplex ultrasound was performed by 17 of the 21 
centres participating in the trial on 272 (52.6%) of the patients in total. Of those patients
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undergoing surveillance, 78 (28.7%) were found to have haemodynamically significant 
stenoses. Nineteen patients (7.0%) of those patients successfully underwent dilatation by 
percutaneous transluminal angioplasty (PTA) (Table 65).









no. patients 47 (34.3%) 31 (23.0%) 78 (28.7%)
no. stenoses 59 39 98
Stenosis dilatations 
no. patients 15 (5.7%) 4 (1.4%) 19 (3.5%)
The largest number of stenoses, 54 (43.5%), were found at the distal anastomosis. 
Smaller numbers were found at the proximal anastomosis, 37 (29.8%), and in the mid 
portion of the graft, 32 (25.8%). The location of one stenosis was not specified by the 
surgeon. The majority of grafts scanned were vein grafts and there was some evidence 
of differences in stenosis rates between the different materials (Table 66).
Table 66. Number of patients with different graft materials undergoing graft surveillance 
and frequency of stenoses
Number of gral:ts
Graft material Performed Scanned (% of 
grafts performed)
Stenosed (% of 
those scanned)
In situ saphenous vein 292 197 (67) 49 (25)
Reversed saphenous vein 90 50 (56) 12 (24)
Composite vein-vein 42 30 (71) 13 (43)
Composite prosthetic-vein 29 12 (41) 2 (17)
Prosthetic 63 32 (51) 3 (9)
Not classified 1 1 (100) 1 (100)
All grafts containing vein 453 289 (64) 76 (26)
Total 517 322 (62) 80 (25)
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Eighty-one percent of male patients and 75% of female patients were eligible for graft 
surveillance. Of the eligible patients, rather more of the males were included in the 
surveillance programme than the females. Amongst the patients with grafts consisting of, 
or containing, vein segments, stenoses were detected more frequently in females (35%) 
than in males (22%) (Table 67). The greater frequency of stenoses in female patients 
was most notable in in situ and reversed vein grafts (Table 67).
Table 67. Frequency of graft stenoses by gender and graft material







In situ saphenous vein 197 28/135 (21) 21 / 62 (34)
Reversed saphenous vein 50 6/38 (16) 6 /12 (50)
Composite vein-vein 30 7/17 (41) 6 /13 (46)
Composite prosthetic-vein 12 1 / 3 (33) 1 19 (11)
Prosthetic 32 2 /16 (13) 1 /16 (6)
All grafts containing vein 289 42/193 (22) 34/96 (35)




The first analyses of graft patency presented are the overall patencies in the two 
treatment groups although these were not the primary analysis of interest. This is 
followed by analysis of the graft patencies by graft material and then the primary efficacy 
analysis, which was the comparison of primary graft patency in the patients receiving vein 
grafts. Finally, the analysis of graft patency in the smaller group of patients receiving 
prosthetic grafts is presented.
Overall patencies by life-table analysis showed little difference between the two 
treatment groups when all patients are included irrespective of graft material (Figures 16- 
18), although patencies in the iloprost treated group were at most time points numerically 
higher in each category of patency. Primary patency at the end of the 12 month follow-up 
period in evaluable patients was 51.3% in the iloprost group (95%CI 44.8-57.8) and 
52.6% in the placebo group (95%CI 45.9-59.3). Assisted primary patency after 12 
months was 57.1% for iloprost (95%CI 50.6-63.6) and 55.9% for placebo (95%CI 49.2- 
62.6). Secondary patency after 12 months was 62.8% for iloprost (95%CI 46.2-69.4) 
compared to 60.2% for placebo (95%CI 53.6-66.8).
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T i m e  ( m o n t h s )
1 2
Patients at risk:
Time (months) 0.07 0.10 0.47 1.50 3.00 6.00 12.00
lloprost 251 233 216 194 185 154 142
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Patients at risk:
Time (months) 0.07 0.10 0.47 1.50 3.00 6.00 12.00
lloprost 250 232 215 2195 186 158 147
Placebo 235 209 198 179 169 141 136
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0 2 6 8 10 124
Time (months)
Patients at risk:
Time (months) 0.07 0.10 0.47 1.50 3.00 6.00 12.00
lloprost 247 240 231 212 204 174 162
Placebo 232 227 215 194 186 153 147
Patency with different graft materials
The possibility of different results in patients with different graft materials was confirmed 
when bypass patency was compared for each type of graft material (Figure 19). The 
best results were obtained in patients who received reversed vein bypass grafts while 
composite vein grafts did not appear to offer any advantage over prosthetic grafts.
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Comparison of primary patency in all vein grafts with all prosthetic and vein-prosthetic 
composite grafts in Kaplan-Meier analyses appeared to confirm the superiority of vein 
grafts (Figures 20 and 21).
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Primary patency of vein grafts in all evaluable patients at 12 months was 50.4% (95%CI 
45.3-55.5) and for all prosthetic grafts 44.2% (95%CI 33.7-54.7).










v e i n  g ra fts 
p r o s t h e t i c  g ra f ts1 0
0
0 2 4 6 8 1 0 1 2
T i m e  ( m o n t h s )
Patients at risk:
Time (months) 0.07 0.10 0.47 1.50 3.00 6.00 12.00
Vein grafts 397 361 337 302 292 241 227
Prosthetic grafts 91 82 78 70 61 52 47
The secondary patency of vein grafts in all evaluable patients at 12 months was 59.4% 
(95%CI 54.0-64.8) compared to a secondary patency in prosthetic grafts at 12 months of 
47.5% (95%CI 36.6-58.4).
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0 2 4 6 8 10 12 14
T i m e  ( m o n t h s )
Patients at risk:
Time (months) 0.07 0.10 0.47 1.50 3.00 6.00 12.00
Vein grafts 349 339 324 293 284 234 222
Prosthetic grafts 85 83 78 71 64 54 48
Vein graft patency
Life-table analysis of patencies in vein grafts, as in the analysis of grafts of all materials, 
did not show any large differences between the treatment groups, although once again 
patencies in the iloprost treated group were generally higher for each category of 
patency (Figures 22-24). The primary patency rates in the two treatment groups were 
not significantly different (p=0.81). Primary patency at the end of the 12 month follow-up 
period in evaluable patients was 52.6% in the iloprost group (95%CI 45.2-60.0) and 
54.2% in the placebo group (95%CI 46.9-61.5). The difference of 1.6% in primary 
patency rates between the treatment groups at 12 months had a 95% confidence interval
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ranging from 12.0% in favour of placebo to 8.8% in favour of iloprost. Assisted primary 
patency after 12 months in evaluable patients was 60.0% for iloprost (95%CI 52.7-67.3) 
and 58.1% for placebo (95%CI 50.9-65.3). Secondary patency after 12 months was 
65.7% with iloprost (95%CI 58.7-72.7) compared to 62.0% for placebo (95%CI 54.9- 
69.1).









20 ilo p r o s t  
p l a c e b o
0 2 6 8 1 0 1 24
T i m e  ( m o n t h s )
Patients at risk:
Time (months) 0.07 0.10 0.47 1.50 3.00 6.00 12.00
lloprost 195 180 164 150 145 121 113
Placebo 202 181 173 152 147 120 114
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0 2 4 6 8 1 0 1 2
T i m e  ( m o n t h s )
Patients at risk:
Time (months) 0.07 0.10 0.47 1.50 3.00 6.00 12.00
lloprost 194 179 163 150 145 125 118
Placebo 200 180 172 153 148 122 118
The time course of graft failures showed that 22% of vein grafts had suffered an
occlusion by the time of discharge, almost half of those occluding in the first 12 months.
Secondary patency, however, was still 87% overall at discharge, the majority of
permanent occlusions occurring after discharge.
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Figure 24. Secondary patency assessments in vein grafts by study treatment
1 00 












Time (months) 0.07 0.10 0.47 1.50 3.00 6.00 12.00
lloprost 191 185 177 165 160 138 131
Placebo 198 194 186 165 161 131 126
Prosthetic graft patency
Life-table analysis of patencies in prosthetic grafts, as in the analysis of grafts of all 
materials and vein grafts alone, did not show any large differences between the 
treatment groups at the end of the follow-up period (Figures 25 and 26). Primary 
patency at the end of the 12 month follow-up period was 46.0% in the iloprost group 
(95%CI 32.2-59.8) and 43.8% in the placebo group (95%CI 26.6-61.0). However, there 
was a maximum difference of 20.4% in favour of the iloprost group between the
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treatment groups at 3 days, the end of the treatment period, with a confidence interval 
ranging from 4.2% to 36.0% in favour of iloprost. Assisted primary patency results in 
prosthetic grafts were identical to primary patency. Secondary patency of evaluable 
patients after 12 months was 52.0% with iloprost (95%CI 38.2-65.8) compared to 50.0% 
for placebo (95%CI 32.7-67.3).
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i lo p ro st  
p l a c e b o
60 2 4 8 1 0 1 2
T i m e  ( m o n t h s )
Patients at risk:
Time (months) 0.07 0.10 0.47 1.50 3.00 6.00 12.00
lloprost 55 51 50 42 38 30 28
Placebo 35 31 30 29 24 22 21
The majority of graft occlusions in the placebo group occurred before discharge, 
whereas those in the iloprost group occurred mostly after discharge. Loss of secondary 
patency in prosthetic grafts occurred most commonly after 6 weeks in both treatment 
groups.
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Limb survival and amputations
Life-table analysis yielded similar limb survival curves in the two treatment groups for 
both vein grafts (Figure 27) and prosthetic grafts (Figure 28). At the end of the 12 month 
follow-up the limb survival rates for iloprost and placebo respectively were 75.9% (95%CI 
69.2-82.6) and 76.0% (95%CI 69.7-82.3) for vein grafts and 68.8% (95%CI 55.7-81.9) 
and 67.7% (95%CI 52.2-82.2) for prosthetic grafts. The overall limb survival figures for 
the different materials were 76.0% for vein grafts and 68.4% for prosthetic grafts.
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0 2 4 6 8 1 0 1 2
T i m e  ( m o n t h s )
Patients at risk:
Time (months) 1 2 3 4 6 9 12
lloprost 56 49 47 45 40 38 35
Placebo 35 35 31 29 26 26 21
Minor amputations, toes or forefoot amputations, occurred in equal numbers in the two 
treatment groups (Table 68). Over 80% (41/49) of the minor amputations were 
performed within two months of the bypass surgery and most of these were performed 
within one month of bypass.
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Table 68. Cumulative minor amputations by month and treatment group
Month Number of patients (%'
lloprost (n=267) Placebo (n=250) Total (n=517)
1 16 (6.0) 19 (7.6) 35 (6.8)
2 19 (7.1) 21 (8.4) 40 (7.7)
3 21 (7.9) 22 (8.8) 43 (8.3)
4 22 (8.2) 22 (8.8) 44 (8.5)
5 23 (8.6) 22 (8.8) 45 (8.7)
6 23 (8.6) 22 (8.8) 45 (8.7)
7 23 (8.6) 23 (9.2) 46 (8.9)
8 23 (8.6) 23 (9.2) 46 (8.9)
9 24 (9.0) 23 (9.2) 47 (9.1)
10 25 (9.4) 23 (9.2) 48 (9.3)
11 25 (9.4) 23 (9.2) 48 (9.3)
12 26 (9.7) 23 (9.2) 49 (9.5)
The proportion of patients undergoing minor amputations was similar in those receiving 
vein grafts (9.1%) and prosthetic grafts (10.7%). The proportion of patients undergoing 
minor amputation in the two treatment groups was also similar for each type of graft 
material: 10.5% with iloprost (95%CI 6-15) and 7.9% (95%CI 4-12) with placebo in vein 
grafts and 6.3% with iloprost (95%CI 0-13) and 15.4% with placebo (95%CI 3-27) in 
prosthetic grafts.
Clinical outcome
The clinical status of the patients at the end of the follow-up showed that over half of the 
patients had a poor clinical outcome at 12 months. Overall 238 (46.0%) of the patients 
entering the study were classified as Fontaine stage I or stage II 12 months later, 78 
patients (15.1%) were still in Fontaine stage III or stage IV, 105 (20.3%) had been 
amputated and a further 85 patients (16.4%) had died. The status of 11 patients (2.2%) 
was not fully documented at the end of follow-up.
The number of patients in each Fontaine stage and those undergoing major 
amputation or dying is shown below according to treatment group (Table 69). The 
staging represents the status of the patient at the end of the 12 month follow-up and the 
last recorded Fontaine stage of those patients who had undergone a major amputation of
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the leg in which the bypass had been performed, or of those who had died is not included 
in this table. There were no significant differences between the iloprost and placebo 
treated groups at 12 months with respect to Fontaine stage or numbers of patients 
amputated or dead.
Table 69. Clinical outcome by treatment group at 12 months
Clinical outcome







Stage I 90 (33.7) 92 (36.8) 182 (35.2)
Stage II 32 (12.0) 24 (9.6) 56 (10.8)
Stage III 14 (5.2) 19 (7.6) 33 (6.4)
Stage IV 23 (8.6) 22 (8.8) 45 (8.7)
Amputation 53 (19.9) 52 (20.8) 105 (20.3)
Death 53 (19.9) 45 (18.0) 98 (19.0)
Amputation or death 101 (37.8) 89 (35.6) 190 (36.8)
Not recorded 7 (2.6) 4 (1.6) 11 (2.1)
The proportion of patients experiencing the two categories of rest pain was similar in the 
two treatment groups at all postoperative time points (Table 70). The percentage of 
patients with no pain at rest increased rapidly from 3.5% pre-operatively to over 60% on 
day 2 and approached 90% of patients in whom this could be assessed by the end of 
follow-up. A small proportion of patients (3%-7%) continued to experience continuous 
rest pain post-operatively. Patients who underwent major amputation or who died were 
included up to the time of their last assessment of symptoms.
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Table 70. Postoperative rest pain by treatment group
Time point Rest pain Number of patients (%)
lloprost Placebo Total
Day 2 None 162 (61.8) 157 (63.8) 319 (62.8)
Intermittent 86 (32.8) 82 (33.3) 168 (33.1)
Continuous 14 (5.3) 7 (2.8) 21 (4.1)
Day 3 None 169 (64.8) 164 (67.2) 333 (65.9)
Intermittent 80 (30.7) 74 (30.3) 154 (30.5)
Continuous 12 (4.6) 6 (2.5) 18 (3.6)
Discharge None 190 (75.1) 181 (76.1) 371 (75.6)
Intermittent 56 (22.1) 48 (20.2) 104 (21.2)
Continuous 7 (2.8) 9 (3.8) 16 (3.3)
3 months None 172 (78.5) 163 (79.9) 335 (79.2)
Intermittent 30 (13.7) 29 (14.2) 59 (13.9)
Continuous 17 (7.8) 12 (5.9) 29 (6.9)
12 months None 154 (88.5) 144 (86.7) 298 (87.6)
Intermittent 17 (9.8) 15 (9.0) 32 (9.4)
Continuous 3 (1.7) 7 (4.2) 10 (2.9)
Use of analgesics post-operatively did not differ greatly between the two treatment groups 
(Table 71). The continuation of epidural anaesthesia post-operatively was recorded in a 
small number of patients on days 2 and 3. On day 2 the use of opiate analgesics was 
also higher than pre-operatively (Table 24), but it was markedly reduced by the time of 
discharge. The number of patients not taking any analgesics fell immediately post- 
operatively to 17% from the 20% recorded before surgery, but rose steadily up to 71% 
three months after surgery. Between three and 12 months the percentage of patients 
assessed not taking analgesics continued to rise, but the actual number of patients fell in 
both treatment groups.
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Table 71. Postoperative analgesic use by treatment group
Time point Analgesics Number of patients (%)
lloprost Placebo Total
Pre-op. None 68 (25.4) 43 (17.2) 111 (21.5)
Non-opiates 113 (42.3) 121 (48.4) 234 (45.3)
Opiates 86 (32.2) 86 (34.4) 172 (33.2)
Day 2 None 45 (17.0) 41 (16.6) 86 (16.8)
Non-opiates 92 (34.7) 81 (32.8) 173 (33.8)
Opiates 125 (47.2) 122 (49.4) 247 (48.2)
Epidural 3 (1.1) 3 (1.2) 6 (1.2)
Day 3 None 70 (26.5) 71 (29.2) 141 (27.8)
Non-opiates 106 (40.2) 104 (42.8) 210 (41.4)
Opiates 86 (32.6) 66 (27.2) 152 (30.0)
Epidural 2 (0.8) 2 (0.8) 4 (0.8)
Discharge None 126 (49.8) 125 (52.5) 251 (51.1)
Non-opiates 100 (39.5) 81 (34.0) 181 (36.9)
Opiates 27 (10.7) 32 (13.4) 59 (12.0)
3 months None 149 (68.0) 149 (73.8) 298 (70.8)
Non-opiates 50 (22.8) 34 (16.8) 84 (20.0)
Opiates 20 (9.1) 19 (9.4) 39 (9.3)
12 months None 136 (79.1) 136 (82.9) 272 (81.0)
Non-opiates 27 (51.7) 21 (12.8) 48 (14.3)
Opiates 9 (5.2) 7 (4.3) 16 (4.8)
Tables 72 and 73 confirm that when the presence of rest pain and analgesic use are 
looked at together, there are no major differences between the treatment groups at 
discharge or at 12 months. They also show that at 12 months, there were very few 
patients who experienced rest pain despite the use of opiate analgesics and also very few 
who were still experiencing continuous pain at rest with or without analgesics. There 
were, however, a large number at 12 months who had no pain or analgesic assessment 
due to amputation or death.
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Table 72. Rest pain and analgesic use at discharge
Rest pain Analgesic







None None 122 (45.7) 124 (49.6) 246 (47.6)
Non-opiates 60 (22.5) 49 (19.6) 109 (21.1)
Opiates 8 (3.0) 8 (3.2) 16 (3.1)
Intermittent None 4 (1.5) 1 (0.4) 5 (1.0)
Non-opiates 38 (14.2) 32 (12.8) 70 (13.5)
Opiates 14 (5.2) 15 (6.0) 29 (5.6)
Continuous None 0 (0.0) 0 (0.0) 0 (0.0)
Non-opiates 2 (0.7) 0 (0.0) 2 (0.4)
Opiates 5 (1.9) 9 (3.6) 14 (2.7)
Not recorded Not recorded 14 (5.2) 12 (4.8) 26 (5.0)
Table 73. Rest pain and analgesic use at 12 months
Rest pain Analgesic







None None 133 (49.8) 132 (52.8) 265 (51-3)
Non-opiates 17 (6.4) 8 (3.2) 25 (4.8)
Opiates 2 (0.7) 1 (0-4) 3 (0.6)
Not recorded 2 (0.7) 3 (1.2) 5 (1.0)
Intermittent None 2 (0.7) 3 (1.2) 5 (1.0)
Non-opiates 9 (3.4) 10 (4.0) 19 (3.7)
Opiates 6 (2.2) 1 (0.4) 7 (1.4)
Not recorded 0 (0.0) 1 (0.4) 1 (0.2)
Continuous None 1 (0.4) 1 (0.4) 2 (0.4)
Non-opiates 1 (0.4) 2 (0.8) 3 (0-6)
Opiates 1 (0.4) 4 (1.6) 5 (1.0)
Not recorded None 0 (0-0) 0 (0.0) 0 (0.0)
Non-opiates 0 (0.0) 1 (0.4) 1 (0.4)
Opiates 0 (0-0) 1 (0.4) 1 (0.4)
Not recorded 93 (34.8) 82 (32.8) 175 (33.8)
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In the early post-operative assessments of trophic lesions, the percentage of patients with 
ulcers was slightly higher in the group of patients treated with iloprost (Table 74), but the 
magnitude of the differences were similar to the 7% difference in incidence of ulcers 
noted prior to surgery (Table 25). The numbers of patients without ulcers increased up to 
three months, but then fell at 12 months, although continuing to rise as a percentage, due 
to the large fall in the number of patients assessed having ulcers.
Table 74. Postoperative ulcers by treatment group
Time point Ulcers Number of patients (%)
lloprost Placebo Total
Pre-op. Absent 126 (48.1) 134 (48.1) 260 (48.1)
Present 141 (51.9) 115 (51.9) 256 (51.9)
3 days Absent 127 (48.1) 133 (54.7) 260 (51.3)
Present 137 (51.9) 110 (45.3) 247 (48.7)
Discharge Absent 134 (53.2) 143 (60.6) 277 (56.8)
Present 118 (46.8) 93 (39.4) 211 (43.2)
3 months Absent 158 (71.8) 153 (75.4) 311 (73.5)
Present 62 (28.2) 50 (24.6) 112 (26.5)
12 months Absent 150 (87.7) 140 (87.0) 290 (87.3)
Present 21 (12.3) 21 (13.0) 42 (12.7)
The percentage of patients with gangrene was higher in the iloprost group at discharge 
(Table 75), but once as with the incidence of ulcers, the difference in incidence of 
gangrene, of the order of 10%, was not very different from the 7% difference observed 
between the treatment groups before surgery (Table 25). The numbers of patients with 
gangrene fell throughout the follow-up period in both groups.
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Table 75. Postoperative gangrene by treatment group
Time point Gangrene Number of patients (%)
lloprost Placebo Total
Pre-op. None 143 (53.6) 152 (60.8) 295 (57.1)
Dry 89 (33.3) 70 (28.0) 159 (30.8)
Wet 20 (7.5) 12 (4.8) 32 (6.2)
Dry and wet 15 (5.6) 15 (6.0) 30 (5.8)
3 days None 143 (54.2) 150 (61.5) 293 (57.7)
Dry 91 (34.5) 69 (28.3) 160 (31.5)
Wet 16 (6.1) 16 (6.6) 32 (6.3)
Dry and wet 14 (5.3) 9 (3.7) 23 (4.5)
Discharge None 146 (57.9) 162 (68.4) 308 (63.0)
Dry 84 (33.3) 57 (24.1) 141 (28.8)
Wet 10 (4.0) 10 (4.2) 20 (4.1)
Dry and wet 12 (4.8) 8 (3.4) 20 (4.1)
3 months None 182 (82.7) 180 (88.7) 362 (85.6)
Dry 27 (12.3) 12 (5.9) 39 (9.2)
Wet 5 (2.3) 7 (3.4) 12 (2.8)
Dry and wet 6 (2.7) 4 (2.0) 10 (2.4)
12 months None 166 (97.1) 158 (97.5) 324 (97.3)
Dry 5 (2.9) 3 (1.9) 8 (2.4)
Wet 0 (0.0) 1 (0.6) 1 (0.3)
Combining information on ulcers and gangrene to give the presence of any trophic lesions 
showed a greater number of patients in the iloprost group with lesions at discharge (Table 
76). However, the number of patients without lesions rose in both groups during the 
follow-up and was numerically greater in the iloprost treated group at 12 months. Almost 
14% of patients who had not undergone major amputation or died continued to have 
trophic lesions after 12 months.
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Table 76. Postoperative ulcers and gangrene by treatment group
Time point Ulcers or 
gangrene



































Following surgery, arterial pressures measured by Doppler at the ankle or calf were 
substantially higher in both treatment groups. At discharge measurements were available 
on 84% of the patients alive without a major amputation and the highest recorded ankle 
pressures and the ABPI were similar in the two treatment groups (Table 77). At 12 
months measurements were recorded on 82% of the patients alive and without a major 
amputation. At this time point the ankle pressure and the ABPI were somewhat higher in 
the iloprost treated group (Table 78). Mean ankle systolic pressures at 12 months in 
surviving limbs were iloprost 145 mmHg (95%CI 137-153) and placebo 136 mmHg 
(95%CI 128-144). Mean ABPI at 12 months in these patients were iloprost 0.92 (95%CI 
0.87-0.97) and placebo 0.86 (95%CI 0.82-0.90).
Table 77. Doppler pressures at discharge
Variable lloprost Placebo Total
Brachial artery 143 ±22 (n=207) 142 ±23 (n=184) 143 ±22 (n=391)
Ankle: mean ± SD 126 ±46 (n=202) 124 ±44 (n=177) 125 ±45 (n=379)
ABPI: mean ± SD 0.88 ±0.30 (n=204) 0.87 ±0.28 (n=179) 0.87 ±0.29 (n=383)
Table 78. Doppler pressures at 12 months
Variable lloprost Placebo Total
Brachial artery 158 ±23 (n=139) 157 ±30 (n=129) 157 ±27 (n=268)
Ankle: mean ± SD 145 ±50 (n=137) 136 ±45 (n=127) 141 ±47 (n=264)
ABPI: mean ± SD 0.92 ±0.28 (n=137) 0.86 ±0.25 (n=128) 0.89 ±0.27 (n=265)
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4.6. Results by trial centre
The type of patients entered into the trial in the different participating centres were similar 
in most respects, but some differences could be observed in the disease severity as 
indicated by the symptom severity score and the pre-operative ankle pressure (Figure
29).
Figure 29. Measures of disease severity by centre
(a) Mean pre-operative symptom 
score by centre
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Although pre-operative disease severity does not necessarily mean a worse outcome in 
terms of bypass patency, it is more likely to be of importance when considering clinical 
outcomes as illustrated by the association of the pre-operative symptom score with 
various outcome measures (Figure 30).
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Figure 30. Association of symptom severity scores with various outcome measures. 
Graphs show median, interquartile range, 10% and 90% deciles and position of outliers.
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Patient management also varied between the centres with respect to vein graft 
surveillance and the use of oral antithrombotic agents after discharge. Vein graft 
surveillance by duplex ultrasound was optional in the study and not performed at all 
centres. It was additionally not performed on all patients in those centres which did have 
the facility and the proportion of grafts in which stenoses were detected varied somewhat 
between centres (Table 79).
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Table 79. Frequency of graft surveillance and incidence of graft stenoses by centre in 
vein grafts or grafts containing vein segments in eligible patients
Centre No. of patients 
operated and 
eligible
No. of patients 
scanned (as % of 
those eligible)
No. of patients with 
stenoses (% of 
those scanned)
No. of patients 
with composite 
vein grafts (%)
1 3 0 (0) - -
2 16 15 (94) 3 (20) 0 (0)
3 26 25 (96) 8 (32) 5 (20)
4 5 5 (100) 2 (40) -
5 59 42 (71) 23 (55) 9 (21)
6 5 1 (20) 0 (0) -
7 9 8 (89) 3 (38) 1 (13)
8 36 36 (100) 12 (33) 6 (17)
9 10 9 (90) 2 (22) 2 (22)
10 8 3 (38) 2 (33) -
11 8 8 (100) - -
12 72 66 (92) 6 (9) 1 (2)
13 22 14 (64) 1 (7) 0 (0)
14 4 0 (0) - -
16 4 4 (100) 0 (0) -
17 3 0 (0) - -
18 17 14 (82) 2 (14) 1 (7)
19 20 18 (90) 4 (22) 5 (28)
20 17 15 (88) 4 (27) 0 (0)
21 1 0 (0) - -
22 7 7 (100) 2 (29) -
Total 352 290 (82) 76 (26) 30 (10)
Four centres included more than 20 patients with vein grafts in the surveillance 
programme and in these centres the incidence of stenoses detected in vein and vein- 
prosthetic composite grafts ranged from 9% to 55%. Amongst these four centres, the 
centre with the highest incidence of stenoses also included the highest proportion of 
composite vein-vein grafts amongst the grafts scanned: 9/42 (21%) compared to 30/289 
(10%) in the study population as a whole and 1/66 (1.5%) in the centre with the lowest 
incidence of detected stenoses.
Usage of oral antithrombotic agents during the post-discharge follow-up varied 
greatly, both by centre (Figure 31). Most striking was the almost universal use of oral
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anticoagulants in the patients included from the Netherlands (centres 6 and 7 in Figure 
31b). The use of aspirin was notably more frequent in the United Kingdom than 
elsewhere (centres 1, 3 and 4 in Figure 31a) while there was commonly an absence of 
any long-term antithrombotic medication in a couple of centres (Figure 31c).
Figure 31. Use of long-term antithrombotic agents by centre
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The randomisation of patients to receive either iloprost or placebo was stratified by centre 
and the distribution of patients in the two treatment groups was therefore well-balanced in 
each centre (Table 80).
Table 80. Distribution of patients in the two treatment groups by centre
Centre n
No. of patients (%)
lloprost Placebo
1 11 6 55) 5 45)
2 29 14 48) 15 52)
3 37 19 51) 18 49)
4 11 7 64) 4 36)
5 77 39 51) 38 49)
6 16 10 63) 6 37)
7 19 10 53) 9 47)
8 42 21 50) 21 50)
9 17 9 53) 8 47)
10 9 5 56) 4 44)
11 12 7 58) 5 42)
12 100 50 50) 50 50)
13 38 20 53) 18 47)
14 4 1 25) 3 75)
16 8 4 50) 4 50)
17 6 3 50) 3 50)
18 23 12 52) 11 48)
19 23 12 52) 11 48)
20 25 12 48) 13 52)
21 1 1 ( 00) 0 (0)
22 9 5 56) 4 44)
Total 517 267 52) 250 48)
Despite the wide variation in overall individual centre patency and amputation results, 
there was generally no evidence of superiority of either iloprost or placebo in individual 
centres (Figures 32 to 35), except in centres 5 and 9 in which the patency appeared 
respectively better and worse with iloprost. Patency rates varied between treatment 
groups by as much as 30%, but the confidence intervals indicated the likelihood that the 
differences may have been random in origin.
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Figure 32. Primary patency at 12 months with iloprost and placebo in all patients by 
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Figure 33. Differences in primary patency at 12 months between the two treatment 
groups by centre (iloprost - placebo percentage with 95% Cl). Centres shown are the 12 
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Figure 34. Percentage of patients with major amputation with iloprost and placebo in all 
patients by centre (percentages and 95% Cl). Centres shown are the 12 largest 
recruiting centres numbered in sequence.
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Figure 35. Differences in major amputation rate at 12 months between the two treatment 
groups by centre (iloprost - placebo percentage with 95% Cl). Centres shown are the 12 
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4.7. Evaluation of the clinical relevance of the primary efficacy endpoint used in 
the trial
In order to evaluate the clinical relevance of primary patency of the bypass, the primary 
endpoint selected for this trial, the association of primary patency with the clinical 
outcome (irrespective of treatment group) was assessed by classifying each patient as 
having a good or poor clinical outcome. A good clinical outcome was defined as a patient 
having an intact limb and peripheral arterial disease Fontaine stage I or II. A poor 
outcome was a patient in stage III or IV or who had undergone a major amputation of the 
limb operated. The resulting association of primary patency with clinical outcome is 
illustrated below for all patients in whom both a clinical outcome and primary patency 
could be established at 12 months (Figure 36).
Figure 36. Concordance of patients with primary patency and a good clinical outcome at 
12 months
Patients with primary patency
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Patients with good clinical outcome
The concordance of primary patency with clinical outcome was thus 80.4% with a false 
positive rate of 6.7% and a false negative rate of 12.9%. Alternatives to primary patency 
could be considered as trial endpoints. The number of patients free of any vascular 
intervention in the relevant limb is another technical endpoint which may convey useful 
clinical information and composite endpoints including both technical endpoints, 
amputation and survival may provide a good overall outcome measure.
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The extent to which the intervention-free rate represents the patients with a good 
clinical outcome is shown below for all patients surviving to 12 months or undergoing a 
vascular procedure prior to that (Figure 37). Information on both interventions and clinical 
outcome was available for 414 patients. It can be seen that a total of 236 patients were 
intervention-free, but that 41 of these had a poor clinical outcome at 12 months. These 
41 cases could be considered as false positives if being intervention-free is interpreted as 
a indicative of a good clinical outcome, a false positive rate of 9.9%.









Patients with good clinical outcome
A certain number of the interventions performed could have been indicated, not by clinical 
symptoms, but according to haemodynamic criteria due to the development of graft 
stenoses. However, these comprised only a small proportion of the interventions 
performed in this study and in each of the cases in this study where a dilatation of a graft 
stenosis was the only intervention performed, the patient had been suffering from 
persisting or recurring symptoms. There were in effect then no false negatives as the 
interventions in all 178 patients were indicated by a poor clinical outcome to the initial 
bypass procedure, even if 46 of them subsequently had a good outcome. There was 
therefore an agreement of intervention as an endpoint with the clinical outcome from the 
initial operation in 90.1% of cases.
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Combined technical and clinical outcome measures
The number of patients in whom the composite endpoint agrees with the clinical outcome 
is illustrated for patients surviving without intervention (Figure 38) and for patients 
surviving with an intact limb and primary patency (Figure 39).
Figure 38. Concordance of patients surviving without intervention and clinical outcome at 
12 months
n=517
Patients surviving without intervention
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Patients with good clinical outcome
The endpoint ‘patients surviving intervention-free’ showed a false positive rate of 41/517 
patients or 7.9% (Figure 38). There are in effect no false negatives as it was assumed 
that all patients undergoing an intervention would have had a poor outcome without it. 
The false positive rate was lower for ‘patients surviving with an intact limb and primary 
patency’ at 28/517 or 5.4%, but the false negative rate was higher at 54/517 or 10.4% 
(Figure 39).
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Figure 39. Concordance of ‘patients alive with an intact limb and primary bypass patency’ 
and clinical outcome at 12 months
n=517
Patients surviving with 
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Summary of concordance of different endpoints with clinical outcome 
The rates of false positives and false negatives which would have occurred taking each of 
the various technical and composite endpoints as surrogates for clinical outcome 
measured in terms of Fontaine stage are summarised below including secondary bypass 
patency which might be expected to be closer to clinical outcome than primary patency 
(Table 81). The best overall agreement of endpoint and clinical outcome was obtained 
with patients who were ‘intervention-free’ or ‘surviving and intervention-free’. Excluding 
patients who had only a PTA of a graft stenosis from those judged to have undergone an 
intervention, did not improve the agreement of these endpoints with clinical outcome.
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Table 81. Rates of false positives and false negatives with various technical and
composite endpoints as surrogates for clinical outcome












































5.2. Discussion of iloprost study results
Underlying statistical and clinical assumptions
The study assumed a primary patency rate in the control group of 75% at 12 months and 
was designed to detect an improvement to 87.5% in the treated group. This represents 
an absolute improvement of 12.5% in patency and a relative improvement of 16.7% in the 
success rate or a relative reduction of 50% in the failure rate. The sample size required 
to demonstrate this with a=0.05 and p=0.10 was calculated to be 221 patients per group. 
Due to the higher proportion of patients receiving prosthetic grafts than had been 
expected, almost 18% compared to the expected 10%, the number of vein grafts included 
in the trial fell slightly short of the desired number with groups sizes of 209 and 215. This 
modest shortfall resulted in a small loss of power to detect the desired difference. More 
remarkable was the much lower than anticipated patency rate in the control group.
It is rare to find reports in the literature of a large series of femorodistal vein grafts 
with such a low primary patency rate at 12 months. Factors which may help to explain 
this are the inclusion of patients with immediate graft occlusion as loss of primary 
patency, the strict monitoring and checking of records against the hospital notes by 
external study monitors, the completeness of the follow-up with very few patients lost and 
the multicentre design of the study. Also, the very fact of the trial taking place may have 
led surgeons to operate in more difficult cases in the belief that the study medication 
would improve the chances in cases which would otherwise have been left or amputated.
A review of the literature found that many trials of adjuvant therapy in peripheral 
bypass excluded immediate bypass occlusion on the grounds that it is a technical failure 
and not a failure of treatment. This may also be the case in many reports of uncontrolled 
surgical series. The checking of trial records against hospital notes helps to ensure a 
common understanding of, and application of, the agreed definitions in a multicentre trial. 
This is particularly important in questions where there is room for interpretation, such as 
in the definition of an intervention and assisted primary patency. The difference in results 
obtained from a typical surgical follow-up and from the more complete follow-up which 
can be achieved when a priority is given to this task has been well illustrated by Jensen et 
al (1996) who showed a reduction in primary patency from 68% in their surgical registry to 
52% in a controlled trial. It should not therefore be assumed that those patients 
successfully followed in this surgical indication are representative of all those entered into 
a trial.
The multicentre nature of this trial compared to the single centre nature of many 
published research projects may also partly account for the poorer than expected results.
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There is a recognised publication bias in favour of larger and more positive studies and 
this may also extend to the uncontrolled surgical series. A small series is less likely to be 
published than a large one and a surgeon may be more interested in publishing a set of 
good results than a bad run of results. Since this study included data from small centres 
as well as large centres, these biases together with the other factors discussed would 
lead to an overoptimistic assessment of primary patency in these procedures when based 
solely on reports in the literature.
In the light of the measured primary patency rate in the control group, calculations 
can be made of the power of the study to demonstrate that the differences observed were 
real and of the sample size which would have been required to demonstrate a treatment 
effect of the desired magnitude in this situation (Table 82).
Table 82. Effect of statistical assumptions on sample size with a=0.05 and (3=0.10






Original protocol assumptions 75.0% 87.5% 221
Actual result in vein grafts 51.8% 52.3% 210,193
Actual result in prosthetic grafts 41.9% 46.0% 3,127
Desired absolute 12.5% reduction in 
failure rate
51.8% 64.3% 342
Desired relative 50% reduction in 
failure rate
51.8% 75.9% 90
Desired relative 16.7% increase in 
success rate
51.8% 60.4% 721
The data in Table 82 illustrate that the difference between the expected patency rate in 
the control group and the patency rate observed in the control group has different effects 
on the required sample size depending on how the underlying assumptions are derived. 
Do a certain proportion of the whole population fail because of poor blood flow, or is it a 
certain proportion of those failing which do so because of poor blood flow? This 
distinction is important if the patency rate in the control group turns out to be quite 
different from that expected. An assumption that 12.5% of all grafts may fail due to 
factors which can be prevented by an improvement in graft blood flow leads to the 
requirement for a larger sample size of 342 patients. If, on the other hand it is expected 
that half of all graft failures (irrespective of how many fail) are preventable by this means, 
then the larger number of failures provides a larger target to shoot at and the sample size 
requirement is greatly reduced. Lastly, if the assumption is based on the relative increase
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in the number of patent grafts, then a significantly larger number of patients will be 
required.
There was in fact an additional factor which was important in constructing the 
original assumptions of this study and that was the minimum effect which would be 
clinically worthwhile. It was considered that an absolute improvement of 10% in primary 
patency at 12 months was the least which would be required to make use of the treatment 
attractive. This was combined with the expectation that early graft failures (between 2 
days and 3 months after surgery), which account for about half of all failures in the first 12 
months, would be those amenable to prevention with the treatment. It was, therefore, 
decided to design a study capable of detecting an absolute improvement of 12.5% in the 
patency rate, assuming a control rate of 75%. In view of the greater than expected 
occlusion rate observed in the control group, it might have been expected that an 
effective agent acting in the desired manner would have produced a larger absolute 
improvement in primary patency. This was not found to be the case. Additionally, the 
95% confidence intervals indicate that any real benefit from iloprost treatment on the 
primary patency of femorodistal vein bypass procedures is unlikely to exceed an 8 .8% 
absolute improvement.
Comparability of treatment groups
The two treatment groups were found to be broadly well-matched in terms of their 
demographic and pre-operative disease characteristics. Four differences between the 
groups are worth exploring for their possible influence on post-operative outcome. There 
was a 3.3 % higher incidence of smokers in the placebo group, 5.2% more women in the 
iloprost group, 3.6% more patients in Fontaine stage IV in the iloprost group and, related 
to this, a significantly greater percentage (9.8%) of patients with both ulcers and 
gangrene in the iloprost group. Of these factors, only the proportion of women receiving 
bypasses has been shown to be associated with the patency of vein grafts (Magnant et al 
1993). Both the presence of trophic lesions and smoking, however, have been linked with 
limb salvage and survival (Woodburn et al 1996).
The magnitude of the imbalances in distribution between the groups with respect 
to sex and smoking seem unlikely to have significantly prejudiced the outcome of the trial 
on their own. The strong association of pre-operative disease severity with limb salvage 
after peripheral bypass surgery previously reported (Woodburn et al 1996) suggests that 
the possible influence on amputation rates of the disparity in incidence of trophic lesions 
should be considered.
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The difference in prognosis of vein grafts and prosthetic grafts was accounted for 
by analysing the technical outcome with the two graft materials separately. Other 
differences between the groups in technical aspects of the bypass procedures were 
restricted to the diameter of the vein grafts, which appeared to be smaller in the iloprost 
group. A smaller vein graft diameter has previously been linked to a poorer long-term 
patency of reversed vein femoro-infrapopliteal grafts (Wengerter et al 1990) and may 
have influenced the comparison of the two treatment groups.
Treatment and post-operative management
The number of patients in whom the treatment was interrupted or discontinued early was 
small, such that it should be considered that the planned treatment regimen was 
adequately tested.
As in earlier studies of an intragraft injection of iloprost, there was a transient, but 
significant decrease in systolic and diastolic pressure for a few minutes after the intra- 
operative administration (Hickey et al 1991). The longer intravenous infusions given post- 
operatively in this study could, if a similar effect was produced, have given rise to a steal 
phenomenon and a reduction in flow through the bypass graft in some patients. This may 
have masked any benefit derived by other patients. In order to investigate this possibility, 
analysis of patency was undertaken dividing patients into those who had experienced falls 
in blood pressure and those who had not. No influence of blood pressure changes on 
bypass patency was found.
Other antithrombotic agents were given to about 65% of patients at some stage 
during the follow-up period. More patients received oral anticoagulants than antiplatelet 
agents. Aspirin was used in 5.7% less patients in the iloprost group than in the control 
group. Antiplatelet drugs have been shown to reduce the likelihood of peripheral bypass 
graft occlusion (Antiplatelet Trialists’ Collaboration 1994b), suggesting that this difference 
could have exerted some influence on the investigation of a treatment effect on bypass 
patency.
Bypass patency
The success of a femorodistal bypass operation for severe ischaemia can be judged in 
terms of bypass patency, avoidance of amputation and resolution of the clinical 
symptoms. The first two of these criteria are those which are most commonly reported in 
the literature. Patency rates reported for femorocrural bypass have improved over time, 
but more recent literature reports still range for example from 45% in prosthetic grafts 
(Sayers et al 1994) to 87% in vein grafts (Porter 1993) at 12 months. It is often difficult to
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know if results being quoted are true primary patency rates or include assisted primary 
patency or refer to secondary patency. The majority of reports come from single centres 
and differences in patient selection, surgical technique and follow-up also contribute to 
the variation in results reported. However, a consistent feature of published series is that 
much better results are obtained with vein grafts than with prosthetics. A surprising 
feature of the primary patency rates in this study, therefore, was that the difference 
between the two materials was only 7.0% at 12 months on life-table analysis. Most 
reported series quote higher patency rates in vein grafts, but the inclusion of over 400 
such procedures in this study from over twenty specialised vascular centres leads to the 
conclusion that these results are representative of the general situation. The findings are 
lent additional weight by the fact that the study was independently monitored and 
produced 12 month follow-up data on patency in over 97% of the cases operated.
Patient selection and clinical outcome
All of the patients included in this trial were deemed by the operating surgeons to be 
critical. It is clear that all of the patients had severe lower limb ischaemia, but interesting 
to note that almost half of the patients failed to comply with the European consensus for 
the definition of critical ischaemia (European Working Group on Critical Leg Ischaemia 
1991). This clearly makes comparison with other series difficult, but more importantly 
raises serious questions about the correct definition of critical ischaemia in relation to 
reconstructive surgery.
The limb salvage rate after bypass surgery was also not significantly influenced by 
iloprost treatment. The overall major amputation rate of 20.3% at 12 months is 
comparable to many published studies (Harling et al 1987), but should probably be 
considered in the context of the overall clinical outcome. In addition to the patients who 
underwent amputation, 16.4% died in the course of the follow up and 15.1% were still 
suffering from severe ischaemic symptoms at 12 months. Less than half of the patients 
had an improved clinical status 12 months after the operation. Clinical outcome in 
patients undergoing bypass surgery is rarely reported and assuming that these results are 
typical, it suggests that bypass patency does not always result in an improved clinical 
outcome. The results concerning mortality, amputation rate and clinical outcome are very 
similar to recent results from a Swedish population based vascular surgical registry 
supporting the generalisability of the findings (Bergqvist et al 1994).
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Study design
Previous studies with iloprost in this indication have shown dramatic effects on distal 
resistance and graft blood flow (Hickey et al 1991, Smith et al 1992) and evidence of a 
beneficial effect on bypass patency (Smith et al 1993). There are a number of 
differences between the earlier studies and the present study. The most striking one is 
that this study is much larger and in this respect more likely to reflect results when iloprost 
is used widely. However, all of the studies were placebo controlled and double blind and 
there are other factors which may influence this conclusion. The treatment regimen in the 
earlier studies consisted of only a single intra-graft injection of iloprost, whereas in this 
study three post-operative intravenous infusions were also given. It had been expected 
that the addition of post-operative infusions would confer an additional benefit due to the 
improvement of tissue perfusion and the anti-thrombotic effect of iloprost, but it is also 
conceivable that a tendency to lower the systemic blood pressure resulted in a steal 
phenomenon in some patients masking the benefit derived in other cases. Analysis of 
early patency by decreased blood pressure did not support this argument, but a more 
subtle steal effect cannot be ruled out.
The other major differences between the study designs relate to the fact that the 
earlier studies were performed in single centres with consistent policies on patient 
selection, surgical technique and anaesthetic regimen, whereas this study was performed 
in 21 vascular surgical centres. Although all centres adhered to a strict study protocol 
with criteria for patient inclusion in the study, there was no way of standardising the 
original decision that the patient was suitable for a femorodistal bypass procedure. It is 
also inevitable that there were differences in preferred surgical techniques and 
concomitant medications. However, the various techniques were generally evenly 
distributed between the two treatment groups, other than the use of vein or prosthetic 
grafts, and there are currently no known interactions between iloprost and other 
concomitant medications used in this study.
The inclusion of prosthetic grafts in a study primarily designed to investigate the 
use of iloprost in vein grafts was unavoidable due to the initiation of treatment pre- 
operatively. It is not always known in advance of the operation if the patient’s vein will be 
of sufficiently good quality to provide a conduit. The decision to use prosthetic material 
may therefore be made during the operation after the patient has been randomised and 
the study treatment initiated. In these circumstances, even if the treatment were 
terminated as soon as it was known that the patient would receive a prosthetic graft, the 
patient would have to be followed up according to the study protocol, in order to monitor 
the safety of the treatment which had been given. Intention-to-treat analysis might also
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be interpreted to dictate that these patients would have to be included in the analysis of 
bypass patency. Since it was thought that the prosthetic grafts might also benefit from 
iloprost treatment, the most straightforward solution was to establish a priori that all 
patients randomised would receive the full treatment regimen, but that those receiving 
vein grafts would be analysed separately from those receiving prosthetic grafts. It was 
anticipated that prosthetic grafts would comprise only ten per cent of the study population 
and that the analysis of them would not, therefore, give a very precise estimate of the 
treatment effect.
Conclusions of iloprost study
In this study no beneficial effect of iloprost was shown in patients receiving vein grafts. 
Although not the primary objective of the study, a reduction in prosthetic graft failure by 
iloprost was shown in the immediate post-operative period offering the possibility that a 
longer term benefit might be shown in such cases if the duration of treatment could be 
extended. The two groups were generally well balanced, but differed slightly in three 
respects: the proportion of females, vein graft diameter and use of aspirin. The extent to 
which these characteristics are might influence the comparison of patency rates is 
disussed in the next section.
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5.2 Discussion of trial methodology
Adjuvant medical therapy in peripheral bypass surgery
It has been pointed out previously that peripheral vascular bypass grafts are an excellent 
model for evaluating antithrombotic therapy (Society for Vascular Surgery Ad Hoc 
Committee on Clinical Research 1992). Compared to CABG procedures patency is 
easier to establish and only one graft is performed per operation. Nonetheless, the 
review of the literature in this field showed that many drug trials have not been well- 
designed by current standards of clinical research. Although there seems to be good 
evidence for the use of aspirin in prosthetic bypass grafts and for another platelet 
inhibitor, ticlopidine, in autogenous saphenous vein grafts, the wider use of these and 
other agents for the maintenance of peripheral bypass grafts cannot be justified on the 
basis of current evidence. Principal criticisms of the trial methodology employed 
concerned the patient selection criteria, the lack of double-blind design and placebo 
controls, and the lack of information on clinical outcome.
Patient selection
Patient selection in clinical trials may be categorised as inclusive or exclusive (Sniderman 
1999). An inclusive design will lead to patient selection largely on the basis of having the 
right disease or in the case of surgery, undergoing broadly the same type of procedure. 
Such a trial will tend to be larger, but may leave open questions concerning benefit or lack 
of benefit in specific sub-groups, such as different graft materials in bypass surgery. It is 
necessary in such a trial to categorise the patients with respect to potentially relevant 
determinants of outcome in order to be able to investigate this question. An exclusive 
design will study effects in a more narrowly defined group of patients, for example, 
patients receiving femorotibial vein grafts with single vessel run-off. In this case the 
specific benefit of the drug will be clear, but the generalisability of the findings to other 
patients with the same disease but undergoing different procedures is not possible.
The composition of the patient groups can influence markedly the likelihood of 
attaining good surgical and clinical results. The importance of severity of disease was 
probably underrated in the iloprost trial as entry was restricted to patients with rest pain or 
trophic lesions. Inclusion of patients with intermittent claudication adding to the range of 
disease severity has enabled other authors to show more clearly the importance of 
symptom severity for clinical outcome (Belkin et at 1995, DeWeese et al 1977, Rafferty et 
al 1987) and also sometimes an association with patency (Ameli et al 1988, Lawson et al
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1999). If these are to be endpoints of the trial or contribute to a composite primary 
endpoint, then there needs to be some balance in the symptom severity.
Including a mixture of patients with rest pain and those with trophic lesions makes 
it difficult to measure the balance of different symptoms between treatment groups. A 
single scoring system summarising the disparate pre-operative symptoms could be used 
either to stratify the randomisation of patients, in a process of adaptive randomisation to 
ensure balanced groups or to explore the influence of symptom severity as an aid to 
testing the robustness of the trial results. The symptom scoring systems utilised here 
appeared to be relevant to the clinical outcome and proved easy to apply in different 
surgicai centres due to the unambiguous nature of the classifications. Extending the 
scoring system to include patients with intermittent claudication would increase the 
usefulness of such a score as few studies concentrate exclusively on patients with rest 
pain and trophic lesions.
The observation that different graft materials give differing patency results in distal 
procedures is not new, but this series indicates that the difference after 12 months 
between vein and prosthetic grafts may be smaller than suggested by other studies 
(Tilanus et al 1985). It was also found that composite vein-vein grafts gave notably poor 
results compared to grafts of a single vein segment, and no better than those obtained 
with prosthetic materials. The inclusion of these grafts may have partly explained the 
small overall difference between vein and prosthetic grafts. This may be linked to the 
higher incidence of stenoses found in the composite grafts and poor quality of the conduit 
rather than the fact of having an extra anastomosis per se. This factor is probably less 
important in trials of shorter and more proximal bypass grafts where prosthetic material 
yields better results and composite vein grafts are rare. In trials in femorodistal bypasses, 
it could be considered whether composite grafts should be excluded in order to avoid the 
risk of unbalancing the treatment groups due to unequal distribution of the small numbers 
of these grafts between the treatment groups. This was arguably a weakness in the 
design of the iloprost study.
Perhaps more importantly for clinical trials of drugs designed to reduce graft 
failure, the meta-analysis of published platelet inhibitor trials presented here indicates that 
some drugs may be effective in one type of graft, but not in another. Such effects need to 
be investigated in prospectively planned analyses, as in the iloprost trial, or in separate 
trials. This is a weakness in about half of the published trials. In the absence of such 
information, meta-analysis of published trials may help to establish the value of treatment 
in important subgroups of patients.
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Study design
The difference in the results of the smaller single centre iloprost studies and the larger 
multicentre study is not unusual in clinical drug development. It may be partly explained 
by the exclusive nature of the initial single centre studies and the inclusive design of the 
larger multicentre study. Whilst it is possible that the assumption that graft blood flow 
was an appropriate surrogate variable was misplaced and that the results from two small 
studies were due to statistical chance. It might also be concluded that the results 
obtained in the initial studies (Smith et al 1993) were not wrong, but that they were simply 
not applicable to the larger and less homogeneous population of patients undergoing 
distal bypass procedures in the average vascular centre. Support for this interpretation 
can be found in the observation that centre 5 in the multicentre iloprost trial, which 
performed one of the earlier studies (Hickey et al 1992), reproduced their earlier result 
with a 20% higher patency rate with iloprost than with placebo. Few (12%) of the 
published studies of adjuvant therapy reviewed had a multicentre design and this is a 
drawback when considering the applicability of the results to patients treated in other 
centres.
The question of sample size is related to this as single centre studies tend to be 
smaller due to the time taken to accumulate a sizeable series of patients in one centre. 
Many of the studies reviewed had an inadequate sample size for the drug effect which 
could realistically be anticipated. A distinction though should be drawn between studies in 
vein grafts and those in prosthetic grafts as the prosthetic graft studies had much higher 
failure rates in the untreated control groups (Green et al 1982, Goldman et al 1983, 
Donaldson et al 1985), reducing the sample size requirements.
Multicentre trials are preferable in establishing the general applicability of results 
obtained from single centre studies. In multicentre trials it remains important to avoid as 
far as possible the inclusion of centres with small numbers of patients. This can 
unbalance the study by failure to complete randomisation blocks leading to bias due to an 
individual surgeon’s influence through patient selection and operating techniques. Small 
numbers of cases per centre also make the investigation of any centre effect more 
difficult due to the resulting wide confidence intervals.
The lack of effect of iloprost in this multicentre trial has been attributed to the 
inclusion of a heterogeneous population and inconsistent surgical policies (Shearman et 
al 1997). However, this explanation could not be substantiated with the information 
available on the centres. Despite the various differences between the centres in patients 
and procedures, most of the individual centres did not differ from each other in the 
treatment effects shown with iloprost. The intercentre differences in disease severity and
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choice of surgical procedure leave the possibility of such differences in outcome in future 
studies and should be investigated in multicentre trials in this indication. However, there 
are certain methodological problems in comparing the results in different centres. The 
sample size is often small resulting in wide confidence intervals. Differences in the 
completeness of the data is a further problem covered in another section. Similar 
problems have been pointed out to influence medical audit (Elfstrom et al 1996), and the 
data presented here emphasise the difficulty in collecting information on sufficient 
numbers of patients to be able derive meaningful conclusions about the success of 
certain types of surgical procedures in individual centres. In spite of a patient recruitment 
phase lasting 18 months, the median number of patients entered per centre was just 17. 
Not all femorodistal bypass procedures performed over this period will have been entered 
into the study, but the exclusion criteria were as few as possible without compromising 
patient safety and the scientific validity of the study. In addition, no other 
pharmacotherapeutic studies were known to be running in this indication in the centres 
participating and difficulty in obtaining patient consent was not raised as a major issue 
limiting recruitment of patients. It seems likely that on average about 50% of the patients 
undergoing such femorodistal bypass procedures at the participating centres were 
entered into the study, although the range may have been very large. A register of all 
eligible patients operated at the participating centres during the recruitment period would 
have been of interest, but was not compiled in this trial.
It is desirable to identify ‘good’ surgical centres for clinical trials in order to be sure 
that benefits of new therapeutic approaches are not masked by surgical deficiencies, but 
it is clearly difficult to collect sufficient results from individual surgeons or centres to be 
sure of reaching reliable conclusions about the technical and clinical outcomes. 
Additional data which could help to assess the centres in future studies would be previous 
data on the number and outcome of similar operations and data on the patients excluded 
during the duration of enrolment into the trial.
A criticism of the iloprost study could be that half of the centres recruited less than 
the planned minimum of ten patients per centre. Whilst overall patency and clinical event 
rates varied more widely amongst the smaller centres, the three largest centres produced 
iloprost effects on patency which varied from significantly better than placebo to 
significantly worse. Data from the larger centres also emphasised the differences which 
can emerge in the characteristics of the patients included by different centres even 
though they are following a common trial protocol. This serves once again to emphasise 
the case for multicentre trials to provide findings of general clinical relevance.
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An alternative approach to assessing the effectiveness of a new treatment in a 
variety of surgical centres is to perform a meta-analysis of the data from a number of 
single centre trials. However, where heterogeneity between the results of different 
studies exists, this should be investigated wherever a plausible explanation exists 
(Thompson et al 1994). This was illustrated with the example of aspirin studies in 
peripheral bypass.
Study endpoints
The usefulness of a new drug for the treatment of almost any condition can be 
determined by the answers to two questions: Does the treatment increase the likelihood 
of living longer? And does it make the patient feel better? This is essentially a quantity 
versus quality issue and can be represented graphically (Figure 40). Answers which 
place the treatment in the upper right or lower left quadrant are clearly useful or not 
useful, respectively, while treatments in the other two quadrants may be useful in some 
patients or under certain conditions.













From reports in the vascular surgery literature, it is often difficult to assess the impact of 
distal arterial reconstructions on the patients. It has been proposed that the clinical 
outcome should be included in studies dealing with lower extremity ischaemia (Rutherford 
et al 1997) and exceptionally studies report clinical outcomes in detail (Ray et al 1995).
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Usually, however, bypass patency and limb salvage results are the only data on which the 
success of distal arterial reconstructions are judged. The large increase in ankle 
pressure recorded after a successful distal reconstruction in a severely ischaemic limb 
(Harling et al 1987) leads to the expectation that a rapid improvement in the clinical 
symptoms would follow and this is probably the reason why bypass patency is generally 
assumed to be a sufficient guide to the success of the intervention. Patency has been 
the most commonly reported endpoint in clinical papers and was the primary endpoint 
chosen for the multicentre trial of iloprost. Unfortunately bypass patency does not tell us 
that the patient feels better or that he will live longer. The bypass patency does, however, 
give us some information on the likelihood that the patient will feel better due to the 
association of patency with clinical outcome in terms of Fontaine stage and major 
amputation. Patency can be best characterised then as an intermediate or surrogate 
measure for a patient feeling better.
Patency as a surrogate endpoint
A surrogate endpoint has been defined by Temple (1995) as follows:
‘a surrogate endpoint of a clinical trial is a laboratory measurement or a clinical 
sign used as a substitute for a clinically meaningful endpoint that measures 
directly how a patient feels, functions or survives. Changes induced by the 
therapy on a surrogate endpoint are expected to reflect changes in a clinically 
meaningful endpoint’.
From the practical point of view in designing a clinical trial, the ideal surrogate endpoint 
should be sufficiently sensitive to demonstrate a treatment effect and clinically relevant 
(Weihrauch et al 1998). In addition, several authors have proposed criteria for 
establishing the value of a surrogate endpoint. Boissel et al (1992) stipulated three 
conditions which should be fulfilled before an endpoint can be considered as a valid 
substitute for a reliable clinical endpoint:
(1) Convenience. It should easy to evaluate and manifest more frequently than 
the corresponding clinical endpoint.
(2) Relationship. The relationship between the surrogate and clinical endpoints 
should be well established, both qualitatively and quantitatively, on the basis of 
pathophysiological and epidemiological studies.
(3) Assessment of clinical benefit. An assessment of the degree of clinical benefit 
to be anticipated should be deducible from the change in the surrogate 
endpoint.
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There is some overlap between these criteria and statements in the ICH guidelines on 
clinical trials, which consider that the strength of evidence for accepting surrogacy 
depends upon the biological plausibility of the relationship, the demonstration in 
epidemiological studies of prognostic value for the clinical outcome and evidence from 
clinical trials that treatment effects on the surrogate correspond to treatment effects on 
the clinical outcome (ICH Expert Working Group 1998).
Fleming et al (1996) considered that for a surrogate endpoint to be valid as a 
primary endpoint in a definitive trial, the concurrence of surrogate and clinical outcomes 
should be very close with the occurrence of false positive and false negative results being 
low, typically in the range of 2.5% to 10%. Figure 41 illustrates the concordance of 
bypass patency and limb survival in patients in the iloprost study excluding those in whom 
neither endpoint could be assessed due to death.
Figure 41. Concordance of secondary bypass patency and limb survival at 12 months 
amongst patients alive and followed up in the iloprost study. The solid shading 
represents the 82.1% of cases with agreement between patency and limb survival.
occluded and 
amputated
The number of false positives which would result from considering patency as a surrogate 
for limb survival would be 16/419 (3.8%) and the number of false negatives would be 
59/49 (14.1%). In total the proportion of correct assessments would be 344/419 cases 
(82.1%). This confirms that bypass patency is of value as a surrogate endpoint for limb
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survival in this kind of patient and bypass procedure, but the proportion of false negatives 
is higher than one would wish for such an endpoint.
The concordance of bypass patency with clinical outcome is shown in Figure 42. 
A good clinical outcome was defined as limb survival with Fontaine stage I or II and a 
poor outcome as amputated or limb survival with Fontaine stage III or IV.
Figure 42. Concordance of secondary bypass patency and clinical outcome at 12 months 
amongst patients alive and followed up. The solid shading represents the 81.4% of cases 
with agreement between the technical endpoint and clinical outcome.





Patients with good clinical o
The number of false positives which would result from considering patency as a surrogate 
for a good clinical outcome as defined here would be 56/419 (13.4%) and the number of 
false negatives would be 22/419 (5.3%). In total the proportion of correct assessments 
overall would be 341/419 cases (81.4%), which is similar to the concordance of patency 
with limb survival, but with more false positives and fewer false negatives. This confirms 
that secondary bypass patency is also of some value as a surrogate endpoint for clinical 
outcome in this kind of patient and bypass procedure, but that it is not wholly accurate as 
an indication of clinical success. It would be useful to present additional clinical 
information if patency is used as a primary trial endpoint. Primary patency, which is more 
commonly used as the primary efficacy variable than secondary patency, showed a 
slightly poorer agreement with clinical outcome.
Surrogate endpoints in some indications have been accepted by drug regulatory 
authorities without clinical trials demonstrating clinical benefit to the patient. Examples of
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this are the licensing of blood pressure lowering agents for the treatment of hypertension 
and lipid-lowering agents for the treatment of hyperlipidaemias. The evidence linking 
blood pressure-lowering and cholesterol-lowering with reductions respectively in the 
incidence of stroke and myocardial infarctions and cardiovascular death is considered 
strong enough to justify use of such drugs before the completion of long-term studies 
showing clinical benefit with the agent in question, although some such agents may not 
produce a net benefit due to additional harmful effects (Psaty et al 1996, Law et al 1994). 
Other examples of surrogate endpoints in cardiovascular disease serve to illustrate the 
importance of having clinical endpoints before the widespread adoption of new 
treatments. Haemodynamic measurements and exercise tolerance in chronic heart 
failure are examples of surrogates which do not provide definitive evidence of clinical 
benefit. Drugs predicted to be useful on the basis of effects on these variables have 
sometimes been found to increase mortality, for example milrinone and flosequinan 
(Packer et al 1991 and 1993).
Ideally, clinical trials using peripheral bypass patency as a primary endpoint should 
show corresponding changes in patients symptoms or clinical outcomes in order to avoid 
being misled by results on a surrogate endpoint. Alternatives to patency as a primary 
endpoint could also provide a more accurate indication of the clinical outcome.
Alternative endpoints to patency
Intervention-free status was investigated as an alternative to bypass patency. No 
reported instance of this endpoint being used in clinical trials of adjuvant therapy was 
found, although numbers of interventions have been reported when comparing the use of 
different surgical techniques, for example by Lawson et al (1999). Despite the potential 
disadvantages of being dependent on the surgeon’s judgement as to whether a further 
procedure is needed and feasible, this endpoint was found to be a more accurate 
indicator of clinical outcome than bypass patency. The rate of false positives or negatives 
was just under 10%, within the range suggested by Fleming et al (1996), as a criterion for 
accepting a surrogate endpoint. In this study all interventions were apparently indicated 
by the poor symptoms, but if this endpoint is used in future trials, this should be 
documented in order to increase confidence in the results.
Philosophically, patency and intervention-status are diametrically opposite 
approaches to obtaining information on clinical outcome. Bypass patency is presumed to 
be informative because it is expected to determine the clinical outcome. Interventions, on 
the other hand, are informative because they reflect the clinical course of the patient 
since the initial bypass procedure. Each approach has some merit. Successful surrogate
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variables such as serum cholesterol and blood pressure tend to be of the former variety. 
The weaknesses of each approach are, firstly, that factors other than patency influence 
the clinical outcome and, secondly, that additional factors besides the symptoms of 
ischaemia will influence whether or not an intervention is performed.
As both patency and interventions are an indirect measure of clinical outcome, a 
more direct measure of the patients symptomatic improvement or quality of life would be 
ideal, but this is difficult to find. Limb survival provides important clinical information, but 
is too blunt a tool to be useful in most trials on patients undergoing peripheral bypass 
surgery, as the amputation rate will be too low in most patient groups to provide a 
sensitive indicator of drug effects. Typically 12 month amputation rates in vein grafts 
would range from about 6% in femoropopliteal grafts (Lawson et al 1999) to 19% in 
femorodistal grafts as seen in this study.
Exercise tests post-operatively are not useful in patients who are asymptomatic or 
in those who have pain at rest. The Fontaine classification is a single scale running from 
asymptomatic to severe symptoms, but is a rather crude system which does not 
distinguish, for example between patients with trophic lesions who have rest pain and 
those who have trophic lesions alone. Pain is also difficult to assess while analgesics are 
being taken. A symptom score such as that proposed here for pre-operative assessment 
of the patients might also be useful post-operatively. However, this has not been tested 
and the ideal score would encompass a wider range of symptom severity than could be 
tested in the patient group studied. Previous attempts at developing a score or more 
sophisticated classification of patients with PAOD have been relatively complicated to 
apply and have involved an element of subjectivity on the part of the patient or the 
clinician (Belch et al 1991, Rutherford et al 1997).
Patency and intervention-free status as endpoints both have the advantage of 
being objectively verifiable. Alternatives to these technical endpoints which would retain 
this advantage and add more clinical information would be a composite endpoint of 
‘survival with an intact limb and patency’ or ‘survival without further interventions’. Of all 
of the endpoints considered, ‘survival without intervention’ was found to be the most 
closely associated with clinical outcome (Figure 43). Including several aspects of the 
patient’s outcome in a single composite endpoint has attractions in selecting a single 
primary trial endpoint, although it would be desirable to know in addition how each 
component of such a composite endpoint had changed. One example of such a 
composite endpoint, ‘survival with an intact limb and patency’, was found in an adjuvant 
therapy trial (Becquemin 1997), but ‘survival without intervention’ does not appear to have 
been used before.
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Figure 43. Intervention-free survival showed the closest agreement with clinical 
symptoms of all of the objective endpoints investigated. The solid shading represents the 
92.1% of cases with agreement between the intervention-free survival and the clinical 
symptoms.
Patients surviving without intervention
Patients dead oh \  
intervention and \  
poor outcome 1 
\  235 /
Composite endpoints have also been advocated in the recently published guidelines on 
non-surgical trials in PAOD (Labs et al 1999). Parallels can be drawn from trials in 
patients with coronary artery disease in which composite endpoints are now frequently 
used and expert endpoint committees appointed to adjudicate all reports of endpoints 
before analysis of the data. A composite endpoint of death, myocardial infarction or 
urgent revascularisation is common in coronary intervention trials (Tcheng 1997) and 
widely accepted as a primary study endpoint. The individual components of the 
composite endpoint are usually reported as secondary endpoints in addition in order to 
give more information. The main weakness in this composite endpoint is probably the 
definition of urgent revascularisation as the criteria for deciding to intervene may be 
difficult to standardise. Perhaps because of this, one major recent trial in unstable 
coronary disease has opted for a more limited composite endpoint of death or Ml 
(Harrington 1997).
The clinical situation after percutaneous transluminal coronary angioplasty (PTCA) 
is not dissimilar to that in peripheral bypass surgery. An equivalent to the PTCA 
composite endpoint of death, Ml or coronary revascularisation would be the use of a
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composite of death, amputation, bypass occlusion or intervention in peripheral bypass 
patients. The omission of any assessment of symptoms of leg ischaemia insufficiently 
severe to lead to surgical intervention would parallel the case of the patients with coronary 
artery disease with mildly disabling angina post-intervention. Some trials of patients with 
coronary disease have attempted to include an index of recurrent angina in the definition 
of a primary composite endpoint (PRISM study investigators 1998, PRISM-PLUS study 
investigators 1998), but despite the attraction of completing the clinical picture, this 
introduces a greater element of subjectivity which may be detrimental to the ultimate 
acceptability of the endpoint. A degree of subjectivity may be impossible to avoid in, for 
example, the criteria for the decision to intervene pre-emptively in a graft deemed to be at 
risk, giving rise to varying differences in rates of primary and assisted primary patency 
across centres.
The striving for objectivity in the endpoint has led, in the case of trials in cardiac 
disease, to the use of independent clinical endpoint committees which review and confirm 
the accuracy of the endpoint classification (Thygesen 1999). Their primary concern is the 
evidence for a myocardial infarction, since death and revascularisation are generally quite 
clear cut, but classification of causes of death is also of importance for secondary 
analyses. There would appear to be less of a need for such committees in peripheral 
vascular disease unless symptomatic assessments were to be included. Death, 
amputation and further interventions are quite easy for an experienced visiting monitor to 
identify and verify in the patient’s notes. The classification of these should also rarely 
cause any difficulty unless it was felt necessary to classify the cause of death.
Only one trial in peripheral bypass surgery has reported using an 
independent expert committee to oversee endpoints serving to reduce clinician bias as 
well as to standardise interpretations across different surgical centres (Becquemin 1997). 
Unfortunately, the extent of the agreement between the investigators’ and the 
committee’s opinions were not reported. Such an arrangement may be particularly 
valuable in a non-blinded trial, where clinician bias should could be an issue. A risk with 
using an endpoint committee is that it can introduce a new variable in the form of 
substantial discrepancies between the results of the investigator who has seen the patient 
at first hand and the endpoint committee which has to rely on documented evidence 
(Deckers et al 1998, Naslund et al 1999). Such a situation can serve to confuse, rather 
than clarify the true results.
The ICH guidelines address the selection of a primary target variable for trials of 
new drugs, recommending that it should be ‘the variable capable of providing the most 
clinically relevant and convincing evidence directly related to the objective of the trial’.
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This points to the selection of the intervention-free status either alone or in combination 
with patient survival rather than bypass patency in future studies. However, the 
guidelines go on to recommend that it should also be ‘a reliable and validated variable 
with which experience has been gained either in earlier studies or in the published 
literature’ and that it should ‘reflect the accepted norms and standards in the relevant field 
of research’ (ICH Expert Working Group 1997 and 1998). Bypass patency is clearly the 
accepted norm at present, so it may be that further studies will have to provide evidence 
for the greater clinical value of reporting interventions before it is likely to be adopted as a 
primary endpoint for important efficacy studies.
The iloprost study only included patients with severe ischaemia and distal bypass 
grafts. The next stage in assessing the usefulness of interventions as an endpoint might 
be to repeat the kind of analysis performed here in patients with less severe limb 
ischaemia and those undergoing femoropopliteal bypass.
There is one major additional advantage of providing the absolute number of 
patients who are ‘alive with an intact limb and patent bypass’ or ‘alive without further 
intervention’. These endpoints lend themselves readily to analysis according to the 
intention to treat principle as there will be no censoring due to death or amputation prior to 
loss of patency or intervention. A recent review has reported that the intention to treat 
strategy is often quoted in clinical papers, whilst clearly being interpreted in different ways 
(Hollis et al 1999). The convention in vascular surgery is to analyse patency data by life- 
table methods assuming that patients with missing observations would have behaved in 
the same way as those observed, i.e. this assumes that data are missing at random. 
However, this is likely to lead to bias (Choi et al 1995) and it has been shown that 
absence of patency data in one femorodistal bypass series was not independent of the 
outcome (Jensen et al 1996). If life-table analysis of patency continues to be the method 
choice, it would be of great value to report one of the suggested composite endpoints in 
addition. The ICH guidelines on the choice of a primary endpoint recommend that it 
should be a single variable, but do also allow for the possibility of a composite endpoint 
resulting from the summation or other combination of several variables or discrete 
categories of event provided that it is well-defined a priori.
Disease severity as an outcome measure
The lack of a suitable scale of disease or symptom severity has been discussed with 
respect to patient characterisation. The same arguments apply in the assessment of 
improvement in symptoms. The Fontaine classification is only able to show large 
changes in symptoms. A symptom score such as that used here for the pre-operative
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characterisation of the patients may also be useful post-operatively and would provide a 
more precise measurement of severity than that offered by the Fontaine classification.
Another version of the composite endpoints discussed earlier has been proposed 
for non-surgical trials, in which the number of ‘optimal response days’ could be counted 
(Labs et al 1999). An ‘optimal response day’ could be defined by relief of clinical 
symptoms in addition to survival without amputation. Such an approach could be adapted 
to peripheral bypass trials and incorporate freedom from re-intervention. Unfortunately, 
such analysis had not been foreseen when this study was designed and the data 
collected did not allow such an analysis to be performed retrospectively. It would be of 
considerable interest to test the feasibility of such an approach.
An alternative approach would be the assessment of quality of life after bypass 
surgery. There is some evidence for the usefulness of a widely accepted, non-disease 
specific quality of life questionnaire (SF36) in demonstrating improvement following 
infrainguinal reconstruction (Chetter et al 1998, Seabrook et al 1999), but this might not 
be sensitive enough to detect postoperative treatment differences in a clinical trial. A 
disease specific questionnaire would be preferable. A German language 86-item quality 
of life scale specifically for PAOD has been developed including questions on symptoms, 
functional status and psychological evaluation (Bullinger et al 1996), but the use of this 
scale in peripheral bypass studies has not so far been published. Other appropriate 
scales are being developed (Beattie et al 1997) and these could also prove to be useful 
tools in investigating the clinical outcome of distal bypass surgery.
Patient management
There were two important issues of patient management which were left to the policy of 
the surgical centre in the iloprost trial: graft surveillance and post-operative antithrombotic 
treatment.
Surveillance of grafts for development of stenoses was performed in most of the 
study centres, but with widely varying detection rates only partly explained by the variation 
in composition of the patient populations and the type of procedures performed. The 
overall stenosis detection rate of 27% was comparable to the literature (Golledge et al 
1996), but elective interventions to dilate the stenosis seldom followed and therefore had 
little impact on the primary patency rates as such interventions were rarely the sole 
reason for loss of primary patency. It had been feared that frequent intervention prior to 
occlusion of the graft might compromise the interpretation of primary graft patency as a 
primary endpoint in the trial, but this was sufficiently infrequent not to be considered a
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problem. This issue could be simplified in future trials by having agreed criteria for 
intervening to dilate a stenosis.
A beneficial effect of aspirin on clinical outcome is beyond dispute (Antiplatelet 
Trialists’ Collaboration 1994b). However, its use as long-term antithrombotic treatment in 
the iloprost study was not stipulated in the protocol as some centres, notably those in the 
Netherlands, prefer to use oral anticoagulants as a routine antithrombotic therapy. The 
use of aspirin was found to vary greatly between centres potentially posing a problem for 
trial interpretation. Both aspirin and oral anticoagulant use were strongly associated with 
an improved clinical outcome in the iloprost trial. This was a weakness in the trial design 
and future trials of short term therapies should probably stipulate the use of one of these 
treatments up to the end of the follow-up. A recently completed, but still unpublished, trial 
may answer the question of the relative merits of these two treatments after peripheral 
bypass surgery (Tangelder et al 1996).
Repeat randomisation
It was found to be common practice amongst published studies in this field to count the 
outcome of each graft in a trial instead of each patient and thus to include some patients 
more than once if grafts were performed in different legs or if a second graft was 
performed after failure (i.e. an endpoint) had occurred in the first graft. This was done 
either by randomising each graft procedure separately or by randomising a patient once 
and counting each graft as a separate outcome in that treatment group. This can give 
misleading information as conventional statistical tests assume that the outcome in each 
case will be independent of the outcome in any other case. Knowing for example that the 
sex of the patient can influence the outcome, tells us that two grafts in the same patient 
will be subject to a common factor influencing the outcome. Other patient specific 
characteristics such as lifestyle, compliance with antithrombotic medication, presence of 
distal disease, plasma fibrinogen and blood viscosity may also link the outcome in the two 
grafts.
Graft or procedure specific influences on outcome such as graft material and vein 
quality would appear to be less important in this respect, but even these may be 
consistent in different procedures in the same patient. A patient who has inadequate vein 
for one procedure is likely still to have inadequate vein for the second. Thus a poor 
outcome for one graft in a patient might be strongly associated with poor outcome of a 
second procedure.
This problem is not unique to trials in peripheral bypass surgery. It has been 
observed and reported to be common in publications of ophthalmological studies in which
189
results of both eyes from the same patient are sometimes included in the analysis, 
invalidating the statistical assumptions (Newcombe et al 1987, Katz 1988). This is 
analogous to the practice of including two legs or grafts from the same patient in 
peripheral bypass surgery.
Future studies
The recommendations for improved study designs could be usefully applied to some 
agents in current clinical use. Although widely used with all types of graft material, it is far 
from clear that aspirin is effective in maintaining the patency of vein grafts. Oral 
anticoagulants have yet to be tested in a trial with a fixed duration follow-up, clear patient 
definition and adequate measures to eliminate bias in the assessment of patency. There 
is some evidence for their use in vein grafts, but none in prosthetic grafts. Ticlopidine has 
been shown to be effective in vein grafts in one of the few well-designed trials, but this 
should be confirmed and a comparison with aspirin is needed.
The evidence for a reduction in cardiovascular death and morbidity by aspirin 
poses an ethical dilemma in performing placebo-controlled trials. Aspirin is probably of 
value in all patients undergoing peripheral bypass surgery as they will be at risk, not only 
of graft thrombosis, but also of coronary or cerebrovascular thrombosis. There will be 
some patients who are intolerant of aspirin, but these may be too few for an adequately 
sized clinical trial to be performed. This points to a need to test other antithrombotic 
agents against aspirin, or a combination of the new agents plus aspirin against aspirin 
alone. There is potentially added value in this approach as two platelet inhibitors working 
by different mechanisms may have an additive or even a synergistic effect when used in 
combination. This has been shown with ticlopidine (Thebault et al 1977) and with some of 
the orally bioavailable platelet glycoprotein llb/llla antagonists (GPIIb/llla antagonists) 
currently in development for thrombotic indications (Keriakes et al 1997, Theroux et al 
1998).
Although there is a paucity of convincing trial data available, there are a number of 
agents which would seem to merit further investigation. As suggested in the previous 
paragraph, aspirin, oral anticoagulants and ticlopidine all need further studies. The data 
on low molecular weight heparins are also promising, but stem from open or single blind 
studies. Double blind trials with these subcutaneously administered drugs have been 
performed in other indications (Cohen et al 1997, FRISC-II investigators 1999) and should 
be performed in patients undergoing peripheral bypass procedures. Other antithrombotic 
agents such as clopidogrel, which inhibits ADP-induced platelet aggregation like 
ticlopidine, but with a better safety profile (Coukell et al 1997), and the aforementioned
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GPIIb/llla antagonists which antagonise the fibrinogen-binding receptor on the platelet 
surface, the final common pathway in platelet aggregation to any stimulus, have potential 
in this indication and should be investigated in well-designed trials.
The majority of interest up till now has been in the development of antithrombotic 
agents for this indication. However, graft stenosis is a major contributing cause of graft 
occlusion and none of the agents currently available have been shown to influence this 
process. A compound which did so could be very valuable and current interest is centred 
on antagonists of the 0^ 3  receptor which is thought to be important in this process 
(Bishop et al 1999) and matrix metalloproteinase inhibitors. In principle, trials of such 
agents would follow the same design as those of antithrombotic drugs with particular 
emphasis on the standardisation of the assessment of stenosis, probably by duplex 
ultrasound. Although the majority of stenoses occur in the first year, a slightly longer 
follow-up of 18 months might be appropriate.
Some years have elapsed since the planning and conduct of the iloprost trial and it 
was noted in the literature review of trials of adjuvant therapy that there was some 
evidence of improvement in trial design since the iloprost trial was initiated. However, 
many of the deficiencies in trial design identified have yet to be routinely addressed. 
Further improvements are needed in order to enable clinicians to make decisions on the 
optimal treatments for maintaining peripheral bypass graft patency and improving the 




• Published studies of adjuvant medical therapy in peripheral bypass surgery frequently 
have weaknesses in study design and patient selection, and most notably in the 
reporting of clinical outcomes.
• A multicentre trial demonstrated a general lack of effect of peri-operative iloprost on 
bypass patency and clinical endpoints when used in patients undergoing femorodistal 
bypass procedures. An absolute increase of 12.5% in the primary patency rate of 
femrodistal vein grafts with iloprost could be excluded.
• A simple symptom severity score was used which could be more useful than the 
Fontaine classification for describing a study population with severe PAOD, as it was 
shown to be strongly associated with the clinical outcome in terms of ‘limb survival’, 
‘patient survival’ and ‘patient survival with an intact limb and patent graft’.
• Patient selection is important and possible interactions between the adjuvant treatment 
and characteristics of the patients or operations should be taken into account when 
planning a study. An example of this is the importance of differentiating between vein 
and prosthetic graft materials which was illustrated by the meta-analysis of outcomes 
of published studies with aspirin and sulphinpyrazone.
• The comparison of different centres in the iloprost trial indicated that the selection of 
patients for this type of operation may vary significantly between centres even when 
following a common protocol, particularly in terms of disease severity.
• The intercentre differences identified did not appear to have played a major role in the 
iloprost study as the outcome was similar in most centres. However, intercentre 
differences in graft stenosis rates could have implications for trials of drugs designed 
to act on stenosis development.
• Studies requiring strict consistency in patient selection, procedures and postoperative 
management may be best performed in single centres, but most studies will require 
the cooperation of more centres in order to achieve the desired numbers of cases. In 
this case careful definitions of policy should be adhered to. Data on a centre’s recent 
results and data on patients not included during a trial will help to assess the impact of 
the selection criteria in a study. Another approach in the absence of adequate 
multicentre trials is to use meta-analysis and identify sources of heterogeneity.
• Bypass patency is of value as a surrogate endpoint for limb survival and clinical 
improvement of clinical symptoms in patients undergoing femorodistal bypass surgery, 
but the number of false negatives and false positives is sufficient to warrant the 
reporting of additional clinical results.
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• An alternative technical endpoint to bypass patency is the intervention-free status of 
the patient. In these investigations, intervention-free status was found to represent 
clinical improvement more accurately than bypass patency. The value of this endpoint 
should be investigated further in other types of patients and procedures.
• Composite endpoints deserve consideration as primary endpoints in clinical trials in 
this field. They can incorporate both technical and clinical outcome measures and 
arguably provide the best overall measure of success in addition to lending themselves 
well to intention-to-treat analysis.
• The need to obtain agreement on strict protocols covering surgical procedures and 
criteria for patient selection and intervention makes performing large multicentre trials 
difficult in this indication. An alternative is to use meta-analysis techniques to analyse 
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Abbreviations listed below are those appearing in the text. Additional abbreviations may 
be used in some tables and these are explained in footnotes to the relevant tables.
Abbreviation Explanation
ABPI Ankle-brachial pressure index
ASA Acetylsalicylic acid, aspirin
CABG Coronary artery bypass graft
CLI Critical limb ischaemia
CRF Case report form
CVA Cerebrovascular accident (used as a synonym for stroke)
DSA Digital subtraction angiography
GCP Good Clinical Practice
GP llb/llla Platelet glycoprotein llb/llla
HUV Human umbilical vein
ICH International Conference on Harmonisation of GCP
LMWH Low molecular weight heparin
Ml Myocardial infarction
PAOD Peripheral arterial occlusive disease
PGEt Prostaglandin E
p g i2 Prostaglandin l2, prostacyclin
PSV Peak systolic velocity
PTA Percutaneous transluminal angioplasty
PTCA Percutaneous transluminal coronary angioplasty
PTFE Polytetrafluoroethylene (a prosthetic graft material)
SDV Source data verification
SFA Superficial femoral artery
TEA Thromboendarterectomy
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